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Prologue
Bipolar disorders (BD) arc among the most hereditary of psychiatric syndromes (Gcrshon et
al. 1976). Whereas the lifetime risk to develop BD in the population is 1-5 "a (Wcissman et al.
1988). healthy first-degree relatives of BD patients (KM) show a 10-20 times increased risk to
develop BD (Goodwin and Ghaemi 1948). BD is a chronic disease; more (hun a third of all
cases develop BD before age of 20. BD Patients have to take medication for u prolonged
period of time, even for the rest of their lives. The impact of illness episodes on social
functioning and intellectual development is paramount. It goes without saying that healthy Fll
subjects worry about their biological vulnerability to develop BD. The present research
project searches for biological determinants involved in psychopathology of BD.
Vulnerability to serotonergic dysfunctions was assessed in healthy subjects at genetic risk for
BD and healthy controls subjects without such a genetic risk.
The appearance of emotional extremes alternated by long-term episodes of normal mood state
and behavior characterizes BD. Depression is one emotional pole. During depression, there is
a slowing or decrease in almost all aspects of emotion and behavior: rate of thought and
speech, energy, sexuality and the ability to experience pleasure. Patients feel sad and
despairing for weeks or months. The other pole is mania, which is characterized by elated or
euphoric mood, faster train of thought, brisker physical and mental activity levels, irritability,
heightened sexuality, and impulsivity. As opposed to hypomania, mania is more severe and
may be associated with psychotic features such as delusions and hallucinations (Honig and
van Praag 1994; Goodwin and Jamison 1990). Based on these symptoms, BD are classified in
two major subgroups: type I and type II. The most important distinction is based on a history
of full mania in BD type I patients, whereas BD type II patients are known with hypomania
(Goodwin and Jamison 1990).
Serotonin (5-hydroxytryptophan or 5-HT) is a monoamine which is involved in brain
information processing and regulation of mood. Serotonergic deficiency has been accepted as
an underlying physiological mechanism in major depression (Charney 1998; Meltzer 1989;
Price et al. 1990; Stahl 1977). In depressed and manic BD patients, there is also evidence for a
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reduced 5-HT activity (Goodwin and Jamison 1990; Prange et al. 1974; Young et al. 1994).
Brain 5-HT dysfunction may be a result of disturbed lipid metabolism, i.e. abnormalities in
cholesterol (Buydens-Branchey et al. 2000; Maes et al. 1997; Swartz 1990; Terao et al. 2000)
and fatty-acids (FAs) (Maes et al. 1996). Several genetic abnormalities affecting the 5-HT
system have been implicated in BD psychopathology (Bellivier et al. 1998; Ginns et al. 1996;
Kunugi et al. 1997; Lesch et al. 1995; Oruc et al. 1997).
Central 5-HT vulnerability in FH can be described as vulnerability to 5-HT dysfunction as
shown in BD patients. Useful paradigms to assess vulnerability to 5-HT dysfunction are
provided by experimental procedures that acutely decrease or elevate brain 5-HT availability.
Next to medication, brain 5-HT activity can be modulated by dietary challenge procedures in
which availability of the amino-acid tryptophan (Tip), precursor of 5-HT, is manipulated.
Acute tryptophan Depletion (ATD) is a method in which Trp and consequently brain 5-HT is
depleted by giving subject an amino-acid drink devoid of Trp (Young et al. 1985).
Scrotonergic functioning can be stimulated by intravenous (i.v.) administration of Trp
(C'harney et al. 1982). Trp is the precursor to brain 5-HT synthesis. The central production of
5-HT by the enzyme tryptophan-hydroxylase is directly dependent on the amount of Trp in
the brain. ATD can be achieved by consuming an AA-drink which is rich in large-neutral
ammo acids (LNAAs) (i.e. valinc, leucine. iso-leucine. tyrosine and phenylalanine) and
devoid of Trp. LNAAs compete with Trp at the blood-brain harrier, for lpitflks .Thrrt^-uhiik
brings Trp at a relatively disadvantage for uptake which results in a central Trp depletion and
lowering of 5-HT (Young et al. 1985). On the other hand, i.v. Trp loading will increase brain
Trp and thus 5-HT availability. Modulations of central availability of Trp have been described
to affect mood (Aberg-Wistedt et al. 1998; Young et al. 1985), cognition (Riedel et al. 1999;
Schmitt et al. 2000) and hormone release (i.e. cortisol and prolactine; PRL) (Goekoop 1998;
Stahl 1992). Compared to controls, 5-HT vulnerability in FH will be reflected as altered
effects of ATD and Trp challenge on mood, cognition, cortisol and PRL release (Riedel et al.
2002; Stahl 1998). For example, compared to controls, major depressed patients (Delgado et
al. 1990; Delgado et al. 1991) and their first-degree relatives are more vulnerable to the mood-
lowering effects of ATD (Klaassen et al. 1999).
It is important to differentiate between trait and state markers. State markers are biological
abnormalities that are only present during illness episodes whereas trait markers are also
present in patients or those at risk. Thus unlike state markers, trait markers are also present in
symptom-free episodes. As healthy FH subjects are genetically at risk for BD, but do not
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show interference ofpsychotropic medication, they constitute an important population which
is very suitable to investigate 5-HT vulnerability and other trail marken« tor HI).
In this thesis 5-HT vulnerability is assessed in FH subjects following ATD and i.v. Tip
challenges. Effects on mood, cognition and hormonal responses in FH subjects arc compared
with effects in healthy matched controls. A distinction is made between effects in relatives of
type I (FH I) and type II (FH II) BD patients Furthermore, in search for trait markers for BD,
abnormalities in baseline cholesterol and FAs and associations with central 5-HT
vulnerability are investigated.
Aims and outline of the studies
In the first part of this thesis, consisting of chapters 2 to 4, 5-HT vulnerability in FH subjects
is investigated by using an ATD paradigm.
A review of studies on ATD in BD patients is given in c/iqp/er.?. In major depressed patients
ATD has been shown to enhance feelings of depression (Delgado et al., 1990). In order to
investigate 5-HT dysfunctions in BD, literature on ATD in BD patients is reviewed. Based on
the available information on ATD paradigms previously applied in BD. a research protocol
will be developed to investigate the effects of ATD in FH subjects.
o/V47"D o« mooJam/s/ress-/Wi«W cor/wo/ response
In c/rap/er J, the effects of ATD on mood and stress-induced Cortisol release are investigated
in FH I and FH II subjects and healthy matched controls. Differences between FH subjects
and controls in ATD-induced mood changes may reflect a central 5-HT vulnerability. Despite
the fact that stimulating effects of 5-HT on cortisol are well known, this is the first study
which investigates the effects of ATD on stress-induced cortisol release. Cortisol has been
described as an important biological marker in BD and cortisol response after ATD might
provide an important indicator of central 5-HT vulnerability FH subjects.
j /» F / / awo* e^ec/i o/,4 7Z)
Cognitive impairments in healthy subjects at genetic risk for affective disorders may reflect a
biological vulnerability. In depressed, manic and euthymic BD patients significant cognitive
deficits has been described. The experiment described in c/»a/?/er 4 addresses the issue of
cognitive functioning in FH. This study questions whether FH subjects show cognitive
impairments on executive functioning, memory, learning and divided and focused attention
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compared to healthy controls. Differences between FH I. FH II and controls in ATD-induced
changes in cognitive performance might reflect 5-HT vulnerability affecting brain areas
normally involved in these cognitive processes.
The second part of this thesis, consists of chapters 5 to 8. In these chapters studies
investigating 5-HT vulnerability in FH subjects following i.v. Trp loading are described.
Neuroendocrine, mood and cognitive changes following Trp might reflect central 5-HT
vulnerability in FH I and FH II subjects. The relationship between potential disturbances in
normal cholesterol and FA metabolism and central 5-HT vulnerability in FH is also
investigated.
C'/KI/J/«V 5 is a literature review of studies on 5-HT challenge paradigms in respectively
euthymic. depressed and manic BD patients. Neuroendocrine parameters such as PRL and
Cortisol have been used extensively as biological markers of 5-HT functioning in the brain.
Relatively high ncuroendocrine and mood responses are indicative of post-synaptic receptor
hypcrsensitivity whereas low responses suggest receptor hyposensitivity. Procedures and
methodology of studies will be critically reviewed: the interference of mood state and
psychotropic medication on effects of ATD is described.
7>T> cAa//t7»ge e^ec/s ow mood am/ AorwoMa/ responses
The effects of i.v. Trp challenge on mood and neuroendocrine responses in FH subjects are
described in t-A«/>/tv tf. In this study central 5-HT vulnerability in FH I and FH II is
investigated by measuring Trp-induced mood changes and levels of cortisol and PRL. In FH
subjects, changes in central 5-HT receptor sensitivity might give rise to blunted or
exaggerated mood and neuroendocrine responses compared to controls, which reflect 5-HT
vulnerability to BD.
7>if e/fcr/.v o/Trp cW/enge on cogm/ive per/brmance i« F//
Brain 5-HT plays an important role in several cognitive domains. Following ATD, cognitive
impairments of for instance planning, learning and memory have been reported. But in
understanding the role of 5-HT in cognition, it is important to differentiate between cognitive
effects of both an acute increase and decrease in brain 5-HT. Studies on cognition following
acute 5-HT stimulation are limited and cognitive effects of i.v. Trp challenging have never
been investigated before. The study in c/w/tfer 7 investigates changes in planning, attention.
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psychomotor performance and memory following i.v. Trp loading. Differences in cognitive
changes following i.v. Tip between FH I, FH II and healthy controls indicate central 5-HT
vulnerability.
,4/lerw/ CÄO/«/<TO/ anJ/um ari<fc />i F// «vk/ its rote i« 5-/
Abnormalities in cholesterol and FAs metabolism have been described in depressed and
manic BD patients. A decrease in cholesterol and FAs lowers membrane micro viscosity,
receptor stability, membrane transport mechanisms and consequently normal 5-MT
functioning in the brain and hence can cause depression. Though changes in cholesterol and
FAs have been previously depicted as state markers in major depression, it is still questioned
whether these abnormalities indicate trait markers. Alternatively it is suggested thai v li.in^os
in normal cholesterol and FA status in healthy FH subjects reflect a trait marker (o BD. The
study in «Aa/Ver Ä investigates whether there arc differences in cholesterol and FAs between
FH and healthy matched controls. The association between cholesterol and FAs status and 5-
HT function as assessed by neuroendocrine responses to i.v. Trp challenge is described.
In rfcytfer 9 a summary of the findings and a general discussion of the combined results is
provided. Implications for further research are given.
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CHAPTER 2
Acute Tryptophan Depletion in bipolar disorders; literature review and
directives for further research
Abstract
Serotonin (5-hydroxytryptophan; 5-HT) has been implicated in the pathophysiology of bipolar
disorders. Acute Tryptophan Depletion (ATD), which decreases serotonergic turnover, is an
established paradigm to study serotonergic vulnerability in affective disorders. Literature on
the application of ATD as a research tool in bipolar patients is limited to three studies, which
revealed inconsistent results on mood modification. These inconsistencies may be attributed
to differences in methodological procedures and / or characteristics of included patients.
Patient selection, methodological aspects and procedures of these studies are critically
considered and recommendations given. A research protocol to test the 5-HT vulnerability in
bipolar disorder is proposed.
Sobczak S, Honig A, Riedel WJ. ,4cta Afofro;H)>cAMirrica, 12(3), 2000
Introduction
In bipolar disorders, there is some evidence for a reduced activity of serotonin
(5-hydroxytryptophan; 5-HT) in both depressed and manic states. Increased platelet serotonin
and lower maximal velocity (Vmax) of 5-HT-platelet uptake, has been reported in untreated
bipolar depressed patients (Marazziti et al. 1991). Post-mortem studies of brains of bipolar
patients have indicated decreased 5-hydroxyindoleacetic acid (5HIAA, the major metabolite
of 5-HT) to 5-HT ratios, which is indicative of reduced 5-HT turnover, in cerebral cortex
(Young et al. 1994). In the pathophysiology of bipolar disorders, genetic modifications
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affecting the 5-HT system, e.g. in the 5-HT transporter, 5-HT receptors and the tryptophan
hydroxylase gene have been described (Lesch et al. 1995; Bellivier et al. 1998). No single
specific 5-HT marker has yet been discovered and there is growing interest in various indices
of 5-HT function in bipolar disorders.Acute Tryptophan Depletion (ATD) is a useful method
to investigate central 5-HT vulnerability. In this paradigm a low brain 5-HT turnover is
obtained by giving subjects a 50-100 g balanced amino acid-drink (AA-drink) including
Large Neutral Amino Acids (LNAAs) like tyrosine, phenylalanine, leucine, isoleucine, valine
and devoid of tryptophan (Trp). The ingested amino acids lower plasma Trp levels by
stimulating peripheral protein synthesis thereby using free Trp. Next Trp competes at a
relative disadvantage with LNAAs to cross the blood-brain barrier. Subsequently, central Trp
depletion occurs and as the rate-limiting step in 5-HT synthesis is dependent on the
availability of Trp, central Trp depletion will transiently reduce central 5-HT activity. Within
5-7 hours, ATD leads to an 80-95% reduction of plasma and CSF Trp and a 30% reduction of
cerebrospinal fluid 5-HIAA concentrations (Carpenter et al. 1998). First-degree relatives, with
no prior depressive episodes, are biologically predisposed to increased vulnerability to the
mood-lowering effects of ATD (Benkelfat et al. 1994) (Klaassen et al. 1999). It has been
Hhnwp.thiit.Mirjirtnt»!.»uiliwah^.trji^wwüirifis^ wrieicas
remitted patients may show clinical relapse after Trp depletion (Delgado et al. 1990). Thus,
Trp depletion may be useful in identifying individuals vulnerable to serotonergic imbalance
and at risk for future depressive episodes.
In this article, literature on Trp depletion in bipolar patients and their first-degree relatives
will be considered first; methodological procedures and patient selection will be critically
reviewed. Secondly, recommendations for future investigation are given.
Literature review
Literature was searched for in electronic libraries: MEDLINE and PSYCHLIT, year 1960 to
2000. To complete the selection, all references in retrieved papers were included in the
review. The keyword, on which the literature was selected, was 'tryptophan depletion'. All
papers on Trp depletion were checked. Only papers describing studies into the effects of ATD
in bipolar patients and their first-degree relatives were included in the review. Papers
describing subjects solely as major depressed and papers, which failed to describe their
subjects as either bipolar or unipolar depressed patients, were not included in the review.
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Results
Fifty papers describing ATD studies were found. Only three studies applied the ATD
paradigm in lithium-remitted bipolar patients (see table I) (Bcnkelfut c( al. 1995. C'assidy et
al. 1998; Cappiello et al. 1997). Five papers on ATD described the number of unipolar and
bipolar depressed patients in the research population (Delgado et al. 1990; Price el ul. 1998;
Neumeister 1998; Leyton et al. 1997). Three papers described the effects of ATD in healthy
first-degree relatives of unipolar and bipolar depressed patients (Klausscn ct ul. 1999;
Delgado et al. 1990; Ellenbogen et al. 1999).
/> .4 7D in ftipo/ur Juort/ers
Three papers described the effects of ATD in type I bipolar patients. These studies were all
carried out according to a double-blind counterbalanced placebo-controlled design (licnkctl'ut
et al. I99S; Cassidy et al. 1998; Cappiello et al. 1997). Bcnkeltat et al. (Benkcllut et ul 1995)
did not find any changes in affective symptoms in long-term (at least one year) remitted
bipolar patients. Mood scales used were Hamilton Depression Rating Scale (IIDKS). Ucigcl
and Murphy Manic-State Rating Scale (BMMS). Zung Depression Scale (ZDS) and Visual
Analogue Mood Scales (VAMS). Patients were 10 men (mean ± SD, age, 39 ± 15 years) who
fulfilled DSM-III-R criteria for bipolar disorders; the duration of illness was 14 ± 11 years. At
time of entry in the study, all patients were on lithium monotherapy (daily dose, 930 ± 386
mg/d) and had been euthymic for at least one year (4 ±11 years). After ATD, plasma Trp
levels decreased by 85%, whereas in the placebo condition plasma Trp levels were elevated
by 39%.
Cappiello et al. (Cappiello et al. 1997) applied the ATD paradigm in seven remitted bipolar
patients (4 women, 3 men; aged 26-58 years). All subjects met DSM-IV criteria for bipolar
manic episode, one patient had a schizoaffective diagnosis, none rapid cycling or mixed.
Patients were on lithium therapy, five additionally on an antipsychotic (3 on haloperidol, 2-10
mg/d, and 2 on perphenazine, 12-48 mg/d). The AA-drink was given as a full-strength drink
(depletion drink) or as a 25% strength mixture (sham drink). Plasma Trp levels decreased
significantly in the Trp depleted condition. Exact changes of plasma Trp levels were not given
and no corrections for plasma lithium, haloperidol or perphenazine level or were made. After
Trp depletion, patients reported increased manic symptoms on Young Mania Rating Scale
(YMRS) scores for three days.
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Cassidy et al. (Cassidy et al. 1998) applied the ATD paradigm in 4 recently remitted manic
bipolar patients (2 women, 2 men, age 52.5 years). Patients were on lithium monotherapy for
1 month (31 ± 16.5 days). The ATD paradigm consisted of full-strength and a 25% strength
sham drink. Mood was rated using YMRS, HDRS and the Carroll Depression Scale (CDS).
Plasma Trp levels decreased 77% in the depletion condition and decreased 7% after the
placebo AA-drink. No clinical changes in manic or depressive symptoms were observed
during Trp depletion. An overview of the studies is given in table I.
Table I: Uouble blind (UB) studies on ATD in bipolar patients (BP) and in subjecti with a I" degree family
history of bipolar disorders
<u/*«r
rtrniW/i« W
[ ut.lJl /WM
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2) ATD in unipolar and bipolar depressed patients •
Five studies described the effects of ATD in a research population including both unipolar
and bipolar depressed patients (Delgado et al. I WO; Price ct al. 1997; Price et >l. 1998;
Neumeister 1998; Lcyton et al. 1997). All studies were conducted according to a double-blind
placebo-controlled cross-over design, and applied the classical ATD paradigm. Subjects were
bipolar and unipolar depressed patients in remission (see table I). In the study of Delgado ct
al.. (Delgado et al. 1990) subjects were receiving antidepressant treatment at the time of
investigation. In the remaining four reviewed studies, testing occurred during a placebo
treatment period (Price et al. 1997; Price et al. 1998; Neumeister 199«; Leyton et al. 1917).
Three of the five studies reported a mood-lowering effect of ATD. using Visual Analogue
Mood Scales (VAS) (Delgado et al. 1990; Price et al. 1997; Price et al 1998). However, the
authors failed to describe differences in mood-response between unipolar and bipolar
depressives. As the number of included bipolar patients was relatively small in these studies
(maximal 10 in a population of 30 subjects) compared to unipolar patients, the study
outcomes might mainly be attributed to ATD effects in unipolar depressive putients.
3) /i TO iw//rs/-deg/-
Three papers describing ATD in first-degree relatives of depressed (including unipolar and
bipolar depressed) patients were available (Klaassen et al. 1999; Benkelfat et al. 1994;
Ellenbogen et al. 1999), see table I. The three studies were all conducted according to a
double-blind placebo-controlled cross-over design. Subjects were free of psychiatric diagnosis
in past and present and were taking no medication except oral contraceptives. Klaassen et al.
(Klaassen et al. 1999) and Benkelfat et al. (Benkelfat et al. 1994) showed enhanced mood-
lowering effects, on the Profile of Mood States depression scale (POMS) scores, in subjects
with a positive family history for depression. Ellenbogen et al. (Ellenbogen et al. 1999) could
not confirm these findings in women with a multi-generation family history of psychiatric
illness. These negative results have been attributed to the exclusion of a large number of
women who had already experienced an episode of depression. All papers failed to describe
differences in mood changes between relatives of bipolar or unipolar depressed patients.
There were no studies investigating ATD in first-degree relatives of bipolar patients
exclusively.
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Discussion
No definitive conclusion on the effects of ATD in bipolar patients can be drawn from the
reviewed literature. First, in the three reviewed studies, all subjects were on psychotropic
medication. Lithium treatment has been shown to alter central S-HT sensitivity. An increased
prolactinc response to Trp after short-term lithium treatment, but not after long-term lithium
treatment has been reported (Price et al. 1989). Lithium does not only affect 5-HT turnover,
but may also be involved in post-synaptic second messenger systems (G proteins or
phosphatidyl inositol) (Bowden and Dickson 1997). Second, the sham condition in the
alternative paradigm is not a useful placebo. It might therefore be premature to draw general
conclusions about the 5-HT vulnerability in bipolar disorders, indicated by ATD.
To investigate the 5-HT vulnerability, ATD should be applied to bipolar patients off
medication, which rises serious ethical concerns. Consequently, the effects of ATD must be
investigated in subjects with no prior psychiatric diagnosis, but at genetic risk for bipolar
disorders.
Until now, a valid comparison of studies is hampered by differences in methodological
aspects and procedures. To draw general conclusions about the effects of ATD in bipolar
disorders, methodological deficits should be improved with regard to several aspects.
1) To increase the power, ATD should be applied to a larger research population including
healthy matched control subjects. The number of subjects in reviewed papers was
maximal 10 (Benkelfat et al. 1995). In none of the studies control subjects were included.
2) The research population must be specified. Several factors including melancholia or a
history of refractoriness to anti-depressant drug can influence the vulnerability to relapse
following ATD. Melancholic traits, suicidal behavior, medical treatment, history of
refractoriness, psychotic features, family history, type of bipolar disorder (both type I and
type II) and last episode must all be described (Delgado et al. 1990; Delgado et al. 1994).
Only Cappiello et al. (Cappiello et al. 1997) described their patients with respect to
schizoaffective. rapid cycling and mixed bipolar disorder.
3) The ATD paradigm must be applied according to a standardized method (the classic
method is according to Young (Young et al. 1985). It is recommended to minimize the
total amount of amino acid intake (5O-75g); offering too much leads to variability because
of vomiting or not ingesting the excessive drink. Beside, different ATD paradigms may
result in different changes in plasma Trp levels. This holds true for reviewed studies;
Cassidy et al. (Cassidy et al. 1998) found a decrease in plasma Trp levels of 77% after
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ATD and an increase of 7% in the placebo condition using the alternative ATI) paradigm.
Benkelfat et al. (Benkelfat et al. 1995) used the classic method and reported a decrease of
85% after Trp depletion and an increase of 45% in the placebo condition.
4) Ratio Trp: LNAAs must be assessed to indicate the effect. .,,•
5) Women should be tested in their follicular phase of the menstrual cycle because pre-
menstrual mood change, hormonal levels and altered ammo acid kinematics may
confound mood change following ATD. To correct for confounding related lo menstrual
cycle. Benkelfat et al. (Benkelfat et al. 1995) applied the ATD paradigm in male subjects.
Cassidy et al. (Cassidy et al. 1998) and Cappiello et al. (Cappiello el al. 1997) did not
correct for menstrual cycle in women.
6) Mood changes should be assessed 5-7 hours after Trp depletion. To investigate changes in
5-HT receptor sensitivity, mood should be reassessed following Trp loading after ATD.
Delgado et al. (Delgado et al. 1994) reported a bimodal mood response on the day after
ATD; subjects refractory to treatment became more depressed, while anli-deprcssanl
responders became less depressed.
7) Mood should be rated using mania and depression scales and bimodal VAS, such as the
bimodal POMS. ATD might elevate or lower mood in bipolar patients, probably
dependent on previous episode. Measuring quick altering mood states can best be done by
using VAS (like POMS) instead of clinical symptom checklists (HDRS or YMRS)
(McNair et al. 1971). Cappiello et al. (Cappiello et al. 1997) and Cassidy et al. (Cassidy et
al. 1998) did not use VAS scales, and therefore might have underestimated mood changes.
Hence, Cappiello et al. (Cappiello et al. 1997) did report a mood-enhancing effect on
YMRS scores.
In summary, until now, studies on ATD in bipolar patient were primary developed to
investigate the 5-HT modulatory properties of lithium treatment. To investigate the
serotonergic vulnerability in bipolar disorders per se, the ATD paradigm should be applied in
remitted bipolar patients off medication, which is ethically and practically impossible.
Therefore it is recommended to test the ATD paradigm in subjects with no prior psychiatric
diagnosis but at a genetic risk for bipolar disorders. A standard ATD paradigm including
control of confounding factors will enhance successful investigation of 5-HT vulnerability in
psychiatric disorders. The effects of ATD have now been reported in first-degree relatives of
unipolar depressives (Ellenbogen et al. 1999).
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First-degree relatives of depressed patients have been shown to report greater mood-lowering
effect after Trp depletion compared to healthy control subjects (Benkelfat et al. 1994;
Klaassen et al. 1999). As ATD in bipolar patients off medication is practically impossible,
ATI) needs to be done in healthy first-degree relatives of bipolar patients (type I and II) and
healthy matched controls. Mood changes are suggested to be more pronounced in subjects
with a positive family history of bipolar disorder compared to healthy matched controls.
Based on the available information on ATD paradigms previously applied in bipolar
disorders, a research protocol has been developed to investigate the effects of ATD in first-
degree relatives of bipolar patients. The study has a placebo-controlled, double blind, cross-
over experimental design. The research population includes both women and men: pre-
menopausul women will be tested in their follicular phase of the menstrual cycle. All subjects
are free of any psychiatric diagnosis but have at least one first-degree relative with bipolar
disorder, which is a mujor inclusion criterion. An explicit distinction is made between
relatives with a bipolar disorder type I or type II diagnosis according to DSMIV criteria.
Healthy matched control subjects are the reference group to whom mood effects are
compared. Number of participants will be at least 15 per group according to previous findings
in first-degree relatives in depressed patients (Klaassen et al. 1999). Treatment consists of a
75g Trp-deficient AA-drink (see also Young et al. 1985)). The placebo mixture is
supplemented with 3g Trp (i.e. 4%). Effects on mood (bimodal POMS) will be assessed
before and within 5-7 hours after ATD. In statistical analyses, the between group's factor
consists of three levels being no relative with bipolar disorder, a type I relative and a type II
relative. It is hypothesized that subjects at genetic risk for bipolar disorders show more
pronounced mood changes following ATD. The effects of ATD in first-degree relatives of
bipolar patients may give insight in the 5-HT vulnerability in bipolar disorders.
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CHAPTER 3
Effects of Acute Tryptophan Depletion on mood and cortisol release in
first-degree relatives of type I and type I I bipolar patients and healthy
matched controls
Abstract
Biological vulnerability for bipolar disorders (BD) in relatives of BD patients has not as yet
been established. Serotonergic vulnerability was studied, using Acute Tryptophan Depletion
(ATD), in healthy first-degree relatives of BD patients and healthy controls. The effects of
ATD on mood and cortisol release in 30 healthy adult, lifetime symptom free, unaffected
first-degree relatives of BD patients (Family History; FH) were compared with effects in 15
healthy matched controls in a placebo-controlled, double-blind, crossover design. During
ATD and placebo, salivary cortisol response was also assessed during a stress-inducing
speech task (S1ST).
First-degree relatives of type II BD patients (FH II) showed an elevation of mood, whereas
control subjects and relatives of type I BD patients (FH I) showed a lowering of mood after
ATD. ATD was followed by a decrease in cortisol level in both FH subgroups, but not in the
controls.
The results suggest a serotonergic vulnerability that affected mood in FH II subjects and
cortisol release in both FH I and FH II subjects.
S Sobczak. A Honig, NA Nicolson, WJ Riedel. Ateuro/wycAo/jAarmoco/ogy, accepted
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Introduction
In the pathophysiology of bipolar disorders (BD), several lines of evidence support the
hypothesis of an underlying dysfunction of the serotonergic system.
Increased platelet serotonin (5-hydroxytryptamine or 5-HT). a lower maximal velocity
(Vmax) of 5-HT platelet uptake and decreased central serotonergic neurotransmitter activity,
indicated by decreased 5HIAA/5-HT ratios, have been reported in untreated bipolar depressed
patients (Wirz Justice and Puhringer 1978; Marazzitiet al. 1991; Leakeetal. 1991; Young et
al. 1994). Polymorphism in the 5-HT-transporter. 5-HT receptors and the tryptophan
hydroxylasc gene have been associated with the pathophysiology of BD (Kunugi et al. 1997;
Oruc et al. 1997; Bellivier et al. 1998).
Acute Tryptophan depletion (ATD) is a direct method to investigate central serotonergic
vulnerability (Delgado ct al. 1994). In this procedure, a lowering of central 5-HT synthesis is
accomplished by giving subjects a 50-100 g balanced amino acid-drink (AA-drink),
composed of amino-acids. including large neutral amino acids (LNAAs: tyrosine, valine,
leucinc, isoleucinc and phcnylalanine), and devoid of tryptophan (Trp) (Young 1991). In
remitted depressed patients, ATD induced depressive symptoms (Smith 1997; Aberg-Wistedt
et al.1998; Moreno 2000). In healthy first-degree relatives of depressed patients. ATD
induced a modest lowering of mood, compared to healthy control subjects (Benkelfat et al.
1994; Klaassen et al. 1999). It thus appears that individuals without prior depressive episodes,
but at a genetic risk for depression, may be biologically predisposed to mood-lowering effects
of ATD.
Until now. little attention has been paid to the effects of ATD in BD, and results are
inconsistent (Sobczak et al. 2000). Cappiello et al. (1997) reported a significant increase in
manic symptoms in recently remitted 91 month) lithium-treated manic patients. In BD
patients who were stable for a longer period (1-15 years), ATD did not induce significant
mood chunges (Benkelfat et al. 1995; Cassidy et al. 1998; Hughes et al. 2000).
In BD patients abnormalities in cortisol homeostasis has been described. Cortisol may
therefore be used as a biological marker of BD. Serotonin increases cortisol release by
stimulating 5-HTuand 5-HT:A receptors in hippocampal areas (Nürnberger et al. 1990;
Swann et al. 1992; Vieta et al. 1999). Changes in cortisol following challenge with selective
5-HT stimulating agents are possible biological markers to assess brain 5-HT function (Abel
and Cleare 1999; Cleare et al., 1998). A blunted cortisol response following an intravenous
Tip challenge in BD patients, as compared to controls, provides evidence for brain 5-HT
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dysfunction (Nürnberger et al.. 1990). To our knowledge, the etVects of ATD on stress-
induced corttsol release have never been described, but might provide an important indicator
of central S-HT vulnerability. Symptoms (according to DSM IV) of BD psychopathology
might contribute to effects of ATD. Therefore we differentiated between relatives of BD type
I and BD type II patients. This is the first study of S-HT vulnerability in which such a
distinction was made between first-degree relatives of type I (FH 1) and type II BD (FH II)
patients.
To gain additional insight into the nature of this biological vulnerability, the current study
investigated serotonergic vulnerability, as reflected in mood and cortisol responses to ATD in
healthy first-degree relatives of BD patients (FH). ATD etTects in FH subjects were compared
with those in healthy matched controls. We hypothesized central serotonergic vulnerability in
FH subjects to be reflected by i) an elevation in mood, as has been reported in BD patients, ii)
more pronounced blunting of stress-induced cortisol release following ATD compared to
controls iii) mood and cortisol effects of ATD were hypothesized to be different in 111 I and
FH II subjects.
Methods
Subjects were first-degree relatives of BD patients and healthy matched controls (see Table I).
Family members were recruited via BD patients in treatment at the Department of Psychiatry,
University Hospital Maastricht, via the consumer organization for manic-depressive patients
and their families, and via advertisements in local newspapers. Healthy control subjects were
also recruited via a newspaper advertisement.
Of the 47 subjects who enrolled in the study, 2 subjects in the FH group were excluded during
the experiment because of intolerance of the drink.
The included subjects were 30 FH (8 men and 22 women) and 15 controls (4 men, 11
women), aged 19-64 years. Table 1 shows demographic characteristics of all subjects who
completed the experiment. Relatives were daughters (n=l 1), sons (n=4), siblings (n=4),
mothers (n=8) and fathers (n=3). Nineteen had a first-degree relative with a BD type I
diagnosis, and eleven subjects were relatives of BD type II patients. Control subject were
successfully matched to FH subjects with respect to age, body mass index (BMI) and
intelligence quotient (IQ). There were no differences between FH subjects and controls with
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respect to number of pre-menopausal versus postmenopausal women or to use of oral
anticonceptives or other medication. Overall, 22 female subjects were pre-menopausal and 11
were postmenopausal. Seven women used oral anticonceptives. Seven subjects were taking
medication with no interference on ATD or cortisol.
Table I Demographic characteristics, bipolar disorder family loading (I", 2™* and 3"" degree), SCL-90, Young
Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HDRS), total scores and General Behavior
Inventory (GBI) scores of the subjects; mean (tSE).
(mean i sc)
Women
Men
RH. of Type 1
Kcl. of Type I I
hamlly member»:
Ilipolur disorder
A|je
iy
BMI
SCI .-90
drpreulon
YMRS
HDRS
C.BI
depression
manla/hypomania
hiphasic
FH
n=22
n-8
n-19
n=l 1
1.3
4 l . 4 i 2.6
I I 7.2 ±2.0
24.7 ± 0.6
103.5 ±2.4
IK 6 *0.6
1.2 ±0.4
1.4 ±0.3
55.7 ±1.7
23.9 ± 0.7
8.3 ± 0.4
Conlrob
n-ll
n-4
0.0
40.3 ± 4.0
I17.3±4.1
24.3 ± 0.9
100.3 ± 2.7
17.1 ±0.3
0.9 ± 0.4
1.2 ±0.4
53.6 ± 2.7
24.6 ±1.8
8.3 ±0.7
The study used a placebo-controlled, double blind, crossover design. The within subjects-
factor treatment condition consisted of two levels: placebo and ATD. The order of treatment
was balanced over two test days, spaced 1-2 weeks apart. The between-subjects factor FH
differentiated subjects with (FH) or without (controls) at least one first-degree relative with
BD. A further distinction was made between having a relative with a type I or type II BD (FH
1 vs. FH II).
To eliminate possible bias due to premenstrual symptoms, all pre-menopausal women were
tested in the follicular phase of the menstrual cycle (Menkes et al. 1994; Rasgon et al. 2000).
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The Trp-<ieficient AA-drink contained a total of 75g of different ammo acids with the
amounts of each specific amino acid according to the proportions described by Young ct al.
(1985): 4.lg L-alanine. 2.4gglycine. 2.4g L-histidine. 6.0g L-isolcucine. 10 Ig L-leucine.
6.7g L-lysine, 4.3g L-phenylalanine. 9.2g L-proline. 5.2 L-senne. 4.3g t.-threomne. 5.2g L-
tyrosine, 6.7g L-valine. 3.7g L-arginine. 2.0g L-cysteine. 3.0g L-mcihioninc. The placebo
mixture contained the same ammo-acids, plus 3.0g tryptophan. To provide caloric energy, 20g
of a maltodexthn (MD/ fat mix) (33% sunflower and 67% maltodcxtnn) wus added. Both
drinks were prepared by adding 300ml tap water with the addition of strawberry or banana
flavoring to compensate for the unpleasant taste (see also Schmitt et al. 2000).
In the FH group, the main inclusion criterion was having at least one first-degree relative with
BD. Control subjects were free of any psychopathologic family loading. To assess FH, all
subjects were interviewed with an abbreviated version of the Family History Research
Diagnostic Criteria (FHRDC) (Endicott et al.1975). Individual diagnoses (type 1 or type II
BD, according to DSMIV) of the patients were verified via each patient's own psychiatrist.
All participants were given a standardized psychiatric examination (Mini International
Neuropsychiatric Interview; MINI) (Sheehan 1994) to determine the present psychiatric state,
according to DSM IV criteria. The 17-item Hamilton Depression Rating Scale (HDRS)
(Hamilton 1967), the Young Mania Rating Scale (YMRS) (Young et al. 1978) and the SCL-
90 (Arrindell and Ettema 1986) were used to verify the absence of depressive, manic and
general psychiatric symptomatology. As an extra check on psychopathology, all subjects
filled out the General Behavior Inventory (GBI), which identifies lifetime sub-clinical
affective symptoms (Depue et al. 1981; Depue et al. 1985; Depue et al.1989; Klein et
al. 1986). Included control and FH subjects did not differ on GBI scores, which meant that
they were successfully matched (see Table 1).
Exclusion criteria were current or past use of psychopharmacological medication, lifetime
psychiatric disorder including alcohol or drug abuse, current active physical illness, lactation
and pregnancy. Physical health was assessed by means of a health questionnaire, a standard
physical examination by a physician and a urine screening. The urine test (Combur®)
included assessment of leukocytes, nitrite, pH, protein, glucose, ketones, urobilinogen.
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bilirubin and erythrocytes. A Quick View, one-step pregnancy test (Quidel®) was carried out
in female subjects to check for unsuspected pregnancy.
One control subject was matched with 2 FH subjects with respect to sex, age, BMI and IQ.
Intelligence (IQ) was estimated using Groninger Intelligence Test (GIT) subtasks
(Vocabulary, Mental Rotation, Mental Arithmetic and Word Analogies) (Luteijn 1966).
The Medical Ethics Committee of the Academic Hospital of Maastricht approved the study.
All participants gave written informed consent.
On each test day, the subjects arrived at 8:30 a.m. after an overnight fast. At 10:00 a.m. (to)
(all limcpoints t(-)x refer to X hours (before) after to) the subjects were administered the AA-
drink, which had to be consumed within two hours. At tj, all subjects ate a protein-poor lunch
which consisted of protein-free bread, tomatoes, marmalade, apples, oranges and herbal tea or
decaffeinated coffee.
Mood assessment was completed at baseline at 8:45 am (t.i), and at t? and t?. The SIST started
at U 7s when the effects of ATD were expected to be present. Three baseline cortisol
measurements were collected before the SIST, at ts, t ^ and U75. After the SIST, saliva
cortisol samples were taken every 15 minutes; at t?, 17.35, t?.s and finally at t? 75. Previous
studies (van Eck et al., 1996) showed cortisol response to the SIST to be maximal during this
time interval.
Blood samples were taken twice, at to and at t<,5. Blood pressure and pulse rate were assessed
before mood rating at to» and at tj,
Afoorf awewmfn/.v
Mood was assessed with the abbreviated bimodal Profile of Mood States (POMS) (McNair et
al. 1971) and the Bond & Lader (B&L) (Bond and Lader 1974) visual analogue scales. The
POMS consists of 32 bipolar sets of adjectives, which measure 5 mood dimensions: anger,
depression, fatigue, tension and vigor.
The B&L is composed of 16 mood items, which measure alertness, contentment, and
calmness.
/«<A«-/»g S/xwA Tos* ( V
The SIST consisted of a 5-minute oral presentation, in front of a video-camera, preceded by
10 minutes of preparation. In a slightly modified version of the task used by van Eck et at.
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(1996). subjects were first given a list of 4 mood terms. Three parallel versions of the list
were available. Subjects were instructed to elaborate on personal experiences evoked by these
mood terms and were told that the speech would be video-recorded lor later evaluation by a
panel of psychiatrists and psychologists (van Eck et al. 19%; Nicolson et al. 1997). After the
screening a SIST practice session, in which an identical version of the mood term list was
used. At the end of the second test day subjects were debriefed.
Sa/ivorv cw/uo/ mmswre men«
Saliva was collected with a cotton roll (Salivette X, Sarstedt). Unccntnfuged samplet war«
stored at -20°C until analysis. Free cortisol levels were determined in duplicate by direct
radioimmunoassay. using an HPLC-purified preparation of cortisol-3-CMO-histamine '*'l
(Ansseau etal. 1984; Sulon. personal communication).
Severity of side effects was determined by a questionnaire with 17 items rated on 4-point
scales. The total sum of reported complaints represents the overall seventy of side effects.
Serwm ammo ac;<&
Serum was taken by venapuncture in sodium heparin tubes. Blood samples were immediately
set on ice and centrifuged (3000 rpm, 10 minutes) within one hour. Plasma samples were
mixed with sulfasalicyl acid and frozen at -80°C until analysis. Total concentrations of plasma
Trp and ratio of Trp: LNAAs were determined by high-performance liquid chromatography
(HPLC) (van Eijk et al. 1993).
Outcome variables were analyzed using General Linear Model (GLM) for repeated measures.
Within-subjects factor was treatment (2 levels: ATD or piacebo); the between-subjects factor
was family history (3 levels: controls, FH I, or FH II). Univariate contrasts were used to test
the primary hypothesis of difference between controls and FH subjects (controls vs. FH I + II)
as well as the hypotheses of differences between controls and FH I and FH II relatives
separately (controls vs. FH I and controls vs. FH II). Differences in baseline values between
test sessions were assessed using GLM. When no baseline differences were found, baseline
values were left out of analyses.
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Cortisol values were '"log-transformed prior to statistical testing, since cortisol distributions
were skewed. Missing values were corrected by using mean of previous and next cortisol
values.
Wilcoxon Matched-Pairs Signcd-Ranks Test was used to test differences in physical
complaints. Statistical analyses were performed with SPSS 9.0 for Windows.
Results
Due to procedural difficulties 1.4% of serum samples were missing.
Plasma Trp concentrations and ratio Trp: LNAAs did not differ at baseline between groups or
treatment conditions, but decreased significantly [F( 1.28)= 151.11, p<0.001] overtime in the
ATI) condition. Relative to baseline. ATD resulted in a 57% decrease in plasma Trp and a
70% decrease in ratio Trp: LNAAs. After receiving placebo, there was a 36% increase in
plasma Trp and 1.0% increase in the ratio Trp: LNAAs. Results are summarized in Figure 1.
Ratio L-Trp: LNAA's Plasma Trp
0.12
0.1
II.IIK
o.o:
DATO
Time (hrs) Time(hrs)
Figure I. Mean (i SE) serum ratio Trp LNAAs (right) and Trp concentrations (left), at to and l».s. • p = 0.05.
One subjects was excluded from the analyses due to 2 missing POMS scores.
At baseline. POMS scores did not differ significantly between FH and controls or
experimental conditions. Figure 2 shows the mood response after ATD compared to placebo.
Controls and I'M I did not differ in ATD induced mood response, but compared to these
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groups, FH I! subjects reported an overall improvement in mood, indicated by the POMS total
score [fR4O)=3.35. p<0.05), a decrease in fatigue (Fl2.40)=3.o5. pvO.O5| and a trend
towards lower anger [F!(2,4O)=3.13, p<0.»). This is an overall effect; within each FH group
mood changes following ATD were no« significant. There was no main effect of ATD, overall
interaction effect of FH with ATD, or effect of treatment order.
Scores on B&L subscales did not differ at baseline and after ATD between experimental
conditions or FH groups.
Difference POMS Tool (core (P rranu» ATI))
f
Time(hrs)
Figure 2. Effect (mean ±SE) of type BD (C, control subjects; first-degree relatives; FH I and FH II subjects) and
ATD on POMS total score at ts and t7. Values are corrected for placebo (P).
Cbr/üo/ measurement
Cbrtwo/ response to rAe S/57"
In both ATD and placebo conditions, cortisol levels increased over time in response to the
SIST [F(6,36)=3.60, p<0.05], A cortisol peak occurred immediately after the speech (t7).
Compared to pre-speech levels (ts), cortisol was increased by a mean of 21%. The three
groups did not differ in pre-speech cortisol levels or in the magnitude of the SIST-induced
cortisol response.
Figure 3 shows the effect of ATD on cortisol release compared to placebo (the cortisol values
in the placebo condition were subtracted).
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In FH subjects (both FH I and FH II) ATD resulted in a significant decrease in cortisol
[F( 1,28)=5.26, p<0.05] compared to placebo. In controls cortisol was lower after ATD
compared to placebo. There were no effects of treatment order.
Of the 630 cortisol samples, 0.4% were missing; two subjects (1 FH and 1 control) were not
included in cortisol data analyses, because of extremely high cortisol levels (above 1600
nmol/1) probably in response to difficulties in taking blood.
Effects of ATD on Cortisol (ATD minus P)
Tinw(hn)
Figure 3. SlST-induced cortisol response after ATD (mean ± SE), expressed as difference from the placebo (P)
condition. Effect of family history (FH) (C, control subjects) on salivary cortisol (10-log concentration: yg/dl).
Somatic s/de e#Sr/.v
Sum of reported side effects did not differ at baseline or between the two experimental
conditions. Correlation analysis of B&L and POMS mood ratings with side effects revealed
no significant correlations of sum complaints with mood changes following ATD.
Pearson's correlation analyses showed no significant associations between ATD-induced
cortisol response and changes in mood ratings.
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Discussion
The aim of the study was to investigate central 5-HT vulnerability in first-degree relatives of
BD patients following a double-blind placebo-controlled ATD paradigm. Plasma ratio Tip:
LNAAs and Trp decreased significantly, which indicates an adequate ATD. Tyrosine
availability did not appear to have interfered with the etTects of ATD. as levels did not differ
between experimental conditions.
We found no overall differences between controls and FH subjects in ATD-induccd mood
response. However, FH II subjects reported a tendency to mood elevation, whereas KH I
subjects and controls experienced a slight mood lowering following ATD. Side etTects were
unlikely to have interfered with mood changes after ATD. as the sum of reported side effects
did not differ between ATD and placebo.
There are no studies available that describe effects of ATD on different types of BD. Our
results are in line with a previous report of elevated mood in recently remitted HI) patients,
who were not further differentiated as type I or type II. following ATD (C'appicllo el al.
1997).
Previous studies of ATD in BD patients suggest that BD patients who were recently in
remission were more vulnerable to the effects of ATD compared to BD patients who were in
remission for a longer period (Benkelfat et al., 1995; Cappiello et al. 1997). It was suggested
that successful short-term lithium treatment was more dependent on 5-HT availability than
successful long-term prophylaxis with lithium. This implies a strong influence of'state'
variables on vulnerability to ATD in BD patients. However previous studies on ATD in BD
patients did not include healthy subjects as a control group and drawing conclusions about
'trait' influence on mood changes following ATD is therefore hampered.
ATD-induced mood lowering in depressed patients and their first-degree relatives suggest
central serotonergic vulnerability (Klaassen et al. 1999; Delgado et al. 1991). We suggest that
mood changes after ATD in FH II subjects might be explained by the same vulnerability. The
discrepancy that FH II of BD patients report an increase in mood whereas relatives of
unipolar patients report a decrease in mood may possibly be due to vulnerability to mania in
FH II subjects. Both mania and depression have been associated with hyposerotonergic
activity (Goodwin, 1990; Price, 1990; Young et al., 1994).
Suicide has also been associated with low central 5-HT (Pfeffer et al. 1998; Asberg 1997).
Meltzer et al. (1984) described an increased serotonergic vulnerability in depressed patients
with a history of suicidal activity.
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Higher rates of suicide has been described in BD type II compared to BD type 1 patients
(Rihmer and Pestality 1999). It is speculated that suicide is another independent factor which
may contribute to serotonergic vulnerability in BD type II psychophysiology.
Compared to controls, FH I subjects did not show mood changes after ATD, which may
suggest a biological distinction between BD type I and type II. FH I subjects are characterized
by cognitive deficits (Sobczak et al. in press). Cognitive dysfunctions in BD patients show a
pattern similar to schizophrenia (Krabbendam et al. 2000). Cognitive deficits have been
described in FH I and not in FH II subjects (Sobczak et al. in press). It was suggested that BD
type I share more similarities with a primary psychotic spectrum whereas BD type II is
characterized by primary affective symptoms. This hypothesis appears to be consistent with
the absence of mood changes observed in schizophrenic patients after ATD (Sharma et al.
1997). Inconsistent findings of previous studies on ATD in BD may possibly be due to a
failure to take differences in BD type I and BD type II into account.
The significant decrease in cortisol release in FH subjects following ATD suggests a 5-HT
vulnerability in FH subjects affecting the HPA-axis. Decrease in cortisol response is
consistent with previous described changes in 5-HT responsivity in BD (Vieta et al. 1999) a
blunted cortisol response has been described in BD compared to controls following
intravenous Trp challenge (Nürnberger et al. 1990).
ATD-induced blunted cortisol response might have been attenuated due to the weak stress-
inducing effect of the SIST procedure. The cortisol peak after the SIST (21%) was modest
compared to the previously reported (±) 90% increase in saliva cortisol concentrations (van
Hck et al. 1996) possibly due to procedural differences in our experiment. First, we used a
modified and perhaps less stressful version of the SIST; in the van Eck et al. study (1996),
subjects were unaware that they would be asked to deliver a speech. Second, our subjects
underwent the SIST three times: once as a training procedure, once after ATD, and once after
placebo.
The ATD-induced mood changes are not likely to be attributable to changes in cortisol
release. First, correlation analyses revealed no significant association. Second, the reported
mood changes were specific for FH II subjects, whereas the cortisol response did not differ
between FH I or FH II subjects. Third, mood ratings showed no differences between
assessments immediately before and after the SIST.
In conclusion, this study provides evidence for 5-HT vulnerability affecting the HPA-axis and
mood in FH subjects. The 5-HT vulnerability affecting mood was present only in FH II
subjects and not in FH 1 subjects. This is consistent with a primarily psychotic
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psychopathology in BD type I and a primarily affective psychopathology in BD type II
patients.
These findings should be replicated in a larger research population with BD type I and type II
patients as well as their relatives.
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CHAPTER 4
Cognition following acute tryptophan depletion: differences between first-
degree relatives of bipolar disorder patients and matched healthy control
volunteers
Abstract
Serotonergic circuits have been proposed to mediate cognitive processes, particularly learning
and memory. Cognitive impairment is often seen in bipolar disorders (BD), in relation to a
possible lowered serotonergic turnover. We investigated the effects of Acute Tryptophan
Depletion (ATD) on cognitive performance in healthy first-degree relatives of bipolar patients
(FH) (n=30) and matched controls (n=15) in a placebo-controlled, double-blind cross-over
design. Performance on planning, memory and attention tasks were assessed at baseline and 5
hours after ATD. Following ATD, speed of information processing on the planning task was
impaired in the FH group but not in the control group. FH subjects with a BD type I relative
(FH I) showed impairments in planning and memory, independent of ATD. In all subjects,
ATD impaired long-term memory performance and speed of information processing. ATD
did not affect short-term memory and focused and divided attention. The results suggest
serotonergic vulnerability affecting frontal lobe areas in FH subjects, indicated by impaired
planning. Biological vulnerability in FH I subjects is reflected in impaired planning and
memory performance. In conclusion, the cognitive dysfunctions in FH subjects indicate an
endophenotype constituting a possible biological marker in bipolar psychopathology.
Serotonin appears to be involved in speed of information processing, verbal and visual
memory and learning processes.
S Sobczak, WJ Riedel, L Booij, M aan het Rot, NEP Deutz, A Honig. Avr/io/og/ca/ A/a/icw, in press
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Introduction
Cognitive deficits have been demonstrated in bipolar disorders (BD) (Savard et al. 1980;
Wolfe et al. 1987; Coffman et at. 1990; Krabbendam et al. 2000). In mania, planning and
reaction time (RT) were impaired (Murphy et al. 1999).
In euthymic BD patients, persistent impairments on visuo-spatial recognition, verbal and
nonverbal memory and learning, retrieval of information from semantic memory an increased
RT on a planning task has been described (Coffman et al. 1990; Atre-Vaidya et al. 1998;
Fcrrier et al. 1999; Rubinsztein et al. 2000).
Cognitive impairments persist during remission of BD (van Gorp et al. 1998; Ferner et al.
1999; Krabbendam et al. 2000; Rubinsztein et al. 2000; Scott et al. 2000) bipolar disorder
type I patients and patients with recurrent episodes appear to show more impairments
(Kessing 199«; Krabbendam et al. 2000; Martinez-Aran et al. 2000). These impairments
might be considered as indicators of a biological vulnerability. In remitted BD patients, poor
cognitive performance may be partly attributed to medical treatment. Therefore, assessment of
cognitive performance in first-degree relatives of BD patients may provide a powerful design
to investigate a biological vulnerability in BD (Sobczak et al. 2000).
There is ample evidence showing serotonin (5-hydroxytryptamine, 5-HT) to be involved in
cognitive functioning, particularly learning, memory and attention processes (Young et al.
1985). Acute Tryptophan Depletion (ATD) is a direct method to investigate the effects of an
acute reduction in central 5-HT activity. Following ATD, a relapse in remitted depressed
patients hus been reported (Salomon et al. 1993; Berman et al. 1996; Smith et al. 1997;
Aberg-Wistedt et al. 1998). Healthy first-degree relatives of depressed patients, show
pronounced mood-lowering effects of ATD compared to healthy control subjects, indicating a
serotonergic vulnerability (Benkelfat et al. 1994; Klaassen et al. 1999).
In healthy subjects no effects of ATD on planning has been found (Park et al. 1994; Schmitt
et al. 2000) but an impaired long-term memory following ATD, including deficits in learning
and memory consolidation has been reported (Park et al. 1994; Riedel et al. 1999; Rogers et
al. 1999; Schmitt et al. 2000; Rubinsztein et al. 2001). After ATD an improvement in focused
attention (Coull et al. 1995; Schmitt et al. 2000) has been reported, which might be explained
by a decrease in 5-HT mediated inhibition of cholinergic neurones in frontal brain areas
(Grafman 1995; Stecklcr et al. 1995; Riekkinen et al. 1998).
The present study was designed to investigate differences in 5-HT-related cognitive
performance in first-degree relatives of BD patients and healthy matched controls. Four
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specific hypotheses were formulated. The first was subjects with at least one first-degree
relative with BD will be more vulnerable to the effects of ATD compared to healthy control
subjects. Therefore, they will exhibit more pronounced changes in cognitive performance
following ATD. Cognitive performance was measured in the domains of planning, learning,
working memory, retrieval, focused and divided attention and concept-shifting.
Secondly, a biological vulnerability in first-degree relatives of BD patients may be reflected
in impaired cognitive performance on planning and memory tasks, independent of ATI).
Third, a biological distinction between relatives of bipolar type I (HI I) and type II (FH II)
patients may be reflected in differences between their cognitive Performances and
vulnerability to ATD.
Fourth, based on previous findings (Riedel et al. 19W; Schmitt et al. 2000) we hypothesized
ATD to improve, frontal lobe mediated, planning, retrieval and focused attention performance
and to impair learning and memory. In order to further study the previous observation of the
ATD effect on consolidation memory, we compared a new picture learning task with the
previously used word learning task.
Methods
Family members were recruited via BD patients treated at the Department of Psychiatry,
Academic Hospital Maastricht, via the local organization for manic-depressive patients and
their families, and via advertisements in local newspapers. Healthy controls were also
recruited via a newspaper advertisements.
Thirty first-degree relatives of BD patients (8 men and 22 women) and 15 controls (4 men, 11
women) completed the experiment, aged 19 to 64 years (mean 41.0, sd 14.4 years). Relatives
were daughters (n=l 1), sons (n=4), siblings (n=4), mothers (n=8) and fathers (n=3). Nineteen
had a first-degree relative with a BD type I diagnosis, and 11 subjects were relatives of BD
type II patients (see table 1). The FH and control group did not differ significantly with
respect to age, Body Mass Index (BMI) or Intelligence Quotient (IQ).
Of the female subjects, 22 were pre-menopausal and 11 were postmenopausal.
Seven women used oral anticonceptives and 7 were taking other medicines which were
unlikely to interfere with ATD.
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Table I. Demographic characteristics of first-degree relatives (FH) and control subjects (C), inclusive mean
number of bipolar depressed family members (I", 2™* and 3"* degree), age, IQ and body mass index (BM1); mean
(±SE).
± se)
Measure FH
Women
Men
KM 1
KM II
family memberi:
liipolur disorder
Age
IQ
BMI
n-22
n-8
n-19
o- l l
1.3
41.40* 2.57
117.17 ± 1.95
24.71 ±0.63
n = l l
n=4
0.0
40.33 ± 4.00
117.27* 4.14
24.34 ±0.91
The study used a placebo-controlled, double blind, crossover design.
The within subjects-factor was treatment and consisted of two levels: placebo and ATD. The
order of treatment was balanced over two test days, spaced 1-2 weeks apart. The between-
subjects factor was FH of BD: with (FH) or without (controls) at least one first-degree relative
with bipolar disorder. A distinction was made between having a relative with a type I or type
II bipolar disorder.
The AA-drink consisted of fifteen amino acids in a total amount of 75g. Relative contribution
(per 100g) of each amino acid is according to the composition described by Young et al.
(1985) with the exception of the amount Trp in the placebo mixture. We used a mixture of 4%
Trp compared to 2.3% Trp in Young et al. (1985). The preparation of the drink was according
to the procedure described in Schmitt et al. (2000).
In the FH group, the main inclusion criterion was having at least one first degree relative with
BD. Control subjects were free from any psychopathologic family loading. They were
matched with FH subjects with respect to gender, age. Body Mass Index (BM1) and
Intelligence Quotient (IQ). IQ was estimated using four Groninger Intelligence Test (GIT)
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subtasks (Vocabulary. Mental Rotation. Mental Arithmetic and Word Analogies) (Luteijn
1966).
All subjects were interviewed with an abbreviated version or the Family History Research
Diagnostic Criteria (FHRDC) to assess their family history (Hndieolt et al. 1475). lndi\ idual
diagnoses (type I or type II according to DSMIV) of the patients were verified via the
patient's psychiatrist.
Exclusion criteria were: current or history of use of psychopharmacological medication.
lifetime psychiatric disorder including alcohol or drug abuse, current active physical illness.
lactation and pregnancy. Physical health was assessed by means of a health questionnaire, a
standard physical examination by a physician and a urine screening. A Quick View. Quidel®,
one-step pregnancy test was carried out in female subjects to check for unsuspected
pregnancy.
The Mini International Ncuropsychiatric Interview (MINI) was taken to examine current
psychiatric disorders and alcohol or drug abuse (Sheehan 1994).
The Medical Hthics Committee of the Academic Hospital of Maastricht approved the study.
All participants signed informed consent.
To eliminate response bias due to premenstrual symptoms, all pre-menopausal women were
tested in the follicular phase of the menstrual cycle (Menkes et al. 1994; Rasgon et al. 2000).
Figure 1 provides an overview of the test day.
On each test day, subjects arrived at 8.30 a.m. after an overnight fast. At 10:00 a.m. (to) they
were offered the AA-drink, which had to be ingested within two hours (all timepoints tx refer
to x hours after to). At t:, a protein-poor lunch was offered (Riedel et al. 1999).
To correct for possible differences in cognitive performance between test sessions, a baseline
cognitive assessment was completed before to on each test day. Thereafter cognitive
performance was assessed at ts. Memory performance was also assessed at t7 25.
Blood samples were taken at to and at t* 5. A physical complaints list was given each time
prior to cognitive assessments (at to. ts and t7).
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VVLT, Word learning 1 WLT, Word learning 2
Cognition
15.00ht5 B
Cognition
17.00ht7
Figure t. Schematic overview or the tent day; Cognition was assessed three times: at to. it and K There were 2
occasions ot word learning in the Visual Verbal Learning Task (VVLT), before (word learning I), and after
ATU (word learning 2). B, blood sampling.
The cognitive test battery took approximately 60 minutes to complete and consisted of tasks
measuring planning, learning, working memory, retrieval, concept-shifting, focused attention
and divided attention.
/VUWM/MJJ: Com/m/er/W 7V»wr «/Zom/on from/JU-TO/J (Ow«>n <?/a/. /995,)
Planning capacity was assessed by a modified version of the One-touch Tower of London
(TOL) task (Owen et al. 1995). Subjects were initially trained the original non-computerised-
TOL (Shallicc 1982). Thereafter, the compu-TOL was introduced. On a computer screen, two
arrays of differently coloured balls (red, yellow and blue) on sticks were presented. Each
arrangement contained three balls, which were held on three sticks; one stick had a capacity of
3 balls, another could hold two balls and the third could only hold I ball. The subjects were
requested to indicate the minimal number of steps necessary to rearrange the balls on the
lower configuration to match the arrangement presented on the top half of the screen. The
rules were: each ball must be replaced separately, once a ball is taken it must be put on a stick,
it is not allowed to put one ball aside and continue with the other balls.
The subjects had to rearrange the balls in their mind's eye (without actually moving the balls).
Once the ideal solution had been found, the subject was asked to count the number of moves
and then respond by pressing the appropriate response button, which represented the right
number of steps necessary to rearrange the balls (2-5). The subjects were instructed to respond
as quickly as possible, but the importance of accuracy was emphasised. They were told that
performance on the task was indicated by both response accuracy and RT.
SO
There was no response-feedback and subjects were allowed to give just one response to each
problem.
The complexity of the task is dependent on the minimal number of steps the rearrangement
can be achieved; 2.3,4 and 5 steps. The training consisted of 10 tnals and the test of 40 trials,
with an equal number of 2. 3. 4 and 5-stcps problems, which were presented in a fixed pseudo-
random order. Only once subjects were entirely familiar with the rules governing the
movements of balls and the concepts involved with solving the compu-TOL problems, were
they given the test form of the task.
The dependent measure was the median RT as a function of difficulty. The number of errors
was checked for confounding of the RT variable.
£«<!m/>tg.' Wrtwr traming Tost f/>£7) fieait
The PLT is a modified version of Rey's Visual design learning Test (Lezak 1995). In the PLT.
subjects were presented three identical trials of 20 unrelated highly recognizable pictures
which were easy to verbalise (e.g. 'bridge' or "tiger"). Pictures were taken from a large file of
pictures used in a longitudinal study of cognitive ageing of the Brain and Behaviour Institute
in Maastricht. The pictures were showed on a computer screen in black ink on a white
background and were presented for 1000ms at a rate of one picture per 2000ms.
Each trial ended with a free verbal recall of the pictures (immediate recall). Thirty minutes
after the third trial, the subject was requested to recall as many pictures as possible without
prior presentation (delayed recall). A yes/no recognition test, consisting of 10 previously
presented and 10 new (comparable) pictures, was given after the delayed recall test. The
pictures remained on the screen for 2000 msec or until the subject responded. Another 1000
msec elapsed before the next picture appeared on the screen. After presentation of each picture
the subject had to respond "YES / NO" as fast as possible to indicate recognition of the picture
(delayed recognition). The RT was recorded. According to the theory of signal detection
(Pollack and Norman 1964), the proportion of correctly recognised (cr) and the proportion of
falsely recognised (fr) words constitute the nonparametric sensitivity measure: A' = 1 - 1/4
(fir/cr + (1 -cr)/( 1 -fr)). A' is in fact the proportion of correctly recognised pictures, corrected for
the subject's response tendency. Because the distribution of A' is skewed due to a ceiling
effect, A' was arcsin transformed before being used in statistical analysis.
In this study a picture list was presented at t<i. After ts, delayed recall and recognition were
assessed once, after a delay of 30 minutes (ts^s).
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The variables used were the total number of pictures recalled after the first three trials as a
measure of short-term memory, the number of correct pictures on delayed free recall as a
measure of retrieval from long-term memory (LTM), A' as a measure of storage in LTM, and
the median RT of correctly recognised target pictures as a measure of speed of retrieval from
LTM. In each of the assessments, a different pictures list was presented. The lists were
comparable with regard to their level of abstraction and the affective tone of the pictures.
Parallel lists were order balanced over assessments.
77rr Kiiuo/ Kerfei/ tram/ng
The VVLT is an adapted version of the Rey Auditory Verbal Learning Test (Lezak 1995). The
test consisted of a list of 30 monosyllabic words (18 nouns and 12 adjectives) in Dutch, which
were presented in three trials on a computer screen. The words occur very frequently in Dutch
and are acquired early in life. Items were presented in the same sequence at a rate of one per 2
seconds. Parallel picture lists were order balanced over the assessments.
The procedure of the VVLT was comparable with that of the PLT; assessments of immediate
recall, delayed recall and recognition were according the same procedure. A yes/no
recognition lest, consisting of 15 former words and 15 new but comparable words, was given
alter the delayed recall test. There were two different recognition lists to probe the long-term
retention of each 30 word list. Both recognition lists consisted of 15 formerly learned and 15
new words (distractors).
The dependent variables were: total number of correct words on immediate recall and delayed
recall. A" und median RT on the recognition task (see PLT).
In this study word lists were presented at to and at t7. After to, delayed recall and recognition
were assessed twice: once after a delay of 30 minutes (to-x>) and once after a delay of 7 hours
(to->7>. After the list presented at t? recall and recognition were assessed only once after a delay
of 30 minutcs(t7.^7).
For learning tasks, measures of delayed recall of words and pictures were considered primary
outcome measures, as previous observations had consistently shown that these measures are
most sensitive to AID (Riedel et al. 1W9; Schmitt et al. 2000; Rubinsztein et al. 2001). The
primary outcome measures were corrected for multiple testing of the same hypothesis
according to the rule of Bonferroni. The measures of immediate recall, recognition and RT
were considered secondary and are reported for the purpose of completeness of description.
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The subjects were briefly shown a set of I. 2 or 3 letters and told to memorise them. This is
called the "memory set" (Stemberg 1969). Subjects then saw a series of 75 letters, each of
them displayed for 1000 msec on a VCR connected to an IBM computer, followed by another
2000 msec before the next letter appeared. Half of the presented letters were part of the
memory set and had to be recognised as targets. The subjects' task was to decide and respond
as rapidly as possible by pressing either 'YES' or 'NO' to indicate whether or not each
successive letter was one of those contained in the memory set. The median RT of correct
responses (targets and non-targets) was taken as a dependent variable. Memory sets and
stimulus sets were generated at random by the computer before each subtask. RT on set size
regression functions were calculated. This function is defined by the equation RT~A * Ss+B,
in which: A = slope of the function (i.e. the amount of extra time needed per item in the
memory set), Ss = size of the memory set. and B = intercept with the Y-axis. The dependent
variable in this task is RT as a function of memory load. Effects of independent variables on
intercept u t «vptessed as main effects and effects on slope are expressed as interaction
effects of independent variables with memory load.
The fluency test measures strategy-driven retrieval of information from semantic memory.
The subjects are asked to report as many four-letter words with the same initial letter within
one minute. The number of correct words was taken as the dependent measure. Nonsense
words were not accepted, but names, conjugations and plurals were allowed. Starting letters
were H, L, M and R (Schmitt et al. 2000).
w: Srroop Co/our » W 7eir (SCB7? fSfroop
The SCWT consisted of three cards displaying each 100 stimuli. The first card included colour
names, which had to be read as quickly as possible. The second card included colour patches,
which had to be named. The third card consisted of colour names printed in incongruously
coloured ink. The colour of the ink had to be named, without paying attention to the word
itself. Outcome variable was interference. The interference, which indicates focused attention
and response inhibition, denotes the percentage extra time needed to complete the third card
relative to the average of the first and second card: (time card III / [(time card I + time card II)
/ 2)] * 100% (Houx et al. 1993).
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The DLT tests both focused attention and divided attention for auditory stimuli. Subjects
received different auditory stimuli simultaneously through a headphone on each side. The
stimuli were numbers ranging from 1-200, presented at random and natural-speech spoken by
a male voice. The test consisted of three subtasks in which the subjects were instructed to
focus to either the numbers presented in the right ear or the left ear while ignoring the
contralateral ear, or to focus both ears simultaneously, and remember the numbers presented.
The subtask in which the subjects were instructed to focus to one side, while ignoring the
other, can be regarded as a measure of focused attention. The subtask in which the subjects
had to remember the numbers presented in both ears is a divided attention task. Each of the
three subtasks is made up of 9 trials, in which 2, 3 or 4 stimuli pairs are presented in random
order. After each trial, the subject had to identify the presented numbers from a list of numbers
on a computer screen. The numbers included all presented numbers plus the same amount of
other, numbers (distracter stimuli). Measures were: total number of correct identifications,
total number of stimuli identified from the ignored side, and number of false alarms (not
presented at all).
on eucri suöiask was calculated 6y the A sensitivity measure (see PLT).
The AST consisted of three parts: on each test sheet 16 small circles (diameter = 15 mm) were
grouped in a large circle (diameter = 8 cm) in which numbers (a), letters (b) or both (c) were
presented in a fixed random order (Jolles et al. 1995). The subject were requested to cross out
the items as fast as possible in correct climbing order. In parts a and b the subjects had to
connect the numbers (1-2-3 etc.) and the letters (a-b-c etc.) respectively. In part C, the subject
was requested to alternate between these sequences (l-a-2-b etc.) in climbing number and
letter order (c). The interference, indicated slowing due to shifting between concepts and was
calculated by subtracting the average time to complete both tasks separately (a and b) from the
time necessary to complete both tasks alternately.
Plasma was taken by venapuncture in sodium heparin tubes. Blood samples were set on ice
immediately and centrifuged (3000rpm, 10 minutes) within one hour. Plasma (100^1) was
mixed with 4 mg sulfasalicyl acid and were frozen at -80°C until analysis. Total
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concentrations of plasma Trp and ratio of Tip: Large Neutral Amino Acids (LNAAs) were
determined by high-performance liquid chromatography (HPLC) (van Eijk et al.
Sbina/ir
The severity of side effects was determined by a 4-point scales questionnaire, which included
17 items. The sum of reported complaints represents the overall severity of side effects.
Primary and secondary outcome variables were analyzed using General Linear Model (GLM)
of variance for repeated measures. Within subjects factors were treatment condition (ATD or
placebo) and time (U t?). Between subjects factor was family history (controls. KM I and
FH II). Univariate contrasts were used to analyze differences between controls and KM subject
groups. Differences in cognitive baseline values between test-sessions were assessed using
general linear model. In case of absence of baseline differences between treatment
conditions, baseline values were left out of analyses.
Order of treatment (placebo/ATD or ATD/placebo) was included as between-subjects factor
in the analysis to check for a possible interaction with treatment.
Where possible, for each task, only one statistical test was used. For Tower of London and
Steinberg tasks, this was accomplished by analyzing RT as a function of task difficulty and
test this model as a function of the independent variables: ATD, time and FH. For tests
yielding multiple variables a distinction was made for primary outcome measures for
hypothesis testing and secondary outcome measures, reported for descriptive purposes.
Multiple tests of the same domain, such as Verbal Learning and Picture Learning and Stroop
Interference and Auditory Focused Attention, were subjected to Bonferroni correction. All
statistical analyses were performed with SPSS 9.0 for Windows.
Results
Baseline performance on all cognitive tests did not differ, between experimental conditions.
Of the 47 subjects (32 FH, 15 controls) who were included, 2 subjects in the FH group
withdrew during the experiment because of intolerance to the drink
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Table 2 shows mean (± se) of dependent variables of the primary and secondary outcome
measures of learning, working memory, retrieval, divided and focused attention and concept
shifting.
On the TOL, there was a significant interaction of family history and ATD on median RT
[F( 1,39) = 4.71, p<0.05]; FH subjects showed an increase in RT after ATD, whereas it tended
to decrease in the control group. The three-way interaction of family history by number of
steps by ATD on median RT was significant [F(3,37) = 4.79, p<0.05]. Univariate contrasts
showed that this effect can be ascribed to a significant increase in median RT of the 4-steps
problems [F( 1,42) = 7.26, p<0.05] exclusively in the FH group and not in the control group.
Sec figure 2. Furthermore, a significant interaction of FH and ATD [F(2,38) = 3.81, p<0.05]
indicated that the slowing of RT following ATD in the FH group could be mainly attributed to
an increase in RT in the FH I group.
S '
number of steps
p O - F H placebo
^ - • - F H ATD
©—C placebo
• -CATD
Figure 2. Effect of family history and ATD and placebo on TOL performance in FH and control (C) subjects;
median reaction time (mean ±SE) of the correct responses in the 2, 3, 4 and S steps problems.
There was a main effect of FH [fT(2,38) = 6.47, p<0.05] on median RT; FH I subjects showed
an overall impaired RT compared to the other groups (p< 0.05).
There was no effects of ATD and FH on number of correct responses. Missing values were
1.4%.
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Learmwg
ATD significantly impaired delayed recall performance on the W L T at t?^? ( / \ 1.41) » 5.95.
p<0.025] and on the PLT at t5[F(l,43) = 4.04. p<0.05; significant after Bonferroni correction).
The effect on the PLT showed a treatment by order interaction | f \ l ,43) - 13.50. p<0.005);
subjects receiving the ATD mixture on day I. showed greater impairment after ATD
compared to subjects receiving the ATD mixture on day 2.
ATD did not affect picture recognition and tended to impair word recognition A' (/-"11.37) •
4.78. p<0.05] at ti^7. but this effect was not maintained after Bonferroni correction.
There were no significant effects of ATD on delayed recall and recognition of words teamed
at baseline and recalled at to (to^o) and t? (to.,'). No effects of ATD on immediate recall and
speed (RT) of recognition were present for both tasks. Missing values on the VVl.T were
0.4%. Missing values on the PLT were 4.2%.
Family history did not affect performance on the PLT. In the VVLT. subjects in the FH group
showed impaired recognition performance , at to^o {/"![ 1.40) * 4.63, p<0.05] and at to^7
(ft 1.42) = 4.94, p<0.05). Recognition RT was impaired in FH at t? for words learned at
«o(U> ->?) [^(2.36) = 3.34. p<0.05]: FH I performed worse (p<0.05) compared to III II
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Table 2: Mean (± SE) of the primary and secondary outcome measures of learning, working memory, retrieval,
divided and focused attention and concept shifting at I» and t- Results are broken down by family history
(control*; C/FM 1/ FH II) and treatment (ATD/ placebo; P). • /r<0.05
(mean t so)
Measure
Learning
Delayed recall
(«words)
Immediate recall
(»word»)
Recognition A' (%)
Recognition RT (ms)
Delayed recall ( I T •?)
(«word«)
Delayed recall (t«---?)
(«words)
Immediate recall
(«words)
Recognition A' (t7->7>
(%)
Recognition A' (to->7>
(%)
Recognition RT (t7->7>
Recognition RT(t«->i)
(ms)
Working memorv
Afemory «unnrnj;
Slope (ms)
1-intercept (ms)
Retrieval
No. correct words (*)
Treatment
A T D *
P
ATD
P
ATD
P
ATD
f
A T D *
P
ATD
P
ATD
P
ATD
P
ATD
P
ATD
P
ATD
P
ATD
P
A T D *
P
ATD
P
Focuued and divided attention
SCHT
Interference (•»)
f) /T
Left side A" (%)
Right side A' (*4)
SiHhsidesA(S)
*^"'^ ^^ *™a' B n l n i l i O
Interference (%)
ATD
P
ATD
P
ATD
P
ATD
P
ATD
P
13.5(0.8)
15.2(0.7)
38.8(2.1)
41.7(1.9)
98(1)
97(1)
640(38)
633(26)
11.1(1.8)
12.5(1.9)
11.3(1.9)
11.4(1.6)
39.7(4.0)
43.0(3.9)
89(3)
91(2)
89(3)
87(4)
647(19)
640(19)
632(19)
634(22)
46(5)
43(5)
448(13)
436(13)
13.8(1.1)
13.6(1.2)
56.9(5.2)
62.0(4.9)
90(3)
91(2)
92(2)
92(5)
85(10)
85(10)
46.3(8.3)
42.9(7.3)
FH 1 fn=20>
13.0(1.0)
13.4(0.8)
13.0(1.0)
13.4(0.8)
97(2)
97(1)
728(47)
677(24)
7.2(5.7)
8.2(5.9)
7.2(5.2)*
6.4(4.7)
30.3(12.6)
31.4(12.6)
85(4)*
89(2)
82(3)
79(3)
686(26)
673(24)
701(25)*
681(23)
48(5)
41(5)
460(14)
469(12)
13.2(1.1)
11.8(0.9)
58.9(4.4)
60.4(5.4)
84(4)
84(4)
91(2)
85(5)
84(1)
84(9)
31.5(5.4)
49.3(9.6)
FH I I fn=/OJ
40.1(2.0)
40.2(1.8)
13.8(0.9)
13.6(1.4)
99(1)
99(1)
587(23)
603(28)
9.00(1.86)
12.70(2.02)
9.40(1.31)
8.80(1.55)
38.30(3.31)
39.40(3.52)
84(4)
92(3)
86(2)
87(4)
614(27)
591(17)
602(22)
627(33)
35(5)
37(5)
432(18)
425(13)
11.6(1.4)
12.4(1.2)
56.2(5.6)
59.2(3.0)
85(4)
85(4)
90(2)
87(4)
85(2)
82(1)
66.8(20.5)
39.4(13 2)
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As expected, the memory' scanning task showed increased RT with increasing memory set
[f\2.4I) = 177.21. p<0.001]. Independent of memory set. ATD significantly slowed overall
RT [f( 1.42) = 4.67. p<0.05], which indicated an ATD-induced increased intercept of the
memory scanning regression function. No effect on slope of the memory scanning function
was present. There was a trend significant interaction of family history and ATI) on RT in the
memory scanning task; the slowing of RT tended to he due to a decrease in RT after ATI) in
control subjects and not in FH subject. No main effect of family history was present. Missing
values were 0.5%.
No effects of ATD and FH were seen on the fluency task.
FocusiPt/ ana" Drvufa/ ,4/tention
The interference measure of the Stroop test did not show significant effects of ATI) and FH.
On the DLT. subjects performed better on the 'right' subtask No significant effects of A l l )
and FH on performance of the subtasks 'right', 'left' or 'both' were present. Missing vulues on
ihe DLT were 1.1%.
Cowcep/ 5/ii/ting
No effects of ATD and FH were seen on AST.
.Somatic swfe ^
Sum of reported physical complaints did not differ at baseline and between both experimental
conditions.
f /asma 7>p /eve/s
Plasma Trp concentrations and ratio Trp: LNAAs did not differ at baseline between groups
and experimental conditions, but decreased significantly [F( 1,28)= 151.11, p<0.001] in the
ATD condition. Relative to baseline, ATD resulted in a 57% decrease in plasma Trp and 70%
decrease in ratio Trp: LNAAs. After receiving placebo, there was a 36% increase in plasma
Trp and 1.0% increase in the ratio Trp: LNAAs. There was no effect of treatment order. As a
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consequence of difficulties in taking blood and during analyses, 1.4% of serum samples were
missing. Results are summarised in figure 3.
Ratio L-Trp: LNAA's
0.12
0.1
0.08
0.04
0.02
D M D
0 6.5
Time (hr»)
0 6.5
Time (hrs)
Figure 3. Mean (± SE) «erum ratio Trp/ L N A A J (right) and Trp concentrations (left), at baseline (to) and 6.5
hours (U<) after ATD and placebo (P).
Discussion
This is the first paper in which an investigation into 5-HT manipulation of cognitive
functioning in healthy first-degree relatives of BD patients is described. ATD resulted in
decreased RT on the compu-TOL, in FH subjects but not in control subjects. FH I subjects
showed impaired baseline RT and seemed to be most vulnerable to ATD-induced impairment
in planning.
Independent of ATD. deficits in planning RT, verbal memory recall and recognition were
found in FH I subjects only. In both FH and controls, ATD impaired delayed recall of visual
and verbal information.
In FH I. the initial suboptimal planning performance in FH I increases vulnerability to
detrimental effects of ATD. This may explain why this subgroup shows an impairment in
planning following ATD, whereas previous studies did not describe effects of ATD on
planning in healthy subjects (Park et al. 1994; Schmitt et al. 2000).
These results suggest a 5-HT mediated frontal lobe dysfunction as a biological marker in BD
type I (Damasio 1994; Dagher ct al. 1999; Elliott et al. 1997; Murphy et al. 1999; Owen et al.
1990; Rubinsztein et at. 2000). Rubinsztein et al. (2000) showed planning dysfunction in BD
patients to improve after clinical recovery (Rubinsztein et al. 2000). As remission is
associated with an increase in 5-HT activity (Risch and Nemeroff 1992), our results arc
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consistent with the improvement in planning after clinical recovery. Planning deficits in BD
might thus be related to a depleted 5-HT state.
Compared to FH II and controls, the FH I subjects showed cognitive deficits on planning and
memory tasks. Indeed, in BD patients planning (or executive functions) and memory
dysfunctions has been repeatedly described (Henry et al. 1973; van Ciorp et al. 1 998; Ferricr
et al. 1999; Murphy et al. 1999; Krabbendam et al. 2000; Rubins/tcin ct al. 2000).
Independent of mood state, specific impairments in memory or executive functions has been
described in remitted BD patients (Atre-Vaidya et al. 1998; Ferner et al. 1999; Krubbendam
et al. 2000; Rubinsztein et al. 2000). Cognitive impairments in FH I. implicate Bl) type I
patients to show more specific similarities of a primary' psychotic spectrum, in contrast to Bt)
type II patients, showing a spectrum more consistent with an affective pattern (Morice 1990;
Krabbendam et al. 2000; Sobczak et al. accepted). Cognitive deficits may be regarded as a
trait marker in BD type 1 psychopathology.
Cognitive deficits in BD may be partially explained by abnormalities in functional brain
structures or metabolism. In BD patients, frontal and temporal lobe areas show decreased
blood flow, metabolism, neuroanatomic changes and a reduction in midsagittal bruin
structures (Coffman et al. 1990), which has been linked to cognitive performance
VBuchsbauvrv \9fcfe; Soar«, and Mann 1997, Ro> c\ a\. 1998, Sink cl al. 199»). The specific
cognitive impairments in FH subjects, found in this study, may reflect some underlying
neuroanatomic abnormality.
In this study, ATD specifically impaired memory performance. The results on memory tasks
might confirm previous findings demonstrating ATD-induced impairments of delayed verbal
recognition (Riedel et al. 1999; Schmitt et al. 2000), visual recognition memory (Rubinsztein
et al. 2001), visuospatial paired associative learning (Park et al. 1994) and stimulus-reward
associations learning (Rogers et al. 1999).
After ATD long-term memory (LTM) performance was impaired for verbal and visual stimuli
on the VVLT and PLT. On the PLT, impairments on LTM were smaller than on the VVLT.
This attenuated effect may be explained by learning pictures being easier than learning words.
The high percentage of correct responses (97%) on the PLT recognition, suggests a possible
ceiling effect. Consequently the PLT might be less sensitive to register changes in memory
performance. The simplicity of picture learning might be attributed to the more differentiating
and specific characteristics of pictures over words (Emmelkamp and Zimmer 1994). The
easier learning of pictures over words may be reflected in a faster consolidation of visual
information, which is a possible explanation of the trend significance impairments in short-
61
term memory (STM) performance on the PLT (Izquierdo 1989; Jolicoeur and Dell'Acqua
1998). The decrease in power and sensitivity of the PLT compared to the VVLT might be
further related to less stimuli (one third smaller) presented, no baseline measures or
interference of procedural learning. No effects of ATD were present on retrieval of
information acquired earlier in life, indicated by the Fluency. This provides further evidence
for a consolidation deficit underlying the impairment in LTM. The impaired LTM
performance for both verbal and visual stimuli, confirms the robustness of the effects of ATD
on memory.
The impaired RT in the memory scanning task showed a decrease in the intercept and not in
the slope of the memory scanning function, which provides evidence for a decrease in
sensorimotor speed after ATD. This detrimental effect of ATD on RT does not seem to be
related to changes in impulsivity, as no effects of ATD on number of errors was found. These
findings are in line with the results of a study of Hasbroucq et al. (1997), who showed
lowering of 5-HT to impair RT, whereas stimulation of central 5-HT activity shortens RT in
healthy volunteers following Fluvoxamine treatment (Hasbroucq et al. 1997). However, a lack
of influence of ATD on memory scanning in normal controls and first-degree relatives of
depressed patients was previously found in our lab (Riedel et al. 1999).
Our study found no effects on attention indicated by DLT, AST and Stroop. A significant
improvement in focused attention on Stroop interference and DLT performance after ATD
has been described in healthy subjects (Schmitt et al. 2000). Table 2 shows that mean
interference tended to decrease following ATD, but this was not significant. In our study, an
attenuated improvement in attention following ATD may be due to differences in research
populations; Schmitt et al. included healthy young (aged 20-29 years) volunteers which were
free of any psychiatric family loading whereas our research population was heterogeneous
with respect to age, psychiatric family loading and thus possible cognitive performance (Houx
et al. 1992; Houx et al. 1993; Schmitt et al. 2000).
The cognitive effects of ATD were not expected to be due to changes in mood for 3 reasons;
there were no differences in baseline mood ratings between FH subjects, controls, ATD or
placebo. FH I subjects seemed to be more vulnerable to the cognitive effects of ATD whereas
mood effects of ATD were pronounced in FH II. correlation analyses revealed no significant
associations between mood and cognition. The effects on mood have been described
elsewhere (Sobczak et al. accepted).
ATD resulted in a significant decrease in plasma ratio Trp: LNAAs (70%) and Trp (57%)
levels. Tyrosine levels and the summated side-effects score did not differ between
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experimental conditions, therefore we suggest that both did not interfere with cognitive
effects of ATD.
In conclusion, this study shows ATD-induced planning impairment specifically in FH
subjects, indicating a specific serotonergic \ ulnerabilit> putativcly originating from frontal
lobe areas. FH 1 subjects performed worse on planning and memory tasks. These cognitive
dysfunctions may indicate an endophenotype constituting a possible biological marker in
bipolar psychopathology.
After ATD. the findings of a decrease in sensorimotor speed and LTM performance for both
visual and verbal stimuli confirm the robustness of the effects of ATD on memory and shows
that the deficits might not be modality-specific. Imaging studies should provide further
evidence on the meaning of cognitive deficits in subjects at risk for BD.
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CHAPTER 5
Serotonergic dysregulation in bipolar disorders; a literature review of
serotonergic challenge studies
Abstract
Serotonin (5-hydroxytryptamine; 5-HT) and endocrine abnormalities have been repcutedly
reported in bipolar disorders (BD). Useful methods to investigate a 5-HT responmvity and the
interaction with neuroendocrine functioning are provided by acute 5-HT challenge and
depletion paradigms. In this review 5-HT challenges are limited to paradigms that stimulate 5-
HT activity in bipolar disorders.
Literature was searched for in electronic libraries: MEDLINE and PSYCHLIT, period 1966 to
2001. Papers describing effects of an acute 5-HT challenge on neuroendocrine functioning in
BD patients were selected.
Review of the literature revealed 15 studies; 5 papers described the effects of 5-HT challenges
in manic BD patients, 4 papers in euthymic BD and 7 in depressed BD patients. The reviewed
5-HT challenge paradigms are acute administration of oral and intravenous (i.v.) dosage of
d,l-fenfluramine, tryptophan, 5-hydroxytryptophan, ipsapirone and buspirone. There were no
papers which investigated neuroendocrine effects of m-chlorophenylpiperazine, clomipramine
and citalopram in BD patients and were therefore not reviewed.
The literature on 5-HT challenge procedures in BD shows evidence for a blunted prolactin
(PRL) in mania and depression as well as blunted cortisol in euthymic BD patients. This
suggests that in both mania and depression similar changes in the 5-HT system are involved.
It is speculated that blunting of cortisol responses in euthymic BD patients may be a result of
chronically altered 5-HT functioning, whereas changes in PRL release following 5-HT
challenges reflect more state-dependent changes in 5-HT activity. 5-HT responsivity in BD
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patients has also been associated with pharmacological treatment, suicidal behavior, weight
loss and age. Recommendations for future research are given.
S Sobczak, A Honig, MA van Ouinen, WJ Riedel. Ä//m/ar Dijocrferj, accepted
Introduction
Serotonergic (5-HT) dysregulation has been shown to be involved in the pathophysiology of
various psychiatric disorders like depression, anxiety disorders, schizophrenia and bipolar
disorders (BD). Neuroendocrine parameters such as prolactin (PRL), growth hormone (GH),
cortisol and adrenocorticotropic hormone (ACTH) have been used extensively as biological
markers of 5-HT functioning in the brain. 5-HT precursors, releasing agents, reuptake
inhibitors, receptor agonists and antagonists have been used as probes in neuroendocrine tests
to study 5-HT. These agents can be regarded as 5-HT challenge agents.
In this paper we evaluate the 5-HT dysregulation hypothesis in BD as assessed by those
challenge paradigms which enhance central 5-HT functioning. Various challenge paradigms
and methodological procedures will be reviewed and recommendations for future
investigations given.
5-HT containing raphe nuclei innervate hypothalamic areas and stimulate release of PRL, GH,
cortisol and ACTH (Quattrone et al. 1978; Abel andCleare 1999; Cleare et al. 1996; Goekoop
1998; Nürnberger et al. 1990; Cleare et al. 1998). ACTH and cortisol release is mediated by
activation of 5-HTi, and 5-HTa receptors in the raphe - Hypothalamus Pituitary Adrenal-axis
(HPA-axis) pathway (Goekoop 1998; Stahl et al. 1993). GH and PRL release reflects
hypothalamic-pituitary stimulation by 5-HT. 5-HT increases release of GH releasing hormone
(GHRH) but has no direct effect on somatostatin (which decreases GH release) (Murakami et
al. 1986; Chihara et al. 1979). Stimulating effects of 5-HT on PRL might be a net effect of
5-HT:,, 2c receptor stimulation and dopaminergic inhibition in the hypothalamus in humans
(Di Renzo et al. 1989; Van de Kar et al. 1989; McNeilly 1986).
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5-HT stimulating agents can be used to assess central 5-HT receptor sensitivity in
hypothalamic areas by measuring endocrine responses, e.g. cortisol, PRL. (iM and ACTH.
Central 5-HT responsivity can be reflected in levels of hormones released (hypothalamic
5-HT pathway) following administration of a challenge agent (Stahl 1W8). Relatively high
neuroendocrine responses may be indicative of post-synapiic receptor hyperscnsitivity
whereas low responses suggest post-synaptic receptor hyposcnsitivity (Riedel et al. 2002).
Changes in postsynaptic signal transduction, presynaptic transporter mechanisms and
dysregulation of the endocrine pathways themselves may also be responsible for changes in
hormonal release following S-HT stimulation (Coccaro et al. 1989; Mann et al. 1992). For
example, in depressed patients compared to healthy controls reduced cortisol and PR I.
responses have been described in response to fenfluraminc challenge (Abel el al. 1997; Clcare
et al. 19%. Cleare and Bond 1995; Lucey ct al. 1992).
In this paper, studies applying agents which enhance 5-HT activity will be reviewed, i.e. 5-HT
precursors. 5-HT reuptake inhibitors. 5-HT agonists, and 5-HT releasing drugs (Yatham and
Steiner 1993).
5-HT abnormalities have repeatedly been reported in BD; e.g. increased 5-HT in platelets, a
lower maximal velocity (Vmax) of 5-HT platelet uptake, decreased brain 5-HT
neurotransmitter activity and decreased postmortem 5H1AA/5-HT ratios (Wirz Justice and
Puhringer 1978; Marazziti et al. 1991; Leake et al. 1991; Prange et al. 1974; Price et al. 1990;
Young et al. 1994). Central 5-HT dysregulation in BD may be due to altered 5-HT
metabolism, modifications in the 5-HT-transporter gene, 5-HT receptor genes or tryptophan
hydroxylase gene (Ginns et al. 1996; Kunugi et al. 1997; Oruc et al. 1997; Bellivier et al.
1998; Lesch et al. 1995). 5-HT responsivity has also been described in healthy first-degree
relatives of BD patients; more pronounced effects on cortisol and mood following Acute
Tryptophan Depletion (ATD) were seen in first-degree relatives of BD patients compared to
matched controls (Sobczak et al. accepted).
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Methods
Literature was searched for in electronic libraries: MEDLINE and PSYCHLFT, period 1966 to
2001. The used keywords were: 'serotonin', 'bipolar disorder', 'depression*, 'prolactin',
'cortisol', 'growth hormone' and 'ACTH'. To complement the selection all references in
found articles were checked. Papers describing effects of an acute S-HT challenge on
neurocndocrine functioning and mood in BD patients were selected. The following 5-HT
challenge procedures were reported: d,l-fenf!uramine, tryptophan (Trp), 5-hydroxytryptophan
(5-MTP), ipsapirone, buspironc, m-chlorophenylpiperazine (m-CPP), clomipramine and
citalopram.
Selection criteria for papers were: I) papers must include BD patients and control groups, 2)
and must present results separately for BD and unipolar depression (UD) patients, 3) number
of BD patients must be 5 or more.
Results
Twenty-eight papers describing 5-HT challenge procedures in BD were found. Of these
papers 11 were not reviewed because they did not fulfill the selection criteria. Eliminated
papers were on d,l-fcnfiuraminc (Shapira et al.. 1992; Lerer et al.. 1996; Lichtenberg et al.,
IW2 (2); Kasper et al. 1990), Trp (Price et al. 1989; Price et al. 1998). 5-HTP (Ansseau et al.
1983; Maes et al. 1997), m-CPP (Anand et al. 1994; Price et al. 1997), clomipramine (Golden
et al. 1992) and citalopram (Kapitany et al. 1999).
Fifteen papers were reviewed: 5 papers studied the effects of 5-HT challenges in manic BD
patients, 4 papers in euthymic BD and 7 in depressed BD patients. Reviewed 5-HT challenge
paradigms are acute administration of oral and intravenous (i.v.) dosage of: d.l-fenfluramine
(n= 7). tryptophan (n= 3), 5-hydroxytryptophan (n= 3) ipsapirone (n=l) and buspirone (n= 1).
An overview of these papers is given in table 1.
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Table I: Studies using acute S-HT challenge procedures in bipolar disorder (BD) patients I iU\-i> on mood.
prolactin (PRU. cottooi (CRT), adrcnoconicotrocwc hormone (ACTH) and growth hormone (GH). Study
dcatf^K were: parallel group« (PG). placebo-controlled ( K ) , dcnible -Mind (DB). eross-mer design (CO).
Control subjects (C), unipolar depressed (UD), dysthemic (Dk schizophrenic (S) and *chi/oaffcctive (SA)
patterns
Krfereace (««Subject» Medication Mrthod Ikttgn Remit
MBkftaarrtal. IW3
M u c M l n t l . 1990
L u l l •»»!«« «1.1992(21
Thakorc ci al.. 1996
Yatham cl al.. 1996
Manneletal.. 1997
Tnplophan
Deakinelal.. 1990
Nürnberger ei al., 1990
Price leal.. 1991
5-bvdratytrvDtoDhan
Mellzer el al.. 1984.
1983. 1984(1.11.111)
Takahashi et a l , 1973
Westenberg el a l . 1982
Binpironr
"lilhamcial.. 1994
luanlrBM«
USsfi!£SI£
Shuheial. 1998
cutfiymic »BD
» t
eurtt>i»c 11 BO
JJC
«qrowd <BO.
2*l'O
4epmM<t » B »
1» I t). *r«%tr«K
21 C
manic: 9 BD
9C
manic: 10 BD
IOC
euthymic: 1S BD.
5 D. 9 SA. 1 other
depressed: 5 BD,
31 UD
22 C
euthvmic: 11 BD
I4C
depressed: 17 BD,
109 UD
58 C
depressed: 14 BD.
22 UD. 8SA,
manic: 2IBD
25 C
manic: 5 BD
depressed: 9UD
depressed: 5 BD.
9UD
12C
rtunic: 11 BD
M C
depressed: 8 BD
26 C
M m »
Mourn
no
no
lithium, haloperidol
amitriptyline.
no
lithium, carbamazepine.
no
no
no
no
no
no
no
no
«On«oral «U>
M»«enM<Ul
Ma«onl
«0»a<ml
30mgoral (d)
60mg oral (d.l 1
6Umgoral (d.l)
100mg/kg i.V.
50mg/kg i.v.
7gi.v.
200mgoral
200mgonl
5.0gcnl
0.5mg/kgoral
0.3mg/kg oral
R i
m
PU
K DB <O
PC
P(;
PG
PG
PC DB CO
PG
PG
PG
PG
PG
PG
Nod i n PKt
in HD on IIUMUB.
•Wnnaw« HU. in • i t n t r i i . HI) und t'l».
fi*«i« >••! rat m »n.«. m^i. ( KT
Hhnwdrid nnfUoMM HI) («141101
Blunted PKI . hut mil CRT r»|»»»c in UD
No difference* between groups. I'KI.. CRT
Illumed C R1 response in BD
RluntcdOHandPKI in HI) (and UD)
Mlunted AC I I I and C RT in BD.
no differences in PRI.. CiH
Blunted ON in 1)1) (< UD). No effect! PRI
Enhanced CRT in depressed and manic
BD patients. Increase related to suicide
attempt* and non-pnychotic features.
Enhanced GH response in manic BD
No stimulating effect» on GH. I Nil. I'KI.,
CRT
No differencei in PRL response between
groups
No difference» CRT resoorac
between groups
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5-HT releasing agents
I) d.l-Fenfluramine
The effects of d.l-fenfluramine on the 5-HT system are multiple; it increases presynaptic
5-HT release, blocks synaptic 5-HT reuptake, and stimulates postsynaptic 5-HT receptors
(5-HT 2*?c) both directly and indirectly (Rowland and Carlton 1986). The 4/- isomer of
fenfluramine has been suggested to act more selectively on the 5-HT system compared to the
/-isomer (Rowland and Carlton 1986; Goodwin et al. 1994), but Coccaro et al. (1996)
concluded that d,l-fcnfluramine does not have a detectable effect on dopamine in men.
Fenfluramine is administrated orally (60mg d,l-mixture, 30 mg d-mixture) and appears to be
well tolerated by healthy subjects (Coccaro et al. 1988).
Thakore et al. (1996) used a 30 mg d-fenfluramine challenge, all other studies used 60 mg
oral d,l-fenfluramine.
In lithium-treated euthymic patients, there were no effects on PRL response (Muhlbauer
1984). Compared to UD patients, cortisol response was blunted in euthymic BD patients
using lithium and carbumczapinc (Mannel et al. 1997). Euthymic patients showed lower
baseline cortisol, and the d.l-fenfluramine induced cortisol response was exaggerated in
lithium treated BD patients compared to healthy control subjects (Muhlbauer and Muller-
Oerlinghauscn 1985).
In medicated manic BD patients, Thakore et al. (1996) found increased basal cortisol levels
and reduced (30 mg oral) d-fenfluramine induced PRL responses compared to control subjects
(Thakore et al. 1996). Yatham (1996) found no differences in baseline and d.l-fenfluramine
induced PRL and cortisol responses between medication-free manic patients and healthy
matched control subjects (Yatham 1996).
In medication-free depressive subjects, a blunted PRL response was found in BD and UD
patients compared to healthy control subjects (Lichtenberg et al. 1992 I). Mitchell et al (1990)
reported reduced basal PRL levels in medication-free BD patients compared to UD (Mitchell
etal. 1990).
In summary, following d.l-fenfluraminc there was a tendency to blunted PRL release in manic
and depressed BD patients off medication compared to healthy controls. In euthymic patients
off medication, PRL response was unchanged compared to healthy controls. Effects on
cortisol response following d.l-fenfluramine did not show clear differences between euthymic,
manic and depressed BD patients and controls.
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5-HT precursor»
2) Trvptophan (Trp)
Tip is the precursor of 5-HT. Tip loading stimulates the 5-HT system in an »specific way by
increasing the conversion of Trp to 5-HTP.
The essential ami no acid Trp administered / v causes a reliable increase in PKL and (ill
(Chamey et al.. 1982). Oral Trp administration results in a less pronounced increase PR I and
GH response (Power and Cowen 1992; Yatham and Steiner 1993; Westcnbcrg ct al. 1982).
The reported effective dosage of i.v. Trp is between 50 mg/kg and 100 mg/kg (Nürnberger et
al. 1990); gastrointestinal side effects can be expected at higher dosages (Nürnberger et al.
1990). Most prominent side effects are nausea, drowsiness and fatigue, which occur more
frequently at higher dosages (Yatham and Steiner 1993).
Blunted cortisol and ACTH responses to 50-mg/kg i.v. Trp were reported in medication-free
euthymic BD patients compared to healthy controls. There were no differences in PRL and
GH responses (Nürnberger et al. 1990).
There were no studies on Trp in manic BD patients. Compared to healthy controls, (ill and
PRL responses to 7.0g respectively 100-mg/kg i.v. Trp were blunted in both depressed BD
and UD patients (Price et al. 1991; Deakin et al. 1990).
In sum following Trp challenge, cortisol and ACTH responses were blunted in euthymic BD
patients compared to healthy controls. GH and PRL responses were lower in depressed BD
patients than in healthy control subjects.
3) 5-Hvdroxvtrvptophan (5-HTP)
5-HTP stimulates the 5-HT system aspecifically. 5-HTP is converted to 5-HT by the enzyme
amino acid decarboxylase. Due to the wide distribution of this enzyme in the brain, 5-HT is
not only synthesized in 5-HT neurons, but also in catecholaminergic neurons, acting as a false
catecholaminergic neurotransmitter (Van Praag et al. 1987).
5-HTP administered in high doses (> 150mg p.o.) influences PRL and GH release. 5-HTP
administered i.v. may cause severe side effects, especially at higher doses (van Vliet et al.
1996; den Boer and Westenberg 1990). Oral administration is less reliable as most 5-HTP is
degraded in the liver (Power and Cowen 1992; Ansseau et al. 1983; Westenberg et al. 1982).
Administration of a decarboxylase inhibitor after oral 5-HT administration is to be
recommended as this increases the availability of oral 5-HTP to the brain (van Praag et al.,
1976).
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With one exception, all studies used a 200mg oral 5HTP challenge. Westenberg et al. (1982)
found no changes in plasma hormones to a S.O g oral SHTP challenge (Westenberg et al.,
1982). No papers described effects of 5-HTP in euthymic BD patients.
In both medicated and medication-free manic BD patients, plasma GH and cortisol response
following oral 5-HTP were more pronounced compared to depressed UD patients (Takahashi
et al. 1973; Meltzer et al. 1983; Meltzer et al. 1984 I, 1984 II, 1984 III). Depressed BD
patients also showed an enhanced 5-HTP induced cortisol response compared to depressed
UD patients.
Tricyclic anlidcpressants (TCA) augmented the 5-HTP induced cortisol response whereas
lithium and monoamine oxidasc inhibitors (MAOI) attenuated this response (Meltzer et al.
1984 III). Increased cortisol response was associated with history of suicide attempts (Meltzer
et al. 1984 I; Meltzer et al. 1984 II).
Thus, compared to UD depressed patients, cortisol response to 5-HTP is increased in both
manic and depressed BD patients and GH response is increased in manic BD patients.
5-HT receptor agonists
4) Buspirone
Buspirone, u postsynaptic 5-HT|, receptor agonist, belongs to the azapirones (Power and
C'owen 1992). Oral buspirone administration (5-10 mg) has been shown to increase PRL
(Meltzer and Maes 1944; Anderson and C'owen 1992). However, effects on ACTH and
cortisol are not consistent and would not be suitable measures of 5-HT functioning (Yatham
and Steiner 1993). Buspirone also has demonstrated affinities for dopaminergic and a;
receptors (Yatham et al. 1999). Although buspirone may cause nausea and drowsiness, it is
generally well tolerated.
There were no studies on buspirone in euthymic or depressed BD patients. In unmedicated
manic BD patients, no differences in PRL response following 0.5-mg/kg oral buspirone were
found compared to healthy controls (Yatham 1994).
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5) Ipsapirone
Ipsapirone. a central acting pyrimidinylpipera/ine derivate is one of the a/apimnes. a group of
selective partial agonists of pre- and post-synaptic 5-HT|, receptors (Power and Cowen 1992).
Administered orally, ipsapirone (> 0 Img kg) produces a dose-dependent increase in plasma
cortisol and ACTH in healthy volunteers (Yatham et al 1999). HPA-axis activation following
ipsapirone administration provides a valid paradigm to evaluate both post- and presynnptic 5-
HTi, receptor functions ;« vm> (Lesch et al. I992). Oral administration (0.1 -0.3 mg kg) of
ipsapirone is generally well tolerated (Lesch et al. 1989). Typically single oral doses of 10
and 20 mg are reported in most studies.
No differences in cortisol responses were reported in unmedicatcd depressed BI) puticnts and
healthy control subjects following a 0.3 mg/kg oral ipsapirone probe (Shiah et al. 1998).
Effects of ipsapirone challenge in manic oreuthymic BI) patients were not reported.
Dhcimfon
The aim of this review was to investigate the 5-HT dysregulation hypothesis in BD patients
following 5-HT challenges.
In euthymic BD patients PRL response following d.l-fenfluramine and Tip were unchanged
compared to healthy controls (Mühlbauer et al., 1984; Nürnberger et al., 1990). Cortisol
responses following d,]-fenfluramine was blunted in euthymic BD compared to UD patients
(Mannel et al„ 1997). D,l-fenfluramine induced cortisol response in euthymic BD stabilized
on lithium patients was enhanced (Mühlbauer et al., 1985). Following Trp, cortisol and
ACTH responses were less pronounced in euthymic BD patients than in healthy controls
(Nürnberger et al., 1990).
In manic and depressed BD patients a tendency towards blunted PRL release following d,l-
fenfluramine (Thakore et al., 1996) and Trp (Mitchell et al., 1990; Lichtenberg et al., 1992
(2)) compared to UD patients and healthy controls was reported. Trp showed a blunted GH
response in depressed BD patients compared to healthy controls (Deakin et al.. I990; Price et
al., 1991). Following d.l-fenfluramine, cortisol response was unchanged in manic and
depressed BD patients as compared to UD patients and healthy controls. On the other hand,
stimulation with 5-HTP seems to enhance cortisol response in manic and depressed BD
patients as compared to UD patients and healthy controls. ACTH response to 5-HT challenges
was not investigated in manic and depressed BD patients.
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te o/<7/w.ts
The reported blunted PRL and cortisol responses following d,l-fenfluramine in manic and
depressed BD patients might be explained by pre- and / or post-synaptic changes. In keeping
with the classical indolamine hypothesis, blunting might be a result of a relative 5-HT deficit
at the synapse (Mann et al., 1995). Receptors and signal transduction at the post-synaptic
element might also be impaired, e.g. due to receptor desensitization, i.e. post-synaptic 5-HT21/
5-HTk (Goodall et al., 1993; Coccaro et al. 1996a; Riedel et al. 2002; Siever et al.1983). On
the other hand, blunted cortisol and PRL responses to d,l-fenfluramine might also be
indicative of reduced availability of presynaptic S-HT release and following increased
neuronal Tiring in depression and mania (Fishbein et al., 1989; Carboni and di Chiara, 1989).
The fact that PRL response was also blunted in depressed BD patients following Trp (Deakin
et al., 1990) makes the explanation of presynaptic 5-HT depletion less probable. It is also
suggested that cortisol hypersccretion in depression influences spontaneous as well as 5-HT
induced PRL release (Dinan and Scott, 1996). Hypersecretion of cortisol in manic and
depressed BD patients was found following 5-HTP challenge (Meltzer et al., 1984 I, II, III),
but these studies did not investigate PRL release. Mitchell et al. (1990) reported an increased
PRL response in BD compared to UD patients but no difference in cortisol response following
d,l-fenfluramine. These findings do not support a direct relationship between cortisol levels
and PRL release. Blunted neuroendocrine responses in both mania and depression described
in this review provides evidence for similar changes in brain 5-HT functioning contributing to
both mood states. Indeed, in BD patients both mania and depressive episodes have been
associated with reduced 5-HT activity (Marazziti et al. 1991; Young et al. 1994).
In the euthymic phase of BD, PRL response following d,l-fenfluramine and Trp does not
differ from healthy controls, suggesting a restabilisation of 5-HT functioning. Hence
following d,l-fenfluramine challenges cortisol response was lower in euthymic BD patients as
compared to UD patients (Mannel et al., 1997). Cortisol and ACTH responses were also
blunted following Trp in euthymic BD patients compared to healthy controls (Nürnberger et
al„ 1990).
Thus it seems that in euthymic BD patients 5-HT challenges result in blunted cortisol and
ACTH responses and no changes in PRL, whereas in mania and depression PRL secretion is
significantly blunted but no effects on cortisol. 5-HT controls the release of cortisol and
ACTH probably by direct stimulation of postsynaptic 5-HTi, receptors (Stahl 1992; Gilbert et
al., 1987). Possibly, functioning of 5-HT;, and 5-HT;c receptors are state-dependent whereby
sensitivity changes during manic and depressive episodes. It may be speculated that
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sensitivity of 5-HTu receptors arc more a trait phenomenon related to chronic 5-HT
dysfunctions (e.g. decreased presynaptic 5-HT release ) in BD developing during the course
of illness.
According to the kindling and stress-sensitization theory the number of illness episodes may
lead to structural neural changes, more neurutransmitter dysfunctions and may ultimately
influence vulnerability to future illness episodes (Post and Weiss. 1997). Vulnerability to 5-
HT dysfunctions may therefore be a direct consequence of history of illness episodes. Such a
relationship has been found in depressed patients by Booij et at. (submitted): in this study
mood lowering effects of ATD were positively related to number of illness episodes.
Another possible explanation might be that 5-HT dysregulation is not so much directly related
to the etiology of BD. but to certain disease-related factors such as suicidal behavior ((.'(Kairo
et al.. 1989; Malonc et al.. 1986; Cocarro and Kavoussi. 1994), co-morbid personality
disorders (Coccaro et al.. 1994 I. 1994 II), aggression and impulsivity (('occaro el al.. 1989).
Indeed, increased cortisol response to 5-HTP seemed to be related to suicidal behavior;
patients with a history of suicide attempts show an enhanced 5-HT induced cortisol response
(Meltzer et al. 1984 II; Meltzer et al. 1984 III). After ATD, 5-HT dysfunction has also been
related to suicidal behavior in depressed UD patients (Van der Does 2001; Booij et al.,
submitted).
Blunted PRL responses to Trp or d,l-fenfluramine in depressed patients has also been
associated with nonmelancholic features (Price et al., 1991), younger age (Mann et al., 1995;
Lerer et al., 1996) and weight-loss (Lichtenberg et al. 1992 I; Deakin et al. 1990).
Pnc/io/ropic merfic
5-HT responsivity in BD may change during pharmacological treatment and with an
increasing number of episodes. Indeed, after treatment with lithium and valproate an increase
in cortisol response to respectively d,l-fenfluramine (Mühlbauer et al., 1985) and 5-HTP
(Maes et al., 1997) has been reported. 5-HT responsivity to 5-HT challenges is thus dependent
on the concurrent use of psychotropic medication. Possibly, pharmacological treatment
induces post-synaptic sensitization of 5-HT receptors in the raphe- HPA pathway. Changes in
5-HT receptor sensitivity may then influence neuroendocrine responses to 5-HT challenges.
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In addition to central 5-HT responsivity, blunted or enhanced neuroendocrine response might
be explained by changes in peripheral 5-HT metabolism in BD. More rapid Trp clearance in
depressed patients compared to controls has been reported after Trp infusion (Deakin et al.
1990). Amamoto (1976) reported a delay in elevation of plasma 5-HT and 5H1AA
concentrations and a delay in 5HIAA urinary excretion in depressed BD patients compared to
control subjects (Amamoto and Sarai 1976).
Afc f/nx/o/og/ca/ conj/</era/(onj
The direct comparison of reviewed papers is hampered by differences in methodology:
First, a major complication in comparing the papers on 5-HT challenges is the use of different
5-HT challenge paradigms. Neuroendocrine responses depend very much on the specificity of
the applied 5-HT challenge agent. TCAs may interfere with dopaminergic and noradrenergic
systems and neuroendocrine effects may therefore partly be explained by changes in
calhccholaminergic neurotransmission (Yatham and Steiner, 1993; Van Praag et al. 1987).
5-HT precursors or 5-HT releasing drugs arc probably most valuable in the assessment of
overall 5-HT responsivity as these agents have stimulating effects on both pre- and post-
synuptic 5-HT receptors of all types. Selective agonists (e.g. 5-HTi,) activate the 5-HT system
more selectively and arc best used as an indicatation of 5-HT receptor sensitivity. Nowadays,
selective rcuptakc inhibitors seem to be most promising as acute 5-HT challenge agents;
citulopram significantly increases PRL and cortisol in healthy subjects (Kapitany et al. 1999).
Second, the lack of consistent findings in this review might be due to differences in research
populations, as some papers included only BD patients, other papers included mixed research
populations of both BD and UD patients. Drawing conclusions about 5-HT functioning in BD
from papers which included mixed research populations are therefore hazardous. No papers
specified a type I or type II BD diagnosis. There is some indication to the importance of this
issue as BD type II seem to be more associated with a central 5-HT dysfunction than BD
type 1 (Sobc/ak et al. accepted). Not all papers included healthy control subjects as a
reference group, some papers included only UD patients as controls. Selected patients also
differed in their mood state, i.e. manic, depressed or eulhymic.
Third, the use of psychotropic medication might have influenced neuroendocrine responding
to 5-HT challenges (Mannel et al.. 1997; Mühlbauer et al., 1984; Mühlbauer et al., 1985;
Thakore et al., 1996; Meltzer et al. 1984 11; Meltzer et al. 1984 III; Maes et al. 1997).
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To draw general conclusions on effects of 5-HT challenge procedures in BD patients the
following methodological recommendations should be considered:
1) Despite their popularity, 5-HT challenge agents ha\c been criticized. Agents which
have a more overall 5-HT stimulating effects may be very useful in the exploration of
5-HT responsivity in BD. Probes with specific receptor agonists like ipsapironc and
buspirone give only an indication of post-synaptic 5-HT functioning, whereas non-
selective receptor agonists and such as m-chlorophcnylpipcrazinc (mC'PP),
d.l-fenfluramine, Trp and 5-HTP act both presynaptically and postsynaptically and
provide therefore an overall indication of the 'net' activity of the 5-HT system (Van
Praag et al.. 1987; Coccaro and Kavoussi. 1994) Both d- and d.l-fenfluraminc are not
available anymore because of side-effects, increased risk for hart valve pulhology and
pulmonary hypertension (McCann et al.. 1997). Trp and 5-HTP have been criticized
for their interference with noradrenergic and dopaminergic ncurotransmilter systems
(Yaiham and Steiner. 1993; van Praag et al.. 19K7). Reuptake-inhibitors may be useful
5-HT challenge agents. Intravenous clomipraminc challenge (-10 mg). a tricyclic
antidepressant (TCA), leads to consistent increases (dose-dependent) in PRL and
cortisol levels in healthy volunteers (Manji et al. 1991) and demonstrated a blunting of
PRL response, as well as a trend toward blunted ACTH and cortisol response in BD
and UD depressed patients (Golden et al. 1992). Compared to clomipramine
citalopram is a highly specific selective serotonin reuptake inhibitor (SSRI) (Stahl
1998); 20 mg i.v. citalopram challenge shows similar results in healthy subjects and
depressed patients (Kapitany et al. 1999). Therefore citalopram challenge should be
preferred over clomipramine challenge as a 5-HT probe.
2) As 5-HT responsivity has been suggested to differ between BD type I and BD type II
(Sobczak et al.. accepted), the effects of 5-HT challenges should preferably be
investigated in research populations composed of equal number of both types of BD
patients. Diagnoses of BD should preferably be made following structured psychiatric
interview.
3) To investigate 5-HT responsivity in BD. patients should be off-medication for at least
2 weeks, or preferably drug-naive. Alternatively, 5-HT challenge paradigms might be
investigated in healthy first-degree relatives of BD patients (Sobczak et al. 2000).
4) Preferably, papers should control for factors which have been described to interfere
with neuroendocrine effects to 5-HT challenge agents, i.e. psychotropic medication,
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number of illness episodes, illness episode, melancholia, history of refractoriness to
medical treatment, co-morbid personality disorders, psychotic features, phase of
menstrual cycle, recent weight loss and family history of affective disorders (Coccaro
et al., 1989; Clear and Bond 1997; O, Keane et a!.. 1991; Fitzgerald et al., 1997).
5) Alterations in 5-HT activity can induce changes in mood and cognition (Riedel et al.
1999; Klaassen et al. 1999). Changes in mood following 5-HT challenges do not
necessary correlate with hormonal responses (Sobczak et al. accepted 2). As central 5-
HT responsivity might be reflected by changes in mood and cognition after
stimulation of the 5-HT system (Cappiello et al. 1997; Sobczak et al. accepted 1), it is
advised to use mood and cognitive measures as dependent variables to assess 5-HT
responsivity. Mood changes should preferably be assessed using Visual Analogue
Scales (V AS).
6) The power of studies using a parallel groups design is less as compared to studies
using a crossover design with the same number of subjects. To increase the power of
the experimental studies using acute 5-HT challenge paradigms, studies should
preferably use a placebo controlled crossover design, including f?eaJfh>' matched
control subjects. In crossover studies, the risk of carry-over effects can be reduced by
using a washout period of at least 2 weeks and taking baseline measures (see also
Newman et al., 1998).
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CHAPTER 6
Mood, prolactin and cortisol responses following intravenous L-
Tryptophan challenge; evidence for serotonergic vulnerability in first-
degree relatives of bipolar patients
Abstract
Central serotonergic vulnerability' indicated by altered mood and neurocndocrinc responses to
an intravenous (i.v.) tryptophan (Trp) challenge was assessed in healthy adult unatTected first-
degree relatives of bipolar disorder (BD) patients (n=30)(Family History; FH). The effects of
a single dose of 7.0g Trp on mood, cortisol and prolactin (PRL) in FH subjects were
compared with healthy matched controls (n=15) in a placebo-controlled, double blind
crossover design.
PRL and cortisol responses increased following Trp. Overall, Trp lowered mood. Hormonal
and mood effects did not differ between FH and controls. Results show some evidence for
differences in serotonergic vulnerability between relatives of type I BD patients and relatives
of type II BD patients.
S Sobczak. A Honig, MA van Dmnen, M Maes. WJ Riedel. 77>ff /n/frnuf/onu/ 7«i/rna/ o/
y, accepted
Introduction
Serotonin (5-hydroxytryptophan; 5-HT) has been implicated in the pathophysiology of bipolar
disorders (BD). Changes in plasma prolactin (PRL), growth hormone (GH), cortisol and
adrenocorticotropic hormone (ACTH), following challenge with selective 5-HT stimulating
agents are important biological markers to assess brain 5-HT function (Nürnberger et al.,
1990). Changes in 5-HT responsivity may be explained by post-synaptic sensitization of 5-HT
receptors, changes in postsynaptic signal transduction, presynaptic transporter mechanisms
and dysregulation of the endocrine pathways themselves (Coccaro et al., 1989; Mann et al.,
1992). Manic BD patients show reduced PRL and exaggerated cortisol responses compared to
controls after acute 5-HT stimulation with 30 or 60mg of respectively d- and d,l- fenfluramine
(Muhlbauer and Muller-Oerlinghausen, 1985; Thakore et al., 1996). In euthymic BD patients,
blunted cortisol and ACTH responses have been described compared to controls (Nürnberger
et al., 1990). These findings suggest altered 5-HT responsivity in BD which may reflect
dysregulation of the 5-HT system.
Effects of Trp on mood in euthymic BD and Unipolar Depression (UD) patients were
decreased talkativeness and energy, and increased drowsiness and elevated mood as measured
with the Visual Analogue Scales (VAS) (Price et al., 1989).
FH subjects show a 10-20% increased risk to develop BD and genetic modifications affecting
the 5-HT system have been associated with BD pathophysiology (Bellivier, 1998).
Investigation of FH subjects is a useful method to assess 5-HT vulnerability in BD
psychophysiology.
The purpose of this study was to show 5-HT vulnerability in FH subjects, including relatives
of type I (FH I) and type II (FH II) bipolar patients, compared to matched control subjects, as
measured by cortisol, PRL and mood responses following i.v. Trp challenge. It is suggested
that 5-HT vulnerability in KH will be reflected in increased hormone and mood responses.
Based on previous findings, we predict that FH II subjects are more vulnerable to the effects
of Trp (Sobczak et al., accepted 1).
Methods
Suft/Vc/.v
Subjects were lifetime physically and psychiatricalty healthy FH subjects (n=30; 10 men, 20
women) and healthy matched controls, free from any psychiatric family history (n=15; 4 men,
11 women). FH subjects had at least one first-degree relative with a type I BD (n=22) or type
11 BD diagnosis (n=8). Subjects were selected using an abbreviated version of the Family
History Research Diagnostic Criteria (FHRDC) (Endicott et al.. 1975), (17-item). Hamilton-
Depression Rating Scale (HDRS) (Hamilton, 1967), the Young Mania Rating Scale (YMRS)
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(Young et al., 1978). the SCL-90 and a standardized psychiatric examination (Mini
International Neuropsychiatric Interview; MINI) (Sheehan et al. 1994). Subjects were free of
cardiac, endocrine and other significant medical problems.
Relatives were children (n=19). parents (n=9) and siblings (n 2). The KH and conm>l group
did not differ significantly with respect to age. body mass index (BM1), intelligence quotient
(IQ) (see Table I), but FH subjects scored significant higher on baseline Hamilton Depression
Rating Scale (HDRS) (F(l,43)=4.30. p<0.05] and Young Mania Rating Scale (YMRS)
[F(l.43)=4.7l,p<0.05}.
Of the female subjects, 21 were pre-menopausal and 10 were postmenopausal.
Table I. Demographic characieriitics; bipolar disorder family loading (I", 2** and 3" degree). Young Mania
Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS) toul score*, mean <S|-
Mtaturt
Woawa
Men
F H I
FHI1
Family members:
Bipolar disorder
Age
"Q
BMI
YMRS
HDRS
FH
n-20
n-10
n=22
n=8
1.3
41 ±2.9
117 ±2.8
25.3 ± 0.6
0.67 ± 0.2
1.30 ±0.3
( oalroh
n- l l
n-4
0.0
40 ±3.7
118 ±2.6
25.0 ±0.7
0.27 ± 0.2
0.33 ± 0.2
The study was conducted according to a mixed between / within groups (3 * 2) design. The
between-groups factor was family history: FH (FH I / FH II) or controls. The within subjects-
factor consisted of two levels of treatment (placebo and i.v. Trp loading) which were
administrated according to a double-blind, order-balanced cross-over design. The order of
treatment was balanced over two test days, spaced 3-5 days apart. Trp or placebo were
administered intravenously at a dose of 7.0 g / lOOOcc water respectively lOOOcc saline over
a 60-min period.
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All pre-menopausal women were tested in the follicular phase of the menstrual cycle. After an
overnight fast subjects arrived at 9.00 a.m.. Immediately the i.v. cannula was inserted in a
forearm vein. At 9.30 a.m. (Ho) mood was assessed and baseline blood samples were taken.
At 10.00 a.m. (to) the Trp or placebo mixture was administrated. Blood samples were taken at
t«o, t75, too and tion (all time points tx refer to X minutes after to, when the treatment
administration started). Mood assessments, including the abbreviated Bimodal Profile of
Mood States (POMS) (McNair et al., 1971) and Bond & Lader (B&L) (Bond and Lader,
1974) VAS, were completed at 10.30 a.m. (tjo), at t«>, to and at t,2o. At tps manic symptoms
were rated using an abbreviated version of the YMRS (abr-YMRS), which consisted of 7
items. Item 4 (sleep), 8 (content), 10 (appearance) and 11 (insight) were omitted, because
these items were not expected to change within a few hours.
Cortisol and PRL analyses were performed using an Automated Chemi luminescence System
(ACS: centaur) from Bayer, Germany. Total concentrations of plasma Trp and ratio of Trp:
Large Neutral Amino Acids (LNAAs; valine, isoleucine, leucine, phenylalanine, tyrosine)
were determined by high-performance liquid chromatography (HPLC).
Severity of side effects was determined by a for 5-HT challenges specially designed
questionnaire (17 four-point items) (Sobczak et al., accepted I).
Outcome variables were analyzed using General Linear Model (GLM) for repeated measures
(SPSS 9.0) (Norton. 1978). Within subjects factor was treatment condition (Trp or placebo).
Between subjects factor was family history (controls vs FH). Significant effects of Trp were
analyzed using treatment order (Trp-placebo or placebo -Trp) as a between subjects variable.
Post-hoc contrasts were used to analyze the secondary hypotheses of differences between
controls and KM I and KM 11. When baseline differences between conditions were detected,
difference scores were constructed and used for GLM analyses of treatment and FH.
Wilcoxon Matched-Pairs Signed-Ranks Test and Mann-Whitney-U Tests were used to test
differences in abr-YMRS scores and physical complaints. Effects of treatment order (Trp-
placebo or placebo Trp) were analysed
Results
At baseline, plasma Trp concentrations [F(l,42)=41,2, p<0.01] and ratio Trp: LNAAs
IK( 1.42)" 22.6. p^O.01] were significantly higher in the placebo compared to the Trp
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compared to FH land controls
Cortisol release after Trp
PRL release after Trp
SEV eff
depic« drug-placebo difference values.
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Effects of Trp on mood are shown in table 2 a/b.
Table 2. Effect» of Trp on mood. Baseline and mean peak values following Trp and placebo (P) are shown, and
are broken down by family history (FH) and controls, a) POMS and B&L subscales b) abr-YMRS.
a)
FH
baseline peak
controls
baseline peak
POMS
B&L
anger
depression
fatigue
vigor
alertness
contentedness
calmnMS
Trp
P
Trp
P
Trp
p
Trp
P
Trp
P
Trp
P
Trp
P
Trp
P
70,6(2,3;
68,9(2,8;
69,9 r2.4;
68,2(2.7)
65,6(2,5)
64,9(2,7)
69,8(2,4)
68,4(2,7)
65,0(3,3)
64,7(2,8)
67,2(2,6)
65,0 (2,9)
67,5(2,3)
67.5(2,7)
64.6 (3,0)
66.7(2,9)
7f,2(2,3)
73,6(2,7)
73,0(2,8)
70,2 (2,4)
64,3(2,6)
77,7(2,6)
74,6 (2,8)
7),4 (2,4)
64,3(3,7)
70,2(3,2)
64,6(2,7)
69,6(2,9)
70,7(2,8)
68,5 (2,4)
70,9(2,5)
72.5(3,0)
64.2 (4,3)
64,6 (4,4)
63,8(4,0)
64,5(4,3)
59,5(3,6)
60,7(3,8)
63,9 (4,9)
64.3 (4,4)
58,7(3,4)
58.4 (3,0)
60,6 (3,5)
60,7(3,5)
64,8(4,7)
64,3(4,5)
63,4(4.7)
59,9(4,0)
66,2 (4,6)
67.4 (4,8)
66,7(4,7)
65,7(4,4)
60,3(3.7)
65,2(4.5)
67,8(4,9)
67,3(4,5)
58,0 (3,0)
65.5 (4,3)
59.5 (3,9)
64.6 (4,4)
66,0(4.6)
63,8(4,2)
67, 0 (4,9)
66,9 (4,8)
b)
YMRS
FH control*
mood
energy
irritation
•pMklng
thinking
agrmtion
Trp
P
Trp
P
Trp
P
Trp
P
Trp
P
Trp
P
0(0)
0(0)
0,7 7(0.07)
0,07 (0.05)
0,74(0,70)
0(0)
0,03 (0.03)
0(0)
0.7 7(0.09)
0,2* (0.08)
0.03 (0.03)
0.03 (0.03)
0(0)
0,07 (0.07)
0.07(0,07)
0.73 (0,09)
0(0)
0(0)
0,07 (0,07)
0,07 (0.07)
0.73(0.09)
0.73(0.09)
0(0)
0(0)
In all groups, Trp significantly increased feelings of anger [fl( 1,42)=6.52, p<0.05], depression
[/=\1.42)= 187.92. p<0.00l], fatigue [/=\I.42)=22.I7. p<0.01], tension [/H[ 1,42)=6.06, p<0.05]
and decreased feelings of vigor [/H( 1.42)= 12.12. pO.01] on the POMS and decreased feelings
of alertness I F\ 1,41)= 16.05. pO.01] on the B&L (see table 2a). There was no main effect of
94
Trp on abr-YMRS. There were no significant difTerences in mood at baseline and following
Trp between FH and control subjects.
After Trp, FH II subjects scored significantly higher on the item irritation [Chi-square 9,214.
d£=2. p<0.01] of the abr-YMRS and trend-significant on total abr-YMRS scores compared to
FH 1 and controls (see table 2b). POMS and B&L ratings after Trp did not differ between FH
I, FH 11 and controls.
/rt/mwrWtff/ons o//noot/ JJ/K/ Aormomj/ re.t/wnj«
Correlational analyses of PRL and cortisol responses to Trp, expressed as drug-placebo
difference, with abr-YMRS, POMS and B&L scores revealed no significant associations.
Reported physical side-effects were significantly higher following Trp |/.--3,95. d M .
pO.Ol] compared to the placebo, but did not differ at baseline or between I'll groups.
Reported complaints were: tiredness, nausea, drowsiness, di/y.incss, hcudachc, dullness,
feelings of weakness, loss of concentration and diminished energy.
There were significant positive correlations between total reported complaints after Tip and
scores on POMS fatigue at U» [r=-0.44. n=36. p<0.05], t |» (r--0.50, n-36. p<0.05) and vigor
scores at t«o lr=-0.45. n=36, p<0.05], Uo [r=-0.38, n=36, p<0.05], ti» (r—0.47, n-36. p^O.05]
and with B&L alertness score at t« [r=-0.50. n=36, p<0.05], tw [r=-0.48, n=36, p<0.05] and at
ti:o [r=-0.45, n=36, p<0.05]. Physical side effects did not correlate with abr-YMRS scores.
Discussion
The aim of the study was to investigate central 5-HT vulnerability in healthy first-degree
relatives of BD patients following i.v. Trp challenge. Trp administration was successful and
resulted in significant increase in plasma Trp and ratio Trp: LNAAs. There was a carry-over
effect of Trp; plasma Trp values were significantly higher on the test day after receiving Trp.
The carry-over effect was lower in FH compared to controls. Trp resulted in robust elevations
of PRL and cortisol in all groups. Following Trp, subjects reported increased depressed mood,
fatigue and tension and decreased vigor and alertness. Mood responses did not differ between
FH and controls. Trp induced feelings of irritation in FH II but not in FH I and controls.
In euthymic or depressed BD patients blunted cortisol and PRL responses have been reported
compared to controls (Deakin et al., 1990; Nürnberger et al., 1990). 5-HT dysregulation in
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BD has been indicated by blunted PRL or cortisol response after (d.l-) fenfluramine
challenges (Mannel et al., 1997; Thakore et al., 1996). Yatham et al. (1996) found no
differences in fenfluramine induced PRL and cortisol responses between BD patients and
healthy controls (Yatham et al., 1996). In BD patients, 5-HT responsivity following
challenging may be associated with disease-related factors, such as current treatment with
psychotropic agents (e.g. lithium), personality traits or suicidal behavior (Meltzer et al., 1984;
Sobczak et al., accepted 2). Hormonal responses to Trp did not differ between FH subjects
and control subjects in this study. A functional distinction between FH 1 and FH II subjects
has been previously described by our group; following ATD, FH II subjects show mood
changes and FH I subjects are characterized by cognitive deficits (Sobczak et al., in press;
Sobczak et al., accepted 1). For this reason we were interested in differences in hormonal
responses and / or mood changes following Trp between FH I and FH II subjects. Figure 1b
shows a slightly increased PRL response in FH II compared to the other groups. However this
effects was not significant. Mood assessments indicated an increase in irritation on abr-
YMRS following Trp FH II. Irritation may be interpreted as a feature of mania, depression or
both. Gender differences between groups were not expected to explain possible differences
between FH II and FH I. PRL response following Trp was higher in women compared to men
[F(1,43V«4.I. p<0.05], but relative contribution of females in the FH I. FH II and control
groups did not differ significantly. Mood and hormonal responses did not differ between pre-
and postmenopausal women. There was also no effect of age.
The Trp-induced mood changes in FH, as measured on POMS and B&L, are in agreement
with findings in BD. Euthymic BD patients reported decrements in talkativeness and energy,
and enhanced drowsiness following Trp (Price et al. 1989). As correlation analyses revealed
no significant association between mood rating and hormonal release, the observed pattern of
mtHKl responses is assumed not to be related to hormonal responses.
Previous observations described 5-HT vulnerability in specifically FH II subjects following
ATD (Sobczak et al., accepted I). The present findings do not provide additional evidence for
this hypothesis but is also not contradictory to a theory of 5-HT vulnerability in FH II. We
speculate that increased feelings of irritation on abr-YMRS and the slightly higher PRL
response following Trp might be indicative for central 5-HT vulnerability in FH II. 5-HT
vulnerability in BD type 11 patients might be related to suicidal ideations, which are more
prevalent in type II than in type I BD patients (Van der Does et al., 2001; Rihmer, 1999).
Meltzer ct al. (1984) also found an exaggerated cortisol response following 5-HTP challenge
to be associated with a positive history' of suicide attempts in BD (Meltzer et al.. 1984).
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Trp is known to induce indolase-activity and via this negative feedback-loop Trp lowers its
own activity. The cany-over effects of Trp was therefore an unexpected finding. Probably, the
indolase-activity is limited to a critical level and an overdose of Trp takes longer then .1 days
to be fully eliminated. A shorter time interval between test days revealed higher baseline Trp
values, but this effects was not significant. The carry-over effect was significant lower in KM
which suggests that Trp catabolism is higher in FH subjects compared to controls. More rapid
Trp clearance in depressed patients compared to controls has been reported after Trp infusion
(Deakin et al. 1990). Amamoto (1976) reported a delay in elevation of plasma 5-HT and
5HIAA concentrations and a delay in 5HIAA urinary excretion in depressed HI) patients
compared to control subjects (Amamoto and Sarai 1976).
Shortcoming of this study are: First, the low number of FH II subjects reduced the power of
this study. FH I subjects showed higher motivations to participate and therefore outnumber
the FH II subjects. Second, physical side effects and sedation induced by Trp might interfere
with effects on mood. Direct effects of 5-HT on vigilance and the conversion of Trp to
melatonin by the enzymes 5-HT N-acetylase and 5-hydroxy indole O-methyl transferase may
explain the sedating effects of Trp. Physical side effects after Trp decreased physical well-
being and might have interfered with mood and may thus explain the decrease in mood
following Trp. Sedation may be experienced as a Stressor and can therefore elicit feelings of
irritation (Gaillard at al., 1993), but no interaction of side-effects on abr-YMRS was shown
which makes this explanation less reliable. Third, Trp significantly increased PRL, but the
specificity of PRL to reflect 5-HT activity has been discussed. Changes in PRL may also be
the result of changes in dopamine synthesis related to availability of tyrosine. Trp can
decrease influx of tyrosine in the brain by competing for the same carrier transport
mechanism (Van Praag et al., 1987). Hence, the ratio tyrosine: LNAAs did not change
following Trp loading. The reported cortisol response following Trp was modest. Usage of a
cortisol challenge paradigm, e.g. a stress-inducing procedure, might be useful in assessment
of cortisol responses after 5-HT modulations. A blunted cortisol response to a stress-inducing
speech task was shown in FH subjects after Acute Tryptophan Depletion (ATD) (Sobczak et
al., accepted I). Fourth, FH subjects have a 10-20% increased risk to develop BD. This
means that of our research population only 3-6 subjects will develop BD in the future. This
study was not designed to investigate the relationship between 5-HT vulnerability and
absolute risk to develop BD. Therefore a cohort of FH subject should be investigated and
followed over time.
In conclusion, this study shows no significant differences in Trp-induced hormonal and mood
changes between FH subjects and healthy matched controls. FH II subjects showed altered 5-
HT responsivity, but findings are borderline and must first be replicated in a larger sample
including FH I, FH II and controls before drawing definite conclusions.
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CHAPTFR 7
Pronounced cognitive deficits following an intravenous I-Tryptophan
challenge in first-degree relatives of bipolar patients compared to health)
controls
Abstract
Cognitive impairment has repeatedly been described in bipolar disorders (BD). Serotonin (,5-
HT) is possibly involved in these cognitive processes, more particularly in executive
functions, learning, memory and attention. The aim of this study was to investigate
serotonergic vulnerability and its relation to cognitive functioning in healthy first-degree
relatives of BD patients. We investigated the effects of an intravenous (i.v.) tryptophan (Trp)
challenge and placebo on cognitive performance in 30 healthy first-degree relatives of bipolar
patients (FH) and 15 matched controls in a double-blind cross-over design. A distinction was
made between relatives of type I BD patients (FH I) and type II BD patients (FH II).
Performance on planning, memory, attention and psychomotor tasks were assessed 3 hours
after Tip infusion.
After Trp. planning and attention were impaired in FH subjects but not in controls.
Independent of Trp, FH subjects showed cognitive deficits on memory, focused and divided
attention and psychomotor performance. FH I subjects showed more pronounced cognitive
impairments then FH II and controls. In all groups, Trp impaired memory and psychomotor
performance significantly. Cognitive deficits in FH following Trp may reflect a central 5-HT
vulnerability in frontal brain areas. Independent of Trp, cognitive deficits in FH provide
evidence for a trait maker for BD.
S Sobczak, A Honig. JAJ Schmitt, WJ Riedel. JVeurojwyc/rop/iarmaro/ogy, submitted
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Introduction
In bipolar disorders (BD) cognitive deficits have been reported repeatedly (Coffman et al.
1990; Savard et al. 1980; Wolfe et al. 1987; Krabbendam et al. 2000). Manic patients showed
impairments on planning and reaction time (RT) (Murphy et al. 1999). During remission,
cognitive deficits may persist (van Gorp et al 1998; Ferner et al. 1999; Krabbendam et al.
2000; Rubinsztein et al. 2000; Scott et al. 2000). Euthymic BD patients showed impairments
on visuo-spatial recognition, verbal and nonverbal memory and learning, retrieval of
information from semantic memory an increased RT on a planning task (Coffman et al. 1990;
Atre-Vaidya et al. 1998; Ferner et al. 1999; Rubinsztein et al. 2000). Euthymic patients with
recurrent episodes appear to show more cognitive impairments (Kessing 1998; Martinez-Aran
et al. 2000). This suggests that these cognitive deficits indicate a trait marker in BD. As first-
degree relatives of BD patients (FH) are free of psychopathology and interference of
psychotropic medication, assessment of cognitive performance in FH subjects may provide a
powerful design to investigate biological vulnerability in BD (Sobczak et al. 2000). Compared
to matched control subjects, healthy first-degree relatives of BD patients showed impaired
speed of information processing, on a planning task, and memory performance (Sobczak et al.
in press).
Serotonin (5-hydroxytryptophan; 5-HT) has been implicated in psychopathology of BD and
has also been associated with cognitive performance, particularly learning and memory
(Young et al. 1994; Riedel et al. 1999; Schmitt et al. 2000). Changes in cognitive performance
following selective 5-HT modulations are important biological markers for brain 5-HT
receptor sensitivity (Sobczak et al. accepted 1; Sobczak et al. accepted 2; Riedel, et al. 2002).
Cognitive deficits seem to be more prevalent in relatives of patients with BD type I
psychopathology (FH I) compared to relatives of BD type II patients (FH II) (Sobczak et al. in
press). Acute Tryptophan Depletion (ATD) impaired planning performance in FH subjects
whereas performance increased in controls, which suggests serotonergic vulnerability in FH
subjects affecting frontal lobe areas (Sobczak et al. in press).
In healthy subjects, independent of FH. ATD impaired memory consolidation (Sobczak et al.
in press; Park et al. 1994; Riedel et al. 1999; Rogers et al. 1999; Schmitt et al. 2000;
Rubinsztein et al. 2001) and improved focused attention (Coull et al. 1995; Schmitt et al.
2000). Acute 5-HT challenges showed impaired memory performance after 5-HTIA challenge
with ipsapirone and impaired signal detection after 5-HT:c challenge with m-CPP (Riedel et
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al. 2002) and impaired psychomotor performance after 5-HTx challenge with m-CPP (Riedel
et al. 2002) and i.v. Trp loading (Winokur el al. I486).
The present study was designed to investigate 5-HT related cognitive functioning in FH
subjects and healthy matched controls. The hypotheses were: Trp will induce more
pronounced cognitive changes in FH subjects: FH subjects will show impaired planning and
memory independent of Tip (implying a trait marker in BD); detrimental effects of Trp will
be more pronounced in FH I; based on previous findings, Trp will improve frontal lobe
mediated planning and attention whereas it will decrease memory and psychomotor
performance independent of FH.
Methods
Subjects were family members and healthy matched controls. Family members were recruited
via BD patients treated at the Department of Psychiatry, University Hospital Maastricht, via
the consumer organization for manic-depressive patients and their families, and via
advertisements in local newspapers. Healthy control subjects were also recruited via a
newspaper advertisement and were free from any psychiatric family history.
FH subjects had at least one first-degree relative with a type I BD or type II BD diagnosis. All
subjects were interviewed with an abbreviated version of the Family History Research
Diagnostic Criteria (FHRDC) to assess FH (Endicott et al. 1975). Individual diagnoses (type I
or type 11 BD, according to DSM1V) of the patients were verified via the patients' own
psychiatrist.
A standardized psychiatric examination (Mini International Neuropsychiatric Interview;
MINI) (Sheehan et al. 1994) was taken of all participants to examine the present psychiatric
state according to DSM IV criteria. The Hamilton Depression Rating Scale (HDRS)
(Hamilton 1967), the Young Mania Rating Scale (YMRS) (Young et al. 1978) and the
SCL-90 (Arrindell and Ettema 1986) were used to verify the absence of depressive, manic
and general psychiatric symptomatology.
Exclusion criteria were: current or past use of psychoactive medication, lifetime psychiatric
disorder including alcohol or drug abuse, current active physical illness, lactation and
pregnancy.
Physical health was assessed by means of a health questionnaire, a standard physical
examination by a physician and urine screening. The urine test (ComburK) included
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assessment of leukocytes, nitrite, pH, protein, glucose, ketones, urobilinogen, bilirubin and
erythrocytes. A Quick View, one-step pregnancy test (Quidel®) was carried out in female
subjects to check for unsuspected pregnancy.
Of the 47 subjects who participated, 2 subjects did not complete the experiment due to
reasons unrelated to the study. The included subjects who completed the experiment were 30
FH (10 men and 20 women) and 15 controls (4 men, 11 women). Table I shows the
demographic characteristics of all subjects who completed the experiment. Relatives were
children (n=19), parents (n=9) and siblings (n=2). Twenty-two were FH I and 8 were FH II
subjects. The FH and control group did not differ significantly with respect to age, body mass
index (BMI), intelligence quotient (IQ) and SCL-90 total score, but FH subjects scored
significant higher on baseline (HDRS) [F(l,43)=4.30, p<0.05] and YMRS [F(l,43)=4.71,
p<0.05].
Of the female subjects, 21 were pre-menopausal and 10 were postmenopausal. Thirteen
women used oral contraceptives.
Each control subject was matched with 2 FH subjects with respect to sex, age, BMI and IQ.
Intelligence (IQ) was estimated using Groninger Intelligence Test (GIT) subtasks
(Vocabulary, Mental Rotation, Mental Arithmetic and Word Analogies) (Luteijn 1966).
The Medical Ethics Committee of the University Hospital of Maastricht approved of the
study. All participants signed informed consent.
Table 1. Demographic characteristics; bipolar disorder family loading (I", 2~" and 3"" degree), SCL-90, Young
Mania Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS) total scores; mean ±SE.
Measure
FHI
FH II
Women
Men
1 Hinllv members:
Bipolar disorder
Age
IQ
BMI
S( I.-90
YMRS
HDRS
FH
n-22
n=8
n=20
n=IO
1.3
41 ±2.9
117 ±2.8
25.3 ± 0.6
102.2 ± 1.8
0.7 ±0.2
1.3 ±0.3
Controls
n=ll
n=4
0.0
40 ± 3.7
118 ±2.6
25.0 ±0.7
98.7 ± 1.8
0.3 ± 0.2
0.3 ± 0.2
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The study was conducted according to a mixed between ' w ithin groups (3 • 2) design The
between-groups factor was FH with 3 levels: controls. KH 1 and FH II.
Treatment, the within subjects-factor, consisted of two levels: placebo and Trp loading. 1 rp
was administered i.v. according to a double-blind, order-balanced cross-over design. The two
test days were spaced 3-5 days apart.
i. v. 7>7>
Trp infusions were prepared by dissolving 7.0 g Trp in lOOOcc water. Saline solution (NaCI)
was added to ensure an isotonic solution (pH =7.4). Each Trp solution was sterilized by
passage through a 0.22-mm polymer (Millipore) filter and tested for pyrogcnicily and sterility.
lOOOcc Saline solution was given on a separate day as a placebo mixture. The lOOOcc solution
was administered within 60 minutes. The appearances of solutions were identical.
To eliminate response bias due to premenstrual symptoms, all pre-mcnopausal women were
tested in the follicular phase of the menstrual cycle (Menkes et al. 1994; Rasgon et al. 2000).
On each test day, the subjects arrived at 9.00 a.m. after an overnight fast. Immediately after
arrival the i.v. cannula was inserted immediately in a forearm vein. At 10.00 a.m. (to) the
saline solution, with or without Trp, was administered.
During the experiment, the subjects remained in the testing room where they were allowed to
do non-strenuous activities. Subjects were allowed to drink decaffeinated coffee, herbal tea or
water and to eat protein-poor fruits like apples and oranges.
Blood samples for assessment of plasma Trp were taken at t-jo, t«o, t?s, t*> and tun (all time
points t\ refer to (-)X minutes (before)/ after ti). Cognitive assessment was completed at t|>«>.
The cognitive test battery took approximately 60 minutes to complete and consisted of tasks
measuring planning, attention, psychomotor performance and memory.
Planning capacity was assessed by a modified version of the One-touch Tower of London
(TOL) task (Owen et al. 1995). Subjects were initially trained the original non-computerized-
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TOL (Shallice 1982). Thereafter, the comp-TOL was introduced. On a computer screen, two
arrays of differently colored balls (red, yellow and blue) on sticks were presented. Each
arrangement contained three balls, which were held on three sticks; one stick had a capacity of
3 balls, another could hold two balls and the third could only hold 1 ball. The subject were
requested to indicate the minimal number of steps necessary to rearrange the balls on the
lower configuration to match the arrangement presented on the top half of the screen. The
rules were: each ball must be replaced separately, once a balls is taken it must be put on a
stick, it is not allowed to put one ball aside and continue with the other balls.
The subjects had to rearrange the balls in their mind's eye (without actually moving the balls).
Once the ideal solution had been found, the subject was asked to count the number of moves
and then respond by pressing the appropriate response button, which represented the right
number of steps necessary to rearrange the balls (2-5). The subjects were instructed to respond
as quickly as possible, but the importance of accuracy was emphasized. They were told that
performance on the task was indicated by both response accuracy and reaction time.
There was no response-feedback and subjects were allowed to give just one response to each
problem.
The complexity of the task is dependent on the minimal number of steps the rearrangement
can be achieved: 2,3,4 and 5 steps. The training consisted of 10 trials and the test of 40 trials,
with an equal number of 2, 3,4 and 5-steps problems, which were presented in a fixed pseudo-
random order. Only once subjects were entirely familiar with the rules governing the
movements of balls and the concepts involved with solving the compu-TOL problems, were
they given the test form of the task.
Performance was indicated by median RT as a function of the number of steps. Number of
correct responses was checked for possible confounding of the RT results.
Secondary outcome variables
•/4/ftvtfiow
The GONT measures response readiness. Every second one digit (0-9) was shown on a
computer screen for 500 msec. The subject was asked to push a button as soon as he saw the
digit except when he saw a "target-digit". When the subject saw the target digit he had to
inhibit pushing the button. The target digit was revealed to the subject prior to the test.
Number of correct responses and RT to the distracters were assessed. This task was aimed at
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measuring attention failures and was adopted after a version described by Robertson el al.
(Robertson et al. 1997).
Siroop Cofar » W f c / (5CI»7)
The SCWT has often been used to test focused attention and response inhibition (Stroop
1935). The test consisted of three cards displaying each 100 stimuli. The first card included
color names, which had to be read as quickly as possible. The second card included color
patches, which had to be named. The third card consisted of color names printed in
incongruously colored ink. The color of the ink had to be named, without paying intention to
the word itself. Outcome variable was interference. The interference denotes the percentage
extra time needed to complete the third card relative to the average of the first and second
card: (time card 111 / [(time card 1 + time card 11)/ 2)] * 100% (Houx and Jolles 1993).
/.Wt «<>>*/ C'AOKT Anac-fton
This is a parametric version of the well-known color-word response conflict task (Stroop
1935). The words Left and Right are displayed either at the left or the right side of a computer
screen. Response instructions are to respond as quickly as possible to the location of the word
irrespective of its meaning. The subjects' task is to respond by pressing a corresponding
button. The output parameters are the RT and accuracy of responding as a function of task
difficulty.
The DLT measures both focused and divided attention for auditory stimuli (Kimura and
D'Amico, 1989). Subjects received different auditory stimuli simultaneously through a
headphone on each side. The stimuli were numbers ranging from 1-200, presented at random
and natural-speech spoken by a male voice. The test consisted of two subtasks in which the
subjects were instructed to focus to either the numbers presented in the right ear, which is a
more sensitive measure than performance on the left ear, or both ears, and remember the
numbers presented (Schmitt et al. 2000). The subtask in which the subjects were instructed to
focus to one side, while ignoring the other, can be regarded as a measure of focused attention.
The subtask in which the subjects had to remember the numbers presented in both ears is a
divided attention task. Each of the two subtasks is made up of nine trials, in which two, three
or four stimuli pairs are presented in random order. After each trial, the subject had to identify
the presented numbers from a list of numbers on a computer screen. The numbers included all
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presented numbers plus the same amount of other, numbers (distracter stimuli). Performance
on each subtask was calculated by the A' sensitivity measure (see W L T ) .
The MCRT measures sensorimotor speed, choice-reaction speed, and choice-reaction speed
with response competition (Houx and Jolles, 1993). The subjects held one button and were
asked to press one of five other buttons located at equal distance from the hold button when
lit. This yields RTs consisting of an initiation phase (time from stimulus onset until release of
the hold button) and a movement phase (time from release of the hold button until the
response button is pushed). The subjects responded either to a single button (simple RT), to
one of 3 buttons that lit up (3-choice RT), or to the right of the lit button (incompatible 3-
choice RT) as quickly as possible. Dependent variables were movement time and initiation
time as a function of task complexity.
The W L T measures, short-term memory (STM) and long-term memory (LTM) performance.
The W L T is an adapted version of the Rey Auditory Verbal Learning Test (Lezak 1995).
The test consisted of a list of 30 monosyllabic words (18 nouns and 12 adjectives) in Dutch,
which were presented in three trials on a computer screen. The words occur very frequently in
Dutch and are acquired early in life. Items were presented in the same sequence at a rate of
one per 2 seconds.
Each trial ended with a free verbal recall of the words (immediate recall). Thirty minutes after
the third trial, the subject was requested to recall as many words as possible without prior
presentation (delayed recall). A yes/no recognition test, consisting of 15 formerly learned
words and 15 new but comparable words (distracters), was given after the delayed recall test
(recognition). The words remained on the screen for 2000 msec or until the subject responded.
Another 1000 msec elapsed before the next word appeared on the screen. After presentation
of each word the subject had to respond "YES / NO" as fast as possible to indicate
recognition of the word.
The RTs were recorded. According to the theory of signal detection (Pollack 1964). the
proportion of correctly recognized words (cr) and the proportion of falsely recognized (fr)
constitute the nonparametric sensitivity measure: A" = I - 1/4 (fr/cr + (1 -crV( 1 -fr)). A" is in
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fact the proportion of correctly recognized words, corrected for the subject's
tendency. Because the distribution of A" is skewed due to a ceiling effect. A' was arc sin
transformed before being used in statistical analysis.
The variables used were the total number of words recalled after the first three tnuls us a
measure of STM. the number of correct words on delayed free recall as a measure of retrieval
from LTM, A' as a measure of storage in LTM, and the median RT of correctly recognized
target words as a measure of speed of retrieval from LTM.
In each of the assessments, a different words list was presented. The lists were comparable
with regard to their level of abstraction and the affective tone of the words. Parallel lists were
order balanced over assessments.
IVr
The fluency test measures strategy-driven retrieval of information from semantic memory.
The subjects are asked to report as many four-letter words with the same initial letter within
one minute. The dependent variable is the number of correct reported words. Nonsense words
were not accepted, but names, conjugations and plurals were allowed. Starting letters were H,
L. M and R (Schmitt et al. 2000).
Outcome variables were analyzed using General Linear Model (GLM) for repeated measures.
Within-subjects factor was treatment (2 levels: Trp or placebo); the between-subjects factor
was family history (3 levels: controls, FH I, or FH II). Univariate contrasts between groups
were used to test the primary hypothesis of difference between controls and FH subjects
(controls vs. FH I + II) as well as the hypotheses of differences between controls and FH I and
FH II relatives separately (controls vs. FH I and controls vs. FH II).
Mann-Whitney-U Tests was used to test differences in side-effects.
Relationships between effects of Trp (determined as difference: Trp minus placebo) on
cognitive measures and mood, peak prolactine and cortisol responses (determined as maximal
response after Trp minus placebo) were evaluated by means of Pearson's product moment
correlation.
Statistical analyses were performed with SPSS 9.0 for Windows.
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Results
Plasma Tip concentrations [F( 1,42)=41.2, p<0.01 ] and ratio Trp: LNAAs [F( 1,42)=22.6,
p<0.0l ] were significantly higher at baseline in the placebo condition. FH subjects showed
lower baseline plasma Trp [F(l,42)=6.4, p<0.05] compared to controls. After correction for
baseline differences, plasma Trp [F(l ,42)=978.7, p<0.001] and ratio Trp: LNAAs
[F(l,42)=502.3, p<0.00l] increased significantly after i.v. Trp loading. Relative to baseline,
the mean peak of plasma Trp and ratio Trp: LNAAs to i.v. Trp loading were 1049.4 umol / L
respectively 2.3. Following placebo, there was no change in plasma Trp and ratio Trp:
LNAAs.
There were no effects of treatment order and FH on increase in Trp values after challenging.
Table 2 shows mean (± se) of planning variables, separated for FH and control subjects.
The three-way interaction of family history by number of steps by Trp on number of correct
responses was significant [F(3,4I) = 3.01, p<0.05] but there were no differences between FH I
and FH II subjects. There was also a main effect of Trp [fXl,42) = 85.53, pO.Ol] on median
RT and a significant two-way interaction of number of steps by Trp on median RT [F(3,40) =
21.50, p<0.01 ]; median RT was increased after Tip on the 3 and 4 steps problems.
There were no effects of treatment order.
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Table 2. Mean (± SE) of the pnmary cognitive outcome measures ( planning) Results are broken do» n by lamily
history (controls. CTH I FH II) and treatment (Trp placebo. P).
0 05. */K0 1
Measarr Trtanacal
Correct responses (•)
2 steps TRP
P
3 steps TRP
P
4 steps TRP
P
5 steps TRP
P
Median RT(mscc)
2 steps TRP
P
3 steps TRP
P
4 steps TRP
P
5 steps TRP
P
9.2(0.2)
9.7(0.2)
9.0(02)
8.9(04)
7.2(0.4)
7.9(04)
8.2(0.2)
8.3(0.4)
4880(262)
5721(693)
7170(896)
6802(656)
9941(808)
8797(738)
13623(1904)
15463(1970)
FH 1 r*-J2)
8.9(03)
8.6(0.4)
9.2(0.1)
8.6(0.4)
74(04)
80(04)
70(0.4)
73«0.5)
5425(433)
5899(603)
7774(772)
7514(690)
11155(1201)
11547(1111)
17665(1266)
18347(1899)
FHIIf«-«
8.6(0.6)
9.0(0.5)
9.0(0.4)
9.0(0.3)
7.9(0.4)
8.1(0.9)
7.0(0.7)
8.8(0.5)
6035(761)
5899(875)
7885(928)
7166(822)
9798(1163)
9554(1256)
17225(2242)
16641(3024)
Table 3 shows mean (± se) of other outcome variables, separated for FH and control subjects.
GOAT
There was a significant interaction of Trp and FH on number of correct response inhibitions;
after Trp FH subjects showed less correct response inhibitions (F(l,43) = 8.76. p<0.0l] but
controls did not. There were no effects on RT of correct responses nor did performance differ
between treatment order or FH I and FH II subjects.
SCHT
The interference measure of the Stroop test did not show significant effects of FH, Trp and
treatment order.
CÄ7"
On incompatible stimuli RT showed a significant interaction effect of Trp and FH (both FH I
and FH) [F(l,43) = 3.98, p<0.05]; RT was impaired after Trp in FH but not in controls, on
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number of correct responses this interaction was trend significant; FH subjects showed less
correct responses after Trp. Independent of Tip, FH subjects tended to be slower on
incompatible stimuli.
There were no significant effects of Trp and FH on accuracy or RT of compatible responses
and there were no effects of treatment order.
FH subjects showed impaired performance on focused attention subtasks 'right' [F(l,43) =
7.24, p<0.05] and divided attention subtask 'both' [F(l,43) = 9.53, p<0.01] independent of
Trp.
There were no main effects of Trp or treatment order. There were no differences between FH
I and FH II.
Movement time was increased after Trp [F(l,43) = 4.42, p<0.05]. There was a main effect of
FH on movement time (F(l,43) = 5.09, p<0.05]; prolonged movement time in FH was due to
prolonged movement time in FH I subjects [F(2,42) = 4.24, p<0.05]. There were no effects on
initiation time and of treatment order.
/Wf/worv
Trp significantly impaired performance on delayed recall [F(l,43) = 7.76, p<0.01] and
recognition A' [F(l,43) = 4.15. p<0.05]. Performance on the recognition task showed a
significant interaction of Trp with treatment order [F( 1,43) = 5.12, p<0.05]; subjects receiving
Trp on the first test day show an improvement in A' following placebo on the second test day,
whereas subjects receiving placebo first were also better on the second test day.
Following Trp, there was a trend towards impaired immediate recall performance [F(l,43) =
3.84. p<0.1].
Performance on recognition A" was impaired in FH subjects [F(l,43) = 5.93, p<0.05]; more
specifically in FH I subjects [F(2.42) = 4.21, p<0.05].
There were no effects on median RT of the recognition task.
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There were no effects of Trp. FH or treatment order on number of correct reported words.
Soma/ir s/de <#«-«
In the Tip condition, significantly more side effects (Z=-3.95. df=l. p«-0.001] were reported
compared to the placebo condition. Reported side effects after Trp were: tiredness, nausea,
drowsiness, dizziness, headache, dullness, feelings of weakness, loss of concentration und
diminished energy. Side effects did not differ between FHI. FH II or control subjects.
Correlation analyses revealed no significant correlation of total physical side effects and
dependent variables on cognitive tasks.
Changes in mood were assessed by the profile of mood states (POMS) consisting of the
subscales anger, depression, fatigue, tension and vigor. Following Trp. decrease in vigor was
positively correlated with decrease in delayed recall performance on the VVLT [r-0.39,
p<0.0l]. Detrimental effects of Trp on recognition A' showed a significant positive
correlation with peak cortisol response following Trp [r=0.37. p<0.05) .
There were no significant correlations between other POMS subscales, prolactine response
and effects of Trp on planning, attention and pychomotor performance.
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Measure Treatment FH I fa=. FH II rn=8>
GOAT
RT (msec)
No. Correct (#)
S'CW
Interference (%)
RT(mscc)
incompatible
compatible
No. Correct (#)
incompatible
compatible
IV. 7'
A' (%)
Right
Both
KT(mscc)
Simple
Choice
Incompatible
Movement time (msec)
IT/. 7"
No. correct words (*)
Immediate rcc.
Delayed rec
Recognition A' (%)
Recognition RT (ms)
No. correct words (tf)
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
TRP
P
325(10)
331(11)
8.8(0.3)
8.2(0.3)
41(1)
43(1)
700(18)
712(21)
690(17)
686(24)
15.5(0.2)
15.3(0.2)
15.8(0.1)
15.9(0.1)
94(9)
93(1)
86(8)
86(8)
114(6)
110(7)
125(6)
123(7)
132(9)
130(10)
1046(28)
1032(33)
42.6(2.8)
42.1(3.2)
14.5(1.5)
15.1(1.6)
53(9)
58(7)
647(20)
640(19)
12.9(1.4)
11.8(1.0)
351(13)
342(11)
8.1(0.3)
8.6(0.3)
41(1)
41(1)
772(26)
732(22)
711(16)
688(15)
15.1(0.2)
15.5(0.2)
15.4(0.2)
15.5(0.2)
89(2)
89(2)
83(8)
83(7)
121(7)
127(7)
131(7)
133(6)
139(8)
137(8)
1185(40)
1166(37)
33.8(2.6)
38.8(3.0)
10.5(1.3)
12.8(1.5)
56(5)
60(4)
833(39)
852(42)
11.0(0.8)
10.7(1.0)
323(18)
307(14)
8.0(0.5)
8.3(0.5)
37(1)
38(2)
683(27)
661(17)
664(27)
661(15)
15.4(0.3)
15.4(0.3)
15.5(0.3)
15.6(0.2)
79(5)
89(3)
81(2)
82(2)
111(6)
105(5)
116(7)
115(6)
125(11)
119(8)
1087(40)
1049(30)
40.6(4.5)
41.0(5.0)
14.1(2.4)
16.1(2.0)
49(8)
49(6)
729(39)
713(24)
12.1(1.2)
12.4(1.5)
Table 3. Mean (± SE) of the
secondary cognitive outcome
measures ( attention,
psychomolor speed and
memory) Results are broken
down by family history
(controls; C/FH 1/ FH II) and
treatment (Trp/ placebo; P).
• /K0.05 . "/X0.1
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Discussion
The primary goal of this study was to investigate 5-HT vulnerability in FH subjects indicated
by cognitive performance following i.v. Tip challenge.
Impaired planning performance and attention after Tip was found in FH subjects but not in
controls, indicated by number of correct responses on the compu-TOL. correct response
inhibitions on GONT and RT and accuracy on the CRT. There were no significant interaction
effects of FH and Trp on memory and motor RT.
Independent of Trp, FH subjects showed cognitive deficits on memory, psychomotor
performance, focused and divided attention as indicated by performance on recognition,
movement time on MC'RT and DLT sensitivity measures. Cognitive deficits on memory and
psychomotor performance were more pronounced in FH I than FH II.
There was a main effect of Trp on memory and psychomotor performance; surprisingly, Trp
impaired delayed recall memory performance, recognition und motor RT on Ml'RT.
Changes in performance on planning and attention following 5-HT modulations has now
repeatedly been described and represent valid parameters of central S-HT vulnerability of
frontal brain areas (Sobczak et al. In press; Schmitt et al. 2000). Impaired performance in KH
on planning and attention following Trp suggest central S-HT vulnerability in frontal bruin
areas (Dagher et al. 1999; Elliott et al. 1997; Murphy et al. 1999; Owen et al. 1990;
Rubinsztein et al. 2001). The findings on planning are in agreement with data of a previous
study of our group, which showed pronounced planning deficits in FH following ATD
(Sobczak et al. In press). Thus both a decrease and increase in central Trp may impair
planning performance in FH. This may be explained by the following mechanism: in FH
subjects the 5-HT system may be vulnerable to abnormalities. As FH subjects do not show
psychopathology and related central 5-HT dysfunctions, it is suggested that an endogenous 5-
HT compensatory brain mechanism conceals the potential central 5-HT dysfunction in FH
subjects. Independent of the direction of 5-HT modulations, acute changes in central 5-HT
may be regarded as a Stressor and thereby disturb the equilibrium between 5-HT and the 5-HT
compensatory mechanism transiently. Consequently cognitive impairments will occur. This
hypothesis is consistent with the kindling and stress sensitization theory of Post et al. (Post
and Weiss 1997) which includes adaptations in second messengers, genetic transcription,
receptors, neurotransmitters and neurons which may occur in response to Stressors in the pre-
morbid state. In FH subjects, who have a biological vulnerability to BD, this stress
sensitization may ultimately result in BD psychopathology. Thus, FH subjects are more
115
vulnerable to the effects of Tip on planning and attention, which may be explained by a
biological vulnerability in FH probably associated with 5-HT mediated functions in frontal
brain areas.
After ATD, attention may be improved (Rosse et al. 1992; Schmitt et al. 2000; Sobczak et al.
in press). We found impaired attention after Trp in FH which is thus in agreement with a
linear negative association of 5-HT with (focused) attention.
Independent of Trp, FH subjects showed cognitive deficits on memory, movement time and
attention. This is in agreement with findings previous findings of our group, which showed
cognitive impairments in FH subjects. Impairments on planning, memory and attention have
also been described in manic, depressed and euthymic BD patients (Zubieta et al. 2000; Rossi
et al. 2000a; Rossi, et al. 2000b; Martinez-Aran et al. 2000; Ferner et al. 1999; Murphy et al.
1999; Rubinsztein et al. 2000). The cognitive deficits in BD may be partially explained by
abnormalities in functional brain structures and / or metabolism (Stoll et al. 2000; Manji et al.
2000; Buchsbaum 1986; van Gorp et al 1999; Coffman et al. 1990). In BD smaller temporal
lobes, temporal horn enlargement, abnormal frontal cortex inositol levels, and phosphor
metabolism (Soares and Mann 1997; Rossi et al. 1991; Shimon et al. 1997; Deicken et al.
1995) have been described. Cognitive impairments persist during clinical remission in BD
and in FH subjects suggesting that these parameters are a trait marker for BD in FH (Zubieta
et al. 2000; Henry et al 1973; van Gorp et al 1998; Murphy et al. 1999; Krabbendam et al.
2000; CofTman et al. 1990; Atre-Vaidya et al. 1998; Ferrier et al. 1999; Rubinsztein et al.
2000).
Overall, there was a tendency of FH I subjects to show more pronounced cognitive
impairments compared to FH II. Previous findings showed FH 1 subjects to be more
vulnerable to cognitive deficits following ATD. However, FH II subjects appear to be more
vulnerable to ATD and Trp-induced mood-changes (Sobczak et al. accepted 1; Sobczak et al.
accepted 2). This difference in vulnerability in FH I and FH II may suggest a biological
distinction (Sobc/ak et al. in press). Cognitive deficits in BD type 1 patients show similarities
with cognitive dysfunctions in schizophrenia, whereas BD type II patients show more
characteristics of unipolar depression (Dickerson et al. 2001; Krabbendam et al. 2000;
Borkowska and Rybakowski 2001).
The unexpected Trp-induced decrements in memory indicate impairments in consolidation
affecting LTM performance. As there was a trend towards impaired immediate recall
performance, the effects on LTM might probably be ascribed to impairments in STM. Deficits
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in STM have also been described following acute 5-HT challenges with ipsapirone (Riedel et
al. 2002) and fenfluramine (Luciana et al. 1998) in healthy subjects.
Previous studies showed that an acute lowering of Trp following ATD induced impairments
of delayed verbal and visual recognition (Sobczak et al. in press: Riedel et al. 1999; Schmitt et
al. 2000; Rubinsztein et al. 2001). visuospatial-paired associative learning (Park ct al. 1994)
and stimulus-reward associations learning (Rogers el al. 1999). The detrimental effects of Trp
on memory were comparative with those descnbed following ATD. The fact that both an
increase and decrease in Trp results in memory dysfunction may also suggest that there is an
optimal 5-HT level for cognitive performance.
The Trp-induced impairment on movement time on MCRT is in agreement with results of
W'inokur et al. (Winokur et al. 1986) who showed decreased motor performance on a symbol-
copying test following i.v. Trp. Hence, W'inokur (1986) reported a positive association of
sedation and RT impairments. In our study, confounding analyses showed that sedation was
not likely to explain effects on psychomotor performance.
Possible confounding factors thai might have interfered with cognitive effects of Trp are
physical side-effects and changes in mood and conisol release following Tip. Direct effect» of
5-HT on vigilance and the conversion of Trp to mclaionm by the en/ymes 5-HT N-acetylasc
and 5-hydroxy indole O-methyl transferases may explain the sedating effects of Trp (Cooper
etal. 1991; Schmitt and Riedel 2001) and melatonin may impair directly cognitive
performance (Slotten and Krekling 1996; Jean-Louis et al. 1998). The effects of Tip on mood
(see: Sobczak et al. accepted 3), showed sedation and mood-lowering after Trp indicated by
increased fatigue, decreased vigor and increased anger, depression and tension respectively.
Correlation analyses showed sedation to be positively associated with impaired memory
performance. There were no other interfering effects of mood and physical side effects.
Cortisol is another potential factor, which might have interfered with cognitive performance.
There is now evidence that acute elevation of cortisol may enhance memory performance
(Buchanan and Lovallo 2001; Adler and Jajcevic 2001) as opposed to more chronically
elevated cortisol levels impair memory (Walder et al. 2000; Greendale et al. 2000). In this
study, Tip induced a significant increase in plasma cortisol (described elsewhere: Sobczak et
al. accepted 3). There was a positive association of cortisol response following Trp and
memory performance suggesting that a blunted cortisol response following Tip is associated
with Trp-induced memory impairments. Taking these findings together, the effects of Trp on
memory might possibly have been influenced independently by both sedation and cortisol
after Tip.
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In conclusion, this study showed Trp-induced planning and attention impairments in FH
subjects. These cognitive deficits reflect a 5-HT vulnerability to BD psychopathology
affecting frontal brain functions. Cognitive deficits in FH on memory, psychomotor
performance and attention independent of Trp, provide evidence for a trait maker for BD.
Independent of FH, the major findings of Trp on cognition were impaired memory and
psychomotor performance. It is suggested that an acute change in central 5-HT following Trp
may disturb an optimal S-HT activity in frontal and temporal brain areas and hence cause
specific cognitive deficits. Imaging studies in combination with specific 5-HT challenges
should provide further insight in 5-HT dysfunction and vulnerability and the relation to
cognitive processes in respectively BD patients and FH subjects.
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CHAPTER 8
Lower high-density lipoprotein cholesterol, decreased tu3 und increased u>6
polyunsaturated fatty acids in first-degree relatives of bipolar patients
Abstract
Lower scrum high-density lipoprotein cholesterol and increased ratio of u>6 / w3 fatty acids
have been reported in unipolar and bipolar depressed patients. These changes in cholesterol
and fatty acid composition have been suggested to affect membrane viscosity and
consequently serotonergic neurotransmitter expression, which may enhance serotonergic
vulnerability.
The goal of this study was to investigate whether baseline cholesterol and fatty acids in
healthy first-degree relatives of bipolar patients indicate a trait marker for bipolar disorders
and whether these changes were associated with central serotonergic vulnerability.
Baseline cholesterol and fatty acids were determined in healthy first-degree relatives of
patients with bipolar disorders (n=30) and healthy matched controls (n=l5) according to a
parallel-group design. Central serotonergic vulnerability was assessed by neuroendocrine
responses following acute intravenous tryptophan loading. The relationship between baseline
serum cholesterol, fatty acids, cortisol and prolactine responses following tryptophan
challenge was studied. First-degree relatives showed significantly lower plasma high-density
lipoprotein cholesterol and C18:3cu3 in phospholipids and cholesteryl esters and increased
C20:4(o6 and total eo6 fatty acids in phospholipids compared to controls. Lower total a>3 fatty
acids in phospholipids and cholesteryl esters were associated with lowered baseline mood.
Lower total w3 and higher total too fatty acids in phospholipids were positively associated
with peak prolactine response to intravenous tryptophan challenge.
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This is the first study which investigates baseline cholesterol and fatty acid status in healthy
subjects at genetic risk for bipolar disorders in relation to serotonergic challenging.
Abnormalities in cholesterol and fatty acids in first-degree relatives of bipolar patients are in
agreement with findings in bipolar and major depressed patients. Increased ratio of a>6 / co3
fatty acids are related to central serotonergic vulnerability. As first-degree relatives of bipolar
patients are free of any psychopathology, abnormalities in cholesterol and fatty acids may
constitute a trait rather than a state marker for bipolar disorders.
S Sobc/ak, A Honig, A Christophe, M Macs, RWC Heisdingen. S De Vriese. WJ Riedel, /(rc/iives o/Genera/
/'.vyc/i/a/ry, submitted
Introduction
Abnormalities in cholesterol and fatty acids (FAs) homeostasis have been described in
psychiatric patients, including unipolar depressed and manic bipolar patients (Hibbeln and
Salem 1995; Horrobin 1990; Stoll et al. 1999a; Swartz 1990). The role of cholesterol and FAs
in the pathophysiology of affective disorders has been related to changes in structural
components of cell membranes in the brain. A decrease in cholesterol and FAs affect
membrane microviscosity and consequently functioning of various neurotransmitter systems,
such us Iryptophan hydroxylase activity, serotonin (5-HT) uptake and monoamine oxidase
activity (Huydens-Branchey et al. 2000; Terao et al. 2000; Engelberg 1992; Maes et al. 1994;
Maes et al. 1996). Consequently, low brain-cell membrane cholesterol and changes in FAs
may decrease 5-HT turnover in the brain and hence precipitate depression (Hibbeln et al.
1998b; Hibbeln et al. 1998a).
Significant lower fraction of cholesterol that is esterified. high-density lipoprotein cholesterol
(HDL-C) and total cholesterol have now repeatedly been described in depressed patients
(Olusi und Fido 1996; Maes et al. 1994; Maes et al. 1997a; Sarchiapone et al. 2001).
Moreover, there is evidence for an inverse relationship between plasma cholesterol levels,
severity of depression and suicidal behavior (Bocchetta et al. 2001: Sarchiapone et al. 2001;
Macs et al. 1996; Morgan et al. 1993). In depression, lowered formation of cholesteryl esters
may be related to decreased activity of lecithin: cholesterol acyltransferase (LCAT). a key
en/yme that reacts preferentially with free cholesterol of the HDL-C particles to form
cholesteryl esters. F.stcrification of HDL-C promotes transport of peripheral cholesterol to the
liver (Subbaiah et al. 1990; Hunt and GrotT 1990).
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In bipolar disorders (BD). both decreased (Swart/ 1440) and increased (Brandrup and
Randrup l%7) plasma cholesterol levels have been described. Manic episodes have been
related more to lower cholesterol levels than depressive or mixed episodes (Nibbeln 1995).
Polyunsaturated fatty acids (PUFAs) can be classified into 2 main groups: the «6 and «3 FAs.
which refer to the position of the first double bound when counting from the methyl carbon
atom at the distal end of the FA chain. Of the (»3 FAs. the parent FA is alpha-linolenic acid
(ALA; 18:3 o>3) and of the UJ6 FAS the parent FA is linoleic acid (LA; 18:2 <u6). As humans
lack the desaturase enzyme, which inserts double bounds in FA chains in these positions,
dietary intake is the only source of these PUFAs. Therefore. u>6 (e.g. in seed oil) and «3 (e.g.
in fish oil) FAs are nutritionally essential fatty acids (F.FAs) (Hunt and CirotT I WO, Shils and
Young 1994). Depressed patients show depletion of u>3 FAs in red blood cell membranes,
particularly docosahexaenoic acid (DMA; C'22:(xu3) (Kdwards et al. 1998; Pcct ct al. 1998).
Decreased tu3 fractions in cholesteryl esters and increased C*20:4a>6 / C'20:5o>3 (arachidonic
acid, AA / eicosapentaenoic acid. EPA) ratio in cholesteryl esters and phospholipids huvc
been described in depressed patients (Macs et al. 1996). The severity of depression has been
associated with lower red blood cell membrane co3 FAs and increased AA / EPA ratio in
serum phospholipids (Adams et al. 1996; Edwards et al. 1998). u>3 FAs may be a promising
therapy in BD; BD patients receiving a>3 FAs therapy remained in remission for a significant
longer time than subjects receiving placebo treatment (Stoll et al. 1999b; Kaplan 1999).
Although abnormalities in cholesterol and FAs homeostasis in affective disorders have now
repeatedly been described, it still remains unclear whether these changes are directly related
to the pathogenesis of depression. It has been suggested that changes in food intake and
starvation during severe depression might lead to abnormalities in cholesterol and FAs
homeostasis (Christophe and Vermeulen 1992) and that changes in cholesterol and FAs
indicate a state marker in depression. As clinical remission following antideprcssant
pharmacological therapy did not alter cholesterol and FAs levels in depressed patients (Maes
et al. 1997b; Adams et al. 1996), abnormalities in cholesterol and FAs might indicate a trait
rather than a state marker. In order to investigate the hypothesis that changes in cholesterol
and FAs constitute a trait rather than a state marker, these parameters should be examined in
healthy subjects at genetic risk for affective disorders (Sobczak et al. 2000).
Neuroendocrine responses following challenge with selective 5-HT stimulating agents, e.g.
tryptophan (Trp), are important biological markers to assess brain 5-HT function (Riedel et al.
2002; Nürnberger et al. 1990). A single dose of 50-100 mg/kg i.v. Trp administration causes a
significant increase in prolactine (PRL). possibly mediated by 5-HT20 5-HT2A and 5-HT 1 A
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receptors. Studies on i.v. Tip challenge in BD showed blunted hormonal responses which
provides evidence for 5-HT dysregulation in BD (Nürnberger et al. 1990).
As healthy first-degree relatives of bipolar patients (FH) are at significant genetic risk for BD,
but do not show interference of psychotropic medication, they constitute a useful population
to investigate trait markers for BD. In this study cholesterol and FA status and its relation to
central S-HT vulnerability was investigated in FH subjects and matched controls. The aim of
the present study was to examine i) whether HDL-C, total cholesterol and w3 FAs were lower
and (06 FAs were higher (reflected in an increased <D6 / <D3 ratio) in healthy first-degree
relatives of bipolar patients compared to healthy controls; as trait marker for BD; ii) whether
these changes are related to mood; iii) whether there are significant relationships between
serum cholesterol, FAs and cortisol and prolactine responses to an i.v. tryptophan challenge,
which indicate central 5-HT vulnerability.
Methods
Subjects were FH subjects and matched healthy controls. FH subjects had at least one first-
degree relative with a type I BD or type II BD diagnosis. Family members were recruited via
BD patients in treatment at the Department of Psychiatry, University Hospital Maastricht, via
the consumer organization for manic-depressive patients and their families, and via
advertisements in local newspapers. Healthy control subjects were also recruited via
newspaper advertisement.
In the FH group, the main inclusion criterion was having at least one first degree relative with
BD. Control subjects were free of any psychopathologic family loading. All subjects were
interviewed with an abbreviated version of the Family History Research Diagnostic Criteria
(FHRDC) to assess FH (Endicott 1975). Individual diagnoses (type I or type II BD, according
to DSM IV) of the patients were verified via the patients' own psychiatrist, applying DSM IV
criteria.
Each control subject was matched with 2 FH subjects with respect to gender, age, body mass
index (BMI) and intelligence (IQ). IQ was estimated using Groninger Intelligence Test (GIT)
subtasks (Vocabulary. Mental Rotation. Mental Arithmetic and Word Analogies) (Luteijn
1966).
Exclusion criteria of all subjects were: i) current or history of use of psychopharmacological
medication; ii) lifetime psychiatric disorder including alcohol or drug abuse; iii) current active
126
physical illness; iv) use of any medication known to a fleet fatty acid and cholesterol
metabolism or endocrine functioning: v) subjects consuming a cholesterol or weight-reducing
diet; and vii) pregnancy and current use of lactation.
Physical health was assessed by means of a health questionnaire, a standard physical
examination by a physician and a unne screening. The unne test (ComburX) included
assessment of leukocytes, nitrite. pH. protein, glucose, keiones. urobilinogcn. bilirubin und
blood. A Quick Vie«, one-step pregnancy tesl (QuidelX) was carried out in fcmulc subjects
to check for unsuspected pregnancy.
A standardized psychiatric examination (Mini International Ncuropsychiatnc Interview;
MINI) (Sheehan et al. 1994) was taken of all participants to examine the present psychiatric
state according to DSM IV criteria. The (17-itcm) Hamilton Depression Rating Scale (MDRS)
(Hamilton 1967). the Young Mania Rating Scale (YMRS) (Young et al. 1978) and the
SCL-90 (Amndell 1986) were used to verify the absence of depressive, manic and general
psychiatric symptomatology (by use of cut-off values).
The Medical Ethics Committee of the Academic Hospital of Maastricht approved of the
study. All participants signed informed consent.
Methods
The study used a parallel-group design. The groups were subjects with (FH) or without
(controls) at least one first-degree relative with BD.
To eliminate response bias related to menstrual cycle, all pre-menopausal women were tested
in the follicular phase of the menstrual cycle (Menkes et al. 1994; Rasgon et al. 2000). As FH
subjects and matched controls consumed a no cholesterol or weight-reducing diet, we did not
register daily nutritional intake.
On each test day, the subjects arrived at 9.00 a.m. after an overnight fast. The i.v. cannula was
inserted immediately in a forearm vein. 20 minutes later, at 9.30 a.m. (t-jo) (all time points tx
refer to (-)X minutes (before) / after to) baseline blood samples were taken for determination
of cholesterol. FAs, PRL and cortisol. Blood samples to assess cholesterol and FAs were
taken once, at t-jo on the first test day.
Cortisol and PRL were assessed following Trp challenge at Uo. t?n, Uo and tio?
Thirty minutes after collection, serum tubes were centrifuged (3000rpm, 10 minutes) and
serum was separated and frozen at -80 °C until thawed for analysis. Samples of FH subjects
and controls were analyzed simultaneously and all samples from multiple tests in the same
patient were measured in the same assay.
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Free cholesterol, total cholesterol, HDL-C and triglycerides were assayed using enzymatic-
colorimetric methods based on the technique of Allain et al. (1974) (Allain et al. 1974). Low-
density lipoprotein cholesterol (LDL-C) was computed as total cholesterol - (HDL-C +
triglycerides / 5). Very low-density lipoprotein cholesterol (VLDL-C) was computed as
triglycerides / 5. The esterified-C ratio was computed as (1- free cholesterol: total
cholesterol) * 100. The ratio HDL-C / LDL-C was also computed.
The analytical inter-assay coefficients of variation (CV) were, respectively, as follows: free
and total cholesterol, 0.9%, HDL-C, 2.3% and triglycerides, 1.3%.
Assays of serum FA were carried out as previously described by Maes et al. (1999) (Maes et
al. 1999). Serum lipids were extracted (Folch 1957) and the phospholipids and cholesteryl
esters isolated by thin layer chromatography (Christophe and Matthijs 1967). Their FAs were
converted into methyl esters (Muskiet 1983) whose weight percent composition was
determined after separation on a 25 m x 250 urn df Restek 2330 (cyanopropyl) column (initial
temperature 150 °C; I min isothermal; programmed to 200 "C at 2 °C /min), installed in a
Varian Model 3500 gas Chromatograph equipped with a flame ionization detector (285 °C)
and with a splii/splitless injector (275°C). Split ratio was 1/15. Peak identification was done
by spiking with authentic standards (Alltech). Peak integration and calculation was performed
clcctronicully with a Varian Model 4290 integrator. Results are given as percentage of total
FAs in both phospholipids and cholesteryl esters. The following saturated fatty acids (SFAs),
Monounsuturuted fatty acids (MUFAs). PUFAs and dimethylaldehydes (dma), were
determined in the phospholipid fraction: CI4:0; C15:0; C16:0; C16:0dma; CI6:lt; C16:lto9;
C16:lw7; C17:0; CI8:0; CI8:0dma; C18:l; C18:2w6; C20:0; C18:3co3; C18:4co3; C20:l;
C20:2w6; C20:3w9; C20:3to6; C22:0; C20:4io6; C20:5w3; C24:0; C22:4to6; C24:l; C22:5co6
(docosapentaenoic acid coo; DPAu>6): C22:5u3; C22:6to3 (docosahexanoic acid; DHA);
C25:O. The sums ( I ) of the percentages of co3 and w6 FAs were computed as well as the
ratios of to6 / io3; C20:4w6 / C2O:5w3; and C22:5co6 / C22:6to3. In the cholesteryl esters the
following FAs were assayed: CI4:0; C15:0; C16:0; C 16:1 co9; C 16:1 co7; C16:2a>6; C17:0;
C18:0; CI8:lco9; Cl8:2to6; C18:3to6; CI8:3w3; Cl8:4w3; C20:0; C20:l; C20:2o>6; C20:3a>6;
C20:3w9; C20:4w6; C2O:5«3; C24:l; C22:5u>6: C22:5to3; C22:6o>3; C23:O; C24:0. The w3
and (i)6 FAs and ratios of co6 / <o3 and c20:4to6 / C2O:5w3 were computed. The analytical
inter-assay CV was 8.5% (n=45).
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Cortisol and PRL analyses were performed using an Automated Chemiluminescence's
System (ACS: centaur) from Bayer. Germany. The analytical inter-assay CV was 1.6 % for
cortisol and 0.08 % for prolactine. All samples from multiple tests in the same patient were
measured in the same assay.
A re tan transformations were used to reach normality of distribution and to adjust for
heterogeneity of variance between study groups (i.e. ratio HDL-C / LDL-C, estenfied
cholesterol fraction and FAs).
Group mean differences (controls vs. FH) were assessed by means of analysis of variance
(ANOVA). Relationships between cholesterol or FAs and baseline HDRS, YMRS and ('log)
SCL-90-depression scores (SCL-90-dep). peak (determined as maximal response alter Trp.
corrected for placebo) prolactine and cortisol responses following Trp were checked by means
of Pearson's product moment and regression analyses. The significance was set at a 0.05
(two-tailed). Statistical analyses were performed with SPSS 9.0 for Windows.
Results
The included subjects were 30 FH (10 men and 20 women) and 15 controls (4 men, 11
women), see table 1. Relatives were children (n=20), parents (n=8) and siblings (n=2).
Twenty-one had a first-degree relative with a type I BD diagnosis, and 9 subjects were
relatives of type II BD patients.
The FH and control groups did not differ significantly with respect to age, body mass index
(BMI), intelligence quotient (IQ) and SCL-90 dep, but FH subjects scored significant higher
on baseline HDRS [t=2.27, df 1,39.6; p<0.05].
Of the female subjects, 21 were pre-menopausal and 10 were postmenopausal.13 women used
oral anti-conceptives. 12 subjects were smokers; 10 in the FH group and 2 controls. Values of
FAs were missing for 2 subjects in the FH group.
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Table I. Demographic characteristics; bipolar disorder family loading (1", 2™' and 3"* degree), SCL-90, Young
Mania Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS) total scores; n=45, mean (±SE).
Measure
Women
Men
Family members:
Bipolar disorder
Age
IQ
BM1
SCI.-90-dep
YMRS
HDRS
FH
n 2(1
n=IO
1.3
40 ±3.0
116 ±2.8
2S.2 ± 0.6
18.9 ±0.7
0.83 ± 0.3
1.43 ±0.3
Controls
n=ll
n-4
0.0
38 ± 3.6
116 ±3.6
24.4 ± 0.6
17.5 ±0.5
0.33 ± 0.2
0.33 ±0.2
Table 2 shows the measurements of serum cholesterol. In FH subjects, HDL-C was
significantly lower [F=7.62, df 1,43; p<0.05] and the HDL-C / LDL-C ratio tended to be
lower [F=2.92.df 1,43; p<0.10] compared to controls (see figure 1).
Triglycerides, VLDL-C and esterified-C did not differ between FH and control groups.
Decreasad HDL-C in FH
Figure I. Decreased high-density lipoprulein cholesterol (HDL-C) in first-degree relatives of bipolar patients
(FH) compared to controls. * p< 0.05
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Table 2. Mianwiiimili nf niuiii i hull mini in fuM-dtyec relatives of bipolar patients (FH) and controls, total
cholesterol, free cholesterol and estentied cholesterol as S of total cholesterol, tnglvceruies. high-density
bpoprotcm cholesterol (HDL-C), low-density lipopcotein cholesterol (LUL-O. vcry-lo»-density lipupcvxein
cholesterol ( V L D U and ratio HDL-C ' LOL-C; mean (±SE). n-45. ™ p< 0.1, • p< 005
FH Controls
Total cholesterol (mg < dl)
Estertffed cholesterol (%)
Free cholntrrol (%)
HDL-C (mg / dl)
Trigryeerid« (mg / dl)
LDL-C (mg dl)
\ LDL-C (mg' dl)
HDL-C/LDL-C
206.27(10.15)
72.11 (ISO)
27.89(180)
$0.96 (1.98)»
114.30(10 03)
IJ4.04<8.91)
22.86(2.01)
0 45 (0.04) ™
203.73(1148)
73.78 (0.26)
26.22 (0.26)
61.07(3.3$)
102.33(13 35)
122.20(10.80)
20 47 (2.67)
0 56(0 06)
Table 3 shows the FA composition in scrum phospholipids of FH subjects and hculthy
controls. FH subjects showed significant increased Lto6 [F=5.52, df 1,41; p<0.05] due to
higher C20:4w6 [F=6.03, df 1,41; p<0.05]. PUFAs [F=9.45, df 1.41; p<0.05) were increased
in FH compared to controls (see figure 2). Though Ito3 did not dilTer significantly between
FH and control subjects, C18:3w3 was significant lower [F=9.90, df 1,41; p<O.OS] in FH
subjects and figure 2 shows a tendency to lower ratio CD6 / o>3 in the FH group.
Increased rat» omega-6 / omega-3 in FH
conrro/s.
^F/r) compare«/ to
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MUFAs were lower in FH subjects compared to controls [F=5.60, df 1,41; p<0.05].
Table 3. Tatty acid composition (wt% of total) of plasma phospholipids and cholesteryl esters in first-degree
relatives of bipolar patients (FH) and controls; mean (±SE). n=45 , " p< 0.1, * p< 0.05.
Fatty acids
Phospholipids
FH Controls
Cholesteryl
FH
esters
Controls
ISFA
IMUFA
EPUFA
20:3CD9
45.92 (0.30)
13.00(0.24)»
39.70(0.29)»
0.12(0.01)
46.01 (0.46)
14.41 (0.63)
38.00(0.53)
0.13(0.01)
13.79(0.28)
20.88 (0.46)
63.79(0.53)»
0.08 (0.03)
14.33(0.42)
22.62 (0.94)
61.70(1.07)
0.05(0.01)
18:2(06
20:2(06
20:3(06
20.4(06 (AA)
22:4o)6
22:5(u6 (DI'A(u6)
£»6
I8:4o)3
20:5o)3 (KPA)
22:5o>3
22:6co3 (DHA)
£o»3
Ratios
E<D6AD3
A A/EPA
DPAufe/DIIA
20.99(0.45)
0.30 (0.02)
2.64(0.12)
9.62 (0.28)*
0.61 (0.02)
0.21 (0.02)
34.37 (0.40)»
0.14(0.02)»
0.10(0.01)
0.93(0.16)
0.74 (0.04)
3.30(0.18)
5.21 (0.33)
7.29(0.43)™
16.84(1.88)
0.07 (0.01)
19.80(1.06)
0.31 (0.01)
2.65(0.21)
8.53(0.34)
0.58 (0.06)
0.21 (0.03)
32.09 (0.96)
0.31 (0.08)
0.08(0.01)
0.99(0.14)
0.78 (0.07)
3.61 (0.51)
5.77 (0.56)
6.22 (0.52)
12.15(2.20)
0.06(0.01)
53.25(0.75)
0.06(0.01)
0.68 (0.04)
6.99(0.31)
0.00(0.00)
0.04 (0.03)
61.26(0.62)
0.43 (0.025)»
0.07(0.01)
1.18(0.32)
0.02 (0.00)
0.80 (0.06)
2.48 (0.34)
33.01 (3.02)
12.90(1.64)
0.04 (0.02)
52.58(1.28)
0.06 (0.00)
0.69 (0.04)
5.98(0.35)
0.00 (0.00)
0.02 (0.04)
59.61 (1.13)
0.54 (0.03)
0.07(0.01)
0.79(0.10)
0.02(0.01)
0.66 (0.06)
2.08(0.16)
31.62(2.98)
9.69(1.74)
0.05 (0.03)
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In table 3. the FA composition of cholesteryl esters is presented. CI8:3a>3 [F=7.44. df 1.41;
p<0.05] was significantly lower and PUFAs (F=4.22, df 1.41; p<0.05) were higher in FH
subjects compared to controls.
Other FA measures in cholesteryl esters did not ditTer significantly between FH and control
groups.
Correlation analyses of free cholesterol. triglycerides. HDL-C. LDL-C. VLDL-C. ratio HDL-
C/LDL-C, estenfied-C with smoking behavior. HDRS. YMRS. peak PRL and peak cortisol
responses revealed no significant asstKiations. One-tailed significant negative correlations
were present between SCL-90-dcp and tnglycendes or VLDL-C [r=-0.30, p<O.I).
There were significant associations between peak PRL response to Trp and Iu>3 (r--0.47.
rXO.Ol), IOJ6 (r=0.60, p<0.01], PUFAs (r=0.43, p<0.01], and ratio u>6 / cu3 [r=0.59. p<0 0l]
in phospholipids (see figure 3).
Regression equation: maximal PRL response to Trp = -2.5 + 1.43 * ratio o>6 / (u3.
o
o
F i g u r e i . / * o i / V / w a j 5 o c i o / / o n fcefn^en r a / i o tu<5 / < u i F/<.« i n />Ao.f/7/i»/i/>ttÜ! a n < / m a t / m o / / » r o / a c f / n « -
r e s p o n s e f m / i g / < / / ; to a n i .v. f r v p / o / > A a n c A a / / e n g e ^ W b / /
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SCL-90-dep scale correlated significantly with I<o3 FAs in phospholipids [r=-0.40, p<0.05]
and cholesteryl esters [r=-0.35, p<0.05] and with the ratio C20:4<o6 / C20:5to3 [r=0.31,
p<0.05] and ratio C22:5w6 / C22:6to3 [r=0.42, p<0.05] in phospholipids. HDRS rating was
negatively associated with SFAs in phospholipids [r=-0.40, p<0.05]. Smoking behavior,
YMRS and peak cortisol responses did not correlate with FAs in phospholipids and
cholesteryl esters.
Discussion
The first major findings of this study were a significantly lower baseline plasma HDL-C and
C 18:3ü)3 in phospholipids and cholesteryl esters and increased C20:4w6 and Eo>6 FAs in
phospholipids in FH subjects compared to controls. PUFAs were higher in phospholipids and
cholesteryl esters in FH subjects. Second, lower Lo>3, higher I(o6, PUFAs and increase in
ratio u>6 / w3 in phospholipids were positively associated with peak PRL response to i.v. Trp
challenging. An increase in depressed mood was associated with lower Iio3 FAs in
phospholipids and cholesteryl esters.
To our knowledge, this is the first study which investigates cholesterol and FAs in healthy
subjects at risk for affective disorders. Lower total cholesterol and HDL-C have also been
found in depressed patients which is in agreement with the results of the present study
(Buydens-Branchey et al. 2000; Maes et al. 1997a). High-density lipoprotein plays an
important role in transport of cholesterol to the liver. Lower HDL-C may affect adequate
cholesterol catabolism. In depression, the combination of lower HDL-C and anti-oxidant
activity by vitamin E may result in membrane abnormalities, cellular dysfunctions and also
cardiovascular pathology (Bilici et al. 2001; Maes et al. 2000; Booth-Kewley and Friedman
1987). Although some (Olusi and Fido 1996) but not all research data (Hibbeln and Salem
1995; Maes et al. 1994) indicate that low cholesterol may be a state marker in depression, we
found no significant correlations between HDL-C or total cholesterol levels and mood in
healthy subjects at genetic risk for BD. In BD patients, lower plasma cholesterol levels have
been described (Swartz 1990; Hibbeln and Salem 1995). As we found low HDL-C in FH
subjects which were tree of psychopathology, the present findings suggest low HDL-C to be a
trait rather than a state marker in BD.
Next, plasma CI8:3«3 was lower in phospholipids and cholesteryl esters and C20:4w6 and
I(o6 FAs were higher in phospholipids in FH subjects compared to controls. Independent of
FH, lower Eco3 FAs were associated with a more depressed mood. These findings are in
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concurrence with findings in BD and depressed patients and may again suggest a trait marker
for BD. In BD patients w3 FAs supplementation has mood stabilizing effects which might be
ascribed to stabilization of the 5-HT system and its anti-kindling properties (Stoll et al. IW**a;
Stoll ct al. 1999b; Kaplan 1999; Sullivan et al. 1994). Repletion of u>3 FAs in UD and FH
subjects may therefore influence membrane functioning and signal transduction in the brain
resulting in normalization of mood (Sullivan et al. 1994; Stoll ct al. 1999a). Literature on FAs
in BD is limited, but the abnormalities in FAs as described in FH subjects are in agreement
with findings in major depression. In depressed patients, lower oi3. higher co6 FAS and higher
ratio <o6 / d)3 have been described (Maes et al. 19%; Maes et al. 1999; bdwards et al. 1998;
Adams et al. 1996). However. PUFAs were unexpectedly higher in FH subjects compared to
controls. Higher PUFAs in FH are due to the increase in ct>6 PUFAs at the expense of a
compensatory decrease in MUFAs.
The present study showed no changes in esterified cholesterol in FH subjects, which might
suggest no changes in LCAT activity. The results of Macs et al.. (1994. 1999) suggested
decreased esterified cholesterol in depressed patients, which might be related to increased pro-
inflammatoire cytokincs in depression (Maes et al. 1994; Macs ct al. 1999) As I H subjects
were healthy and free of any psychopathology, acute activation of the inflammatory response
system and consequently changes in esterified cholesterol were not expected.
In the second part of the study, the association between baseline cholesterol and FAs with
hormonal responses to an i.v. Trp challenge was investigated. Lower I « 3 and higher I<u6
FAs in all subjects was accompanied by enhanced PRL response following i.v. Trp challenge.
This suggests that the abnormalities in FAs in FH subjects may be associated with increased
5-HT receptor sensitization. In general, 5-HT receptor sensitization indicates 5-HT
vulnerability in subjects at risk for affective disorders (Riedel et al. 2002). Thus, these results
provide evidence for a direct relationship between peripheral FA level and central 5-HT
functioning. A shift towards lower 0)3 and higher o)6 FAs, as described in FH subjects and
major depressed patients, may therefore explain central 5-HT dysfunctions, severity of
depression and suicidal behavior in these subjects (Adams et al. 1996; Maes et al. 1996; Peet
et al. 1998). Indeed, deficits in w3 FAs have been associated with reduced brain 5-
hydroxyindoleacetic (5-HIAA) concentrations and increased 5-HT receptor sensitization in
humans (Hibbeln et al. 1998a; Hibbeln et al. 1998b). The beneficial effects of treatment with
(o3 FAs in BD and depressed patients may thus be obtained by an improvement in 5-HT
functioning (Stoll et al. 1999b; Stoll et al. 1999a; Sullivan et al. 1994; Mimikjoo et al. 2001).
In depressed patients, suicide and central 5-HT dysfunctions have also been related to low
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HDL-C and total cholesterol (Buydens-Branchey et al. 2000; Sarchiapone et al. 2001;
Engelberg 1992; Bocchettaet al. 2001; Weidneretal. 1992; Maes et al. 2000). The findings
of the present study provide no evidence for an association between cholesterol and central 5-
HT vulnerability. In previous studies, no significant correlation between serum cholesterol
levels and brain 5-HIAA levels or d-fenfluramine-induced PRL and cortisol response was
shown in depressed patients and healthy controls (Sarchiapone et al. 2001; Hibbeln et al.
1998a). Hence, Buydens-Branchey et al.(2000) and Terao et al. (2000) found a significant
negative association between lower HDL-C, serum total cholesterol and neuroendocrine
responses to oral meta-chlorophenylpiperazine (m-CPP) (Buydens-Branchey et al. 2000;
Terao et al. 2000).
Potential conl'ounders were not expected to explain abnormalities in cholesterol and FAs in
FH subjects. Firstly, FH subjects were successfully matched to controls with respect to age,
gender and BMI. Secondly, all subjects were screened for no cholesterol-restricted or weight-
reducing diet. In addition, there were no abnormalities in C20:3u)9 (Mead acid) in any of the
subjects, suggesting that a dietary restriction in LA, LNA, w3 or u>6 FAs was not present
(Christophe and Vcrmeulen 1992). Statistical analyses revealed no significant correlation
between smoking behavior and cholesterol and FAs.
Concluding, the findings of the present study showed abnormalities in baseline HDL-C, w3
and (i>6 FAs in FH subjects, which are in concurrence with findings in patients with BD. As
FH subjects are at genetic risk for BD but free of psychopathology and concurrent
psychotropic medication, abnormalities in cholesterol and FAs constitute a trait rather than a
state murker in HD. Abnormalities in a>3 and to6 FAs in our study are related to 5-HT receptor
sensitivity and may affect 5-HT vulnerability in FH subjects of BD patients.
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Epilogue
The primary aim of this thesis was to study the vulnerability of the central scmtoncrgic
system in first-degree relatives of bipolar patients (FH). First-degree family members of
bipolar patients arc at a significant genetic nsk (10-20%) compared to controls in the general
population (1-5 %) to develop bipolar disorders (BD). This research project was conceived to
gain insight in the serotonergic vulnerability in Fll subjects and thereby in the
pathophysiology of BD.
The increased genetic risk to BD in healthy FH subjects may be reflected in biological murker
systems. Biological markers which are present in healthy Fll subject and BD putients but not
in healthy subjects without an increased genetic risk to BD. arc suggested to constitute truit
markers for BD. The advantage of investigating healthy FH subjects in search for biological
markers is the lack of interference of current or past psychopalhology and psychotropic
medication.
Disturbances in brain serotonin (5-hydroxytryptophan; 5-HT) activity have been assumed to
exist in affective disorders including BD. We examined the vulnerability to central 5-HT
dysfunction in FH subjects by means of 2 experimental manipulations. The experimental
manipulations were based on changes of central 5-HT activity following dietary modifications
(i.e. at the level of amino acid and protein manipulations) in brain tryptophan (Trp)
availability. Brain 5-HT was lowered following Acute Tryptophan depletion (ATD) and
elevated by intravenous (i.v) Trp loading. The effects of ATD in FH were described in the
first part of the thesis. In the second part, the results of i.v. Trp challenge in FH were
presented. We investigated whether FH subjects were more vulnerable to dysregulation of
mood, cognition and hormonal release following ATD and i.v. Trp. In BD and major
depression, abnormalities in cholesterol and fatty acids have been described and related to 5-
HT dysfunctions in the brain. The relation between plasma levels of cholesterol, fatty acids
and central 5-HT vulnerability was also investigated. Effects in FH subjects were compared
with effects in healthy matched controls.
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In this final chapter an attempt is made to integrate the findings presented in the preceding
chapters. This will be discussed with reference to four dependent measures in this thesis:
mood, cognition, hormones and lipid metabolism (i.e. cholesterol and fatty acids).
Differences between FH I and FH II will be discussed and possible biological explanations
given. Conclusions will be drawn with respect to 5-HT vulnerability and cholesterol and fatty
acids metabolism in FH subjects. Based on the results of the present studies, directives for
future research will be given.
Summary and integrative findings
Serotonergic vulnerability to bipolar disorders is reflected in mood response following
serotoncrgic manipulations in first-degree relatives of type II bipolar patients specifically
We found no overall differences between controls and FH subjects in respectively ATD and
Trp-induced mood responses. However, FH II subjects showed different mood responses
following Tip manilupations, i.e. ATD (chapter J and chapter 6). Following ATD, FH II
subjects reported an overall elevation in mood, i.e. less feelings of anger, whereas FH I
subjects and controls experienced a slight mood lowering.
We argue that mood changes following ATD in FH II subjects indicate 5-HT vulnerability.
This 5-HT vulnerability in FH II is explained by the same 5-HT dysfunctions found in
unipolar depressed patients and their first-degree relatives (Klaassen et al. 1999; Delgado et
al. 1989; Delgado et al. 1991). Hence, subjects vulnerable to unipolar depression show
enhanced mood-lowering following ATD (Klaassen et al. 1999), whereas FH subjects who
are vulnerable to HD show an elevation of mood. Elevation in mood has also been reported
following ATI) in remitted BD patients (Cappiello et al. 1997). This discrepancy in mood
response between FH II subjects and relatives of unipolar depressed patients may be due to a
vulnerability to (hypo)mania in FH II. Mania is also associated with hyposerotonergic activity
(Prange et al. 1974; Goodwin and Jamison 1990; Price et al. 1990). The direction of mood-
chunges can be explained by vulnerability to (hypo)mania respectively depression. It is
therefore argued that general vulnerability to affective disorders in FH II predicts pronounced
ATD-induced mood changes.
The overall mood-lowering effect of i.v Trp loading was unexpected but may be partially
explained by sedation (Price et al. 1989; Winokur et al. 1986). Nevertheless, especially FH I!
subjects reported a distinct mood response compared to FH I and controls. Suicide is more
prevalent in BD type II than BD type I patients (Rihmer 1999) and has been associated with
5-HT dysfunction (Pfeffer et al. 1998; Roy et al. 1989; Asberg 1997; Meltzer et al. 1984).
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Therefore suicide provides another independent indication that the pathophysiology of KH II
but not of FH 1 is associated with 5-HT vulnerability.
The fact that the effects of ATD and Tip on mood in FH II were modest hampers firm
conclusions about the existence of central 5-HT vulnerability in FH . Modest efk\ is « uc
probably due to: i) the relatively low number of included FH II subjects, ii) the marginal
effects of Tip manipulations on brain 5-HT function, tii) the difficulty of registering slight
mood changes in otherwise healthy subjects.
Nevertheless, one of the prime findings in this dissertation is that the separate effects of ATD
and Trp on mood suggest 5-HT vulnerability in FH II but not in FH I subjects and controls.
Cognitive «/vs/wtef/o« ;«/ir5f-</*jfree re/a/»v*5 o/"ft»po/ar /wfi<w.v ron.T/fru/f> a fro// m«ir*rr /{>r
Compared to controls. FH subjects showed cognitive deficits on i.e. planning, memory,
psychomotor performance, focused and divided attention independent of 5-HT modulations
( d i f f e r ¥ and cAdp/w 7). The fact that cognitive impairments exist in FH subjects and persist
during clinical remission in BD suggests that these parameters reflect a trait marker for HI)
(Zubieta et al. 2000; Henry et al. 1973; van Gorp et al. 1998; Murphy et al. 1999;
Krabbendam et al. 2000; Coffman et al. 1990; Atre-Vaidya et al. 1998; Ferner et ai. 1999;
Rubinsztein et al. 2000). Moreover, the cognitive deficits in FH subjects were mainly
attributed to impaired performance in FH I and not in FH II subjects. Compared to FH II and
controls, FH I subjects showed significantly impaired performance on planning, memory and
psychomotor performance. Thus cognition as a general trait marker for BI) seems to be quite
inappropriate. Cognition seems to be more specific as a trait marker in BD type I
psychopathology. Another subgroup of psychiatric patients who constitutes specific cognitive
impairments as trait markers are schizophrenic patients (Krabbendam et al. 2000). We
therefore argue that the cognitive impairments in FH I implicate symptoms of psychotic-
disorders (Sobczak et al. in press; Krabbendam et al. 2000) more than of a primary affective
disorder (Dickerson et al. 2001; Morice 1990; Borkowska et al. 2001). Whether 5-HT
vulnerability is involved in the pathogenesis of cognitive dysfunctions in FH I and BD
remains speculative, it could be hypothesized that vulnerability of dopaminergic and
noradrenergic systems are involved in cognitive dysfunctions (Schmitt and Riedel 1999).
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Sero/o/wg/c vw/werafc/7/'ry /'«//rs/-cfegree re/a//ves o/Wpo/ar pa/j'en/s m/g/i/ q^ecr cogwi/ive
processes /neo/a/etf" Av/row/a/ /o/>e areas
The results of ATD showed detrimental effects on planning in FH subjects, but not in controls
(c/rap/er 4). Following Tip, FH subjects showed impaired planning performance and attention
(c/fop/er 7).
Planning and attention are cognitive functions which are primarily regulated by frontal brain
areas (Owen et al. 1990). This suggest that mainly frontal-lobe related cognitive functions are
vulnerable to 5-HT dysfunctions in FH (Dagher et al. 1999; Elliott et al. 1997; Murphy et al.
1999; Rubinsztein et al. 2001). Indeed, we found no differences between FH and controls in
effects of ATD and Trp on more temporal lobe mediated cognitive functions such as memory,
learning and psychomotor performance. These results are in agreement with findings in BD
patients, who showed improvement of planning deficits after clinical recovery which involves
an increase in 5-HT activity (Rubinsztein et al. 2000).
The fact that both a decrease and increase in central Trp may impair planning performance
can be explained by the following mechanism: in FH subjects the 5-HT system is not
pathologically disturbed but only vulnerable to dysfunctions. Probably an endogenous
compensatory brain mechanism conceals the potential central 5-HT dysfunction in FH
subjects. Following ATD and Trp, acute changes in 5-HT occur. Independent of the direction
of S-HT modulations, these may be regarded as Stressors and thereby transiently disturb the
equilibrium between 5-HT and the compensatory mechanism. Consequently cognitive
impairments will occur. This hypothesis is consistent with the kindling and stress sensitization
theory of Post and Weiss (1997) which includes neural changes in the brain in response to
Stressors during the pre-morbid state. In FH subjects, this stress sensitization will result in
brain abnormalities, disturbance of the compensatory mechanism and ultimately in BD
psychopathology.
Hence, the increased vulnerability in FH to cognitive deficits following ATD and Trp may
also be explained by their initial suboptimal performance (as has been described above). On
the other hand baseline impairments on memory and psychomotor performance in FH did not
result in more pronounced cognitive deficits following ATD and Trp. This explanation also
suggest vulnerability to ATD and Trp-induced cognitive impairments to be more pronounced
in FH I. Indeed, the results showed some evidence for more pronounced cognitive effects of
ATD and Trp in FH 1 (i.e. on planning).
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In conclusion. FH subjects show 5-HT vulnerability affecting cognitive functions located
mainly in frontal brain areas. The findings seem to be consistent with initial cognitive
dysfunctions in FH I subjects.
I/sag* p/Yorftsc»/ am/ P/M. rw/xwues /W/oH-Mg ^TD a « / 7>p oi
some ev/dewe /far 5-//F »•w/neroAi/iA- in F//.
Cortisol response following stress was lowered after ATD in FH subjects whereas it tended to
increase in controls (<7iqp/?r J). Trp induced a robust elevation of PRL and cortisol release,
however no significant differences were found in hormonal responses between FH and
controls (r/Ky>/er 6). Controls and FH subjects did not show differences in baseline cortisol
and prolactine levels prior to experimental 5-HT manipulations.
As the methodological procedures between the studies with respect to hormonal assessments
di tiered in several ways, results from comparisons of the findings must be interpreted with
caution.
The decrease in cortisol following ATD in FH provides some evidence for a disturbance in
the connection of 5-HT and HPA-axis functioning. Previous studies showed no significant
effects of ATD on cortisol release, however findings are limited (Price et al. 1998; Goddard el
al. 1995). To our knowledge there were no studies which investigated the effects of stress-
induced cortisol response following ATD. The fact that assessment of stress-induced cortisol
response following ATD differentiated between FH subjects and controls suggests that stress-
induction following 5-HT challenges is a sensitive procedure to investigate 5-HT
vulnerability. Results of i.v. Trp challenge on hormones did not confirm 5-HT vulnerability in
FH. Possibly, including a stress-inducing task following the i.v. Trp challenge will make the
i.v. Trp challenge more sensitive to assess 5-HT vulnerability in FH.
In BD patients, there is evidence for 5-HT mediated abnormalities in cortisol release (Vieta et
al. 1999; Rybakowski and Twardowska 1999). Following i.v. Trp challenge a blunted cortisol
response has been described in BD patients compared to controls (Nürnberger et al. 1990).
Nevertheless, using hormones as peripheral markers to indicate 5-HT dysfunction following
5-HT challenges in BD revealed inconsistent results and interfering factors such as current
mood-state and usage of psychotropic medication might partially explain the findings
(Sobczak et al. accepted; Van Praag et al. 1987). Thus, usage of hormonal responses as
biological markers following ATD and Trp in BD and FH subjects remains speculative and
needs further investigation.
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Compared to FH 1 and controls, FH II subjects showed a tendency towards a more
pronounced Trp-induced PRL response. However, overall effects of ATD and Trp on cortisol
and PRL were similar in FH I and FH II.
Thus using cortisol and PRL as biological markers provides some evidence for 5-HT
vulnerability in FH. However the effects were borderline, and might probably be improved by
methodological adjustments i.e. including a stress-inducing procedure prior to hormonal
assessments.
a />/o/og/'ca/ /mwter/ör A/po/ar t/Kort/ers vv/w'c/i »
FH subjects showed lower baseline plasma high-density lipoprotein-cholesterol (HDL-C) and
C18:3u>3 in phospholipids and cholcsteryl esters and higher C20:4u>6 and Iw6 fatty acids
(FAs) in phospholipids compared to controls. These findings are in agreement with lower
cholesterol levels, i.e. HDL-C and increased u>3 / co6 ratio in BD and unipolar depressed
patients (Buydens-Branchey et al. 2000; Swartz 1990; Hibbeln and Salem 1995; Maes et al.
1997). In depression, low cholesterol and changes in FAs have been suggested to constitute
state markers (Olusi and Fido 1996). Hence as FH subjects are free of psychopathology and
psychotropic medication, the low HDL-C and abnormalities in FAs provide evidence for trait
rather than state markers to BD.
Abnormalities in cholesterol and FAs may affect membrane microviscosity, receptor
functioning, S-HT transportation and turnover in the brain and hence precipitate BD and
depression (Buydens-Branchey et al. 2000; Terao et al. 2000; Engelberg 1992; Maes et al.
1994; Maes et al. 1996; Hibbeln et al. 1998a; Hibbeln et al. 1998b). Indeed we found a
significant positive association between increase in ratio <o6 / w3 and peak PRL response to
i.V. Trp challenging. At baseline, lower Lw3 FAs were also associated with lower mood in FH
and control subjects. Probably, the abnormalities in FAs in FH subjects are associated with
altered 5-HT receptor sensitization and reflect 5-HT vulnerability to BD. This implies a direct
relationship between peripheral FAs levels, central 5-HT functioning and mood.
The abnormalities in cholesterol and FAs may influence the view on 5-HT vulnerability to
BD tremendously. It is suggested that abnormalities in metabolism of cholesterol and FAs
may be related to changes in brain 5-HT and psychopathology. A shift towards lowered w3
and HDL-C and increased «6 FAs has been related to 5-HT dysfunctions, severity of
depression and suicidal behavior in major depressed patients (Adams et al. 1996; Maes et al.
146
1996; Pert et al. 1998; Buydens-Branchey et al. 2000; Sarchiapone et al 2001; Bocchetta et
al. 2001; Engelberg 1992; Rabe-Jablonska and Poprawska 2000; Wcidner et al. 1992). As cu9
FAs did not differ between groups, we do not assume that differences in dietary intake explain
the changes in cholesterol and FAs metabolism in depression and Bl) The results suggest a
genetically predisposition for disturbances in HDL-C. «»3 and it* FAs metabolism in Bl).
How abnormalities in cholesterol and FAs are genetically linked with BD psychopathology
remains unresolved and should be investigated in future research. IX-spite the fact that these
subject were healthy, the magnitude of lipid abnormalities resemble abnormalities described
in BD and major depression. This suggests that there is probably a complex genetic relation
between lipid abnormalities and neurotransmitter dysfunctions which may ultimately result in
BD psychopathology. To elucidate these hypotheses, future research should concentrate on
genetic linkage between enzymes of lipid metabolism and genes associated with BD.
The abnormalities in cholesterol and FAs tended to be more pronounced in FH I subjects
compared to FH II. Changes in cholesterol and FAs has been associated with cognitive
dysfunction and white matter changes in the brain (Yehuda ct al.. 199V; Benton et al. 1995;
Muldoon et al., 1997). In BD patients, structural brain changes have been associated with
impaired cognitive performance (Dupont et al., 1990). It sounds thus plausible that the
changes in HDL-C, «3 and cu6 FAs in FH I may explain the cognitive deficits. Hence, in this
study the number of participating FH II subjects was too low to draw general conclusions
about cholesterol and FAs abnormalities in these subjects.
In conclusion, abnormalities in cholesterol and FAs in FH subjects indicate biological
vulnerability to BD and may underlie 5-HT vulnerability. In future research, brain imaging
should be applied to investigate the relationship between abnormalities in cholesterol, FAs,
cognitive dysfunctions and structural brain changes in FH, BD patients and several control
groups including healthy subjects, subgroups of psychiatric and somatic patients.
re/artves o//y/je / aw*/ fvpe // Aipo/ar
The integrative findings of the presented studies provide evidence for a biological distinction
between FH I and FH II subjects.
In general, FH II subjects were more vulnerable to mood changes following 5-HT
manipulations by ATD. FH I subjects were characterized by cognitive deficits and a tendency
towards more pronounced vulnerability to 5-HT induced cognitive changes. It is concluded
that FH II subjects share more symptoms of primary affective disorders whereas FH I subjects
show characteristics of primary psychotic disorders. Vulnerability to mood changes in FH II
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seemed to be directly related to changes in brain 5-HT levels which indicates central 5-HT
vulnerability in these subjects. There was less evidence for 5-HT vulnerability in FH I
subjects. We suggest that the cognitive dysfunctions in FH 1 may be a consequence of central
vulnerability to dysfunctions in other neurotransmitter, e.g. dopamine and / or noradrenaline
and / or structural brain changes in which abnormalities in cholesterol and FAs play an
important role.
Conclusions
The use of acute experimental dietary Trp manipulations turned out to be a useful method to
investigate 5-HT vulnerability to BD. In this thesis it was demonstrated that mood, cognitive
and hormonal responses to changes in central Trp availability indicate central 5-HT
vulnerability. Changes in mood following 5-HT manipulations tended to be more prominent
in FH II subjects (r/w/j/er J and 6). FH I subjects specifically showed cognitive deficits
(cAo/»/fr </ and 7) and tended to be more vulnerable to cognitive changes following ATD and
Trp challenging. The stress-induced cortisol release was blunted in FH subjects following
ATD. This suggests that the relationship between 5-HT and HPA-axis functioning is altered
in FH (r/ia/>ter J). Hormonal responses to Trp and ATD as indicator of 5-HT vulnerability did
not distinguish between FH 1 and FH II (r/iap/er 3 and 6). In FH subjects, abnormalities in
cholesterol and FAs have been described and linked with central 5-HT vulnerability (c/iapter
At). We assume that changes in lipid metabolism may play an important role in 5-HT
vulnerability to BD.
In conclusion, the studies described in this thesis show a biological distinction between FH I
and FH II subjects. As FH II subjects were more vulnerable to mood changes following 5-HT
manipulations, we suggest that 5-HT vulnerability seem to be more specifically present in FH
II subjects. The fact that both a decrease and increase in 5-HT result in mood changes implies
thut these subjects are generally vulnerable to a 5-HT imbalance. FH 1 subjects seemed to be
less vulnerable to 5-HT changes. Cognitive deficits in FH I may constitute a trait marker to
BD which may be explained by disturbances in other neurotransmitter systems or lipid
mctubolism.
When interpreting the results it must be kept in mind that effects of 5-HT manipulations were
measured in healthy subjects instead of patients who will probably show more pronounced
effects on mood, cognition and hormonal release. FH subjects do not show psychopathology
und potential 5-HT dysfunctions are probably compensated for by biological coping
mechanisms. This may explain why we did not report the same magnitude of effects of ATD
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and Trp as found in BD and unipolar depressed patients. Next, the number of included KH II
was relatively low compared to FH I subjects Therefore, effects in FH II subjects may be
preliminary and further research on 5-HT vulnerability should distinguish between KM I and
FH II.
In search for biological markers to BD. the findings of abnormalities in cholesterol and I'As
seemed to be very promising. Probably there is an important relationship between lipid
metabolism and brain neurotransmitter functioning Changes in cholesterol and FAs seemed
to be an important process which may explain neurotransmitter dysfunctions in BD,
depression and possibly other psychiatric disorders. Further research to biological markers in
BD should investigate the role of cholesterol and FAs in brain ncurotrunsmilter functioning,
i.e. 5-HT. dopamine and noradrenahne in type 1 and type II BD patients anil their llrsi-dcgrcc
relatives.
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Eerstegraads familieleden van manisch-depressievc pati£ntcn die /clfnooit kenmerken
hebben gehad van een mamsch-deprcssieve stoomis (MDS) hebben genetisch een serhoogd
risico om ook MDS te onlwikkclen Met pnmaire doel van du proefschrift was het in kuart
brengen van biologische factoren die dc kuctsbaarhcid voor MDS bij gc/ondc lamilicleden
van MDS patienten weergeven. Disfunctioneren van het serotoninc (5-hydroxytryplofaan; 5-
HT) systcem in de hersenen van MDS t'ungeerde hierbij als uitgangspunt. Door hct bcsludcrcn
van het S-HT systcem bij familieleden. die een verhoogd nsico hebben, kan een uitspraak
gedaan worden over dc betrokkenheid van 5-HT bij MDS. Met funclioncrcn vun het 5-HT
systcem kan onder/ocht worden met behulp van cxperimenlclc manipulaties die dc aclivilcit
van 5-HT in de hersenen vertagen of verhogen. De 5-HT funeties bij gezonde eerstegruads
familieleden van MDS pationten werden vergeleken met een qua leeftijd, geslacht en
opleiding vergelijkbare controle groep zonder verhoogd genetisch risico. Hen abnormale 5-
HT funetie bij normaal gedrag duidt op een 'kwetsbaar' serotonine systeem. Aangcnomcn
wordt dat een serotonerge kwetsbaarheid bij familieleden van MDS patic'nten gegencruliseerd
kan worden naar MDS patienten, d.w.z. dat 5-HT dus mogelijk een rol speelt in de
pathofysiologie van MDS. In dit proefschrift werd de serotonerge kwetsbaarheid onderzocht
met behulp van twee experimentele procedures: Acute Tryptofaan Depletie (ATD) en
intraveneuze (i.v.) tryptofaan (Trp) toediening. Het eerste gedeelte van het proefschrift
beschrijft onderzoeken waarbij gebruik werd gemaakt van ATD. In het tweede gedeelte
worden effecten van Trp toediening en de relatie met cholesterol en vetzuren uitgewerkt. De
serotonerge kwetsbaarheid wordt in dit proefschrift bepaald door effecten van dc ATD en Trp
op 3 soorten afhankelijke variabelen: stemming, cognitie en hormonale responsen. In alle
onderzoeken wordt een onderscheid gemaakt tussen familieleden van type I en type II MDS
patienten.
/ bevat een algemene inleiding over de onderwerpen en onderzoeken die in dit
proefschrift aan bod komen. Aan de orde komen onder andere het genetische risico bij
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familieleden en de relevantie om biologische risicofactoren te onderzoeken die een betere
inschatting van de kans op het krijgen van MDS weergeven. Er werd een körte inleiding
gegeven tot de indeling van verschallende classificaties van MDS en de daaraan gerelateerde
Symptomatologie. Het verschil tussen depressie, manie en hypomanie, type I en type II MDS
wordt uitgelegd. Het onderzoeken van een serotonerge kwetsbaarheid bij familieleden van
MDS patienten is gebaseerd op reeds eerder beschreven disfuncties van het 5-HT systeem in
de hersenen van MDS patignten. De aanmaak van 5-HT in de hersenen is direct afhankelijk
van de beschikbaarheid van het aminozuur Tip. ATD is een methode waarbij de hoeveelheid
beschikbaar Trp in de hersenen daalt na inname van een eiwitdrankje waarin het aminozuur
Trp ontbreekt. Aan de andere kant heeft een i.v. toediening van Trp een verhoging van Trp en
5-HT in de hersenen tot gevolg. ATD en i.v. Trp toediening zijn dus aminozuur manipulaties
die geschikt zijn om de serotonerge kwetsbaarheid bij familieleden van MDS patienten te
onder/oeken. Eveneens wordt de rclatie tussen serotonerge kwetsbaarheid en afwijkingen in
de cholesterol en vetzuur huishouding bij familieleden van MDS patignten onderzocht. In dit
hoofdstuk wordt een overzicht gegeven van de doelstellingen die ten grondslag liggen aan de
verschillende onderzoeken die beschreven staan in dit proefschrift.
In /loo/äv/wA 2.J en 4 wordt de serotonerge kwetsbaarheid bij MDS onderzocht met behulp
van ATD. //»o/i/v/w/t 2 bevat een literatuurstudie naar de effecten van ATD bij MDS
patienten. In fc;»/ä!vruik J en 4 worden de effecten van ATD en placebo bij 30 gezonde
eerstegraads familieleden van MDS patienten en 15 gematchte controle proefpersonen
gepresenteerd. De serotonerge manipulaties bestaan uit inname van een 75gr aminozuur
mengsei met Trp (placebo) en zonder Trp (ATD). In ieder hoofdstuk worden specifieke
hypothcsen van dit onderzoek uitgewerkt.
Een literatuurstudie naar de effecten van ATD bij MDS patienten is beschreven in
2. Het aantal onderzoeken naar de stemmingsveranderingen na ATD bij MDS patienten was
beperkt en vertoonde inconsistente resultaten; er waren maar 3 artikelen over ATD bij MDS
patienten beschikbaar. Inconsistente bevindingen die beschreven zijn in de artikels hangen
mogelijk samen met verschillende gevolgde methodologische procedures en / of verschillen
in eigenschappen van de MDS patienten die onderzocht werden. De gehanteerde
methodologische procedures en proefpersonen selectie bij deze verschillende onderzoeken
worden kritisch becommentarieerd. Vervolgens worden aanbevelingen gedaan voor een
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gestandaardiseerd onderzoeksprotocol ten behoeve v«n onderzoek naar de serotonergc
kwetsbaarheid bij MDS.
In /»oo/ifcrwt J wordt de serotonerge kwetsbaarheid van cerstegnadi familiclcdcn van MDS
patienten onderzocht. De effecien van ATD versus placebo op stemming en con i so I sccrciie
worden onderzocht bij familieleden en vergeleken met gczonde controle personen. Cortisol
wordt gemeten in speeksel. zowel voor als na een stresserende procedure, de zogenaamde
stress-inducerende spreek laak (SIST). Uit dc resultaten blijkt dat eerslcgraads familieleden
van type II MDS patienten meer gevoelig ziin voor dc effecten van ATD vergeleken met
familieleden van type I patienten en controle personen Familieleden van type II paiientcn
rapporteren juist een verhoging in stemming, terwijl een gcliikwaardigc ilahng in stemming
werd gevonden bij familieleden van type I patientcn en controle personen. IX- stress
gelnduceerde cortisol response is verlaagd na ATD bij familieleden, maar met bij controle
personen.
Geconcludeerd wordt dat de effecten van ATD op stemming bij familieleden van type II
patienten in ovcreenstemming zijn met bevindingen bij MDS patienten herder ondcr/ock
heeft aangetoond dat MDS patienten na ATD een tijdelijke toename in manische Symptomen
kunnen ervaren. Het huidige onderzoek suggereert daarom een serotonerge kwetsbaarheid bij
familieleden van type II MDS patienten. Daarnaast waren er zowel bij familieleden van type I
en type II patienten aanwijzingen voor een serotonerge kwetsbaarheid vanwege een
afwijkende hormonale respons op ATD.
beschrijft de effecten van ATD op cognitieve processen, met name planning,
geheugen, leren en aandacht. Uit eerder onderzoek blijkt dat 5-HT een belangrijke rol speelt
bij het functioneren van diverse cognitieve processen. MDS patienten hebben veelal cmstige
cognitieve disfuncties die mogelijk terug te voeren zijn op een abnormaal funetioncrend
centraal 5-HT systeem. In dit onderzoek worden de cognitieve prestaties op de af/onderlijke
cognitieve taken gemeten voor ATD (baseline) en 5 uur na ATD. ATD heeft bij familieleden
een negatief effect op snelheid van informatieverwerking gemeten met de planningstaak, maar
niet bij controle personen. Onafhankelijk van de effecten van ATD is de cognitieve capaciteit
op o.a. planning en geheugen verminderd bij eerstegraads familieleden van type I patienten
vergeleken met familieleden van type II patienten en controle personen. In zowel familieleden
als controle personen heeft ATD een afname in de prestatie op consolidate van nieuwe
informatie in het lange termijn geheugen en snelheid van informatieverwerking tot gevolg.
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De effecten van ATD op planning worden geinterpreteerd als aanwijzingen voor een
serotonerge kwetsbaarheid gelokaliseerd in frontale hersengebieden van eerstegraads
familieleden. Geconcludeerd wordt voorts dat de cognitieve defecten bij familieleden van
type I patienten mogelijk een overeenkomst vertonen met Symptomen van een psychotische
stoornis. Cognitieve stoornissen kunnen gezien worden als potentiöle markers die een aanleg
voor MDS weerspiegelen.
5, 6, 7 en Ä wordt de serotonerge kwetsbaarheid voor MDS onderzocht
met behulp van zogenaamde acute manipulaties die het centrale serotonerg systeem
stimuleren. //rw/iA'"'* 5 beschrijft een literatuur Studie naar de acute effecten van 5-HT
verhogingen bij MDS patienten. In Aoq/y.s/wÄ 6 en 7 worden de resultaten van een onderzoek
naar de elTecten van 7.0gr intraveneuze Trp toediening (opgelost in lOOOcc water en
fysiologische zout) en placebo (lOOOcc fysiologisch zout) bij 30 gezonde familieleden van
MDS patiönten en 15 gematchte controle personen beschreven. In /!oo/£fr/«£ 6 staan de
effecten van Trp op stemming en hormoon respons weergegeven. //oq/i&r/u/t 7 behandelt de
effecten van Trp op cognitie. Een mogelijke relatie tussen serotonerge kwetsbaarheid bij
familieleden cn afwijkingen in de cholesterol en vetzuur huishouding werd onderzocht in
5 beschrijft een literatuur Studie naar de effecten van acute 5-HT verhogingen bij
MDS patienten. De hormoon responsen van o.a. Cortisol, prolactine (PRL) en
adrenoeorticotroop hormoon (ACTH) op 5-HT verhogingen blijken goede indicatoren te zijn
voor het onder/oeken van de serotonerge kwetsbaarheid. In het algemeen kan worden
aangenomen dat een verlaagde 5-HT gei'nduceerde hormoon respons het gevolg is van o.a.
post-synaptische desensitisatie van 5-HT reeeptoren of presynaptische neurotransmitter
depletie. Daarentegen kan een verhoogde 5-HT geVnduceerde hormoon respons juist een
sensitisering van post-synaptische 5-HT reeeptoren indiceren. De bij MDS patienten
toegepaste acute 5-HT verhogingen zijn: acute intraveneuze en orale toediening van d,l-
fenfUiraminc. tryptofaan, 5-hydroxytryptofaan. ipsapirone and buspirone. De effecten van
deze 5-HT verhogende Stoffen worden apart gepresenteerd voor respectievelijk MDS
patiönten in remissie of gedurende een manische of depressieve episode. De literatuur geeft
aanwijzingen voor een mogelijke verlaagde prolactine response bij manische en depressieve
BD patiönten en een verlaagde cortisol response bij MDS patienten in remissie. De conclusie
is dat aan /owel depressie als manie mogelijk vergelijkbare serotonerge disfuneties ten
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grondslag liggen. Er wordt gesuggereerd dat een lagere Cortisol response ecn chronisch
disfunctioneren van net serotonine systeem weerspiegelt terwijl verandenngen in prolaciine
response juist meer een indicatie gcven van stemmingsgcbondcn \erundcnngcn in dc
serotonine huishouding.
In fcx>/£&ruJt 6 wordt de serotonerge kwetshaarheid voor MDS onder/ochl bij gc/onde
eerstegraads familieleden van MDS patienten. De senrtonerge kwetshaarheid wordt gemeten
door middel van verandenngen in stemming, conisol en prolactinc in rcspons op ccn acute
i.v. Trp toediening. Een verhoogde of verlaagde hormoon rcspons is indicalicf voor ccn
verandenng in pre- en post-synaptische neurotransmitter activiteit en 5-HT receptor
gevocligheid in de herscnen. Intravencu/e toediening \an Trp resultecrt in ecn vcrlaging van
stemming en verhoogde afgiften van cortisol en proluctine. In bcginscl lijkcn cr geen
verseht Men te bestaan tussen familieleden van MDS patiCntcn en contmlc pcrsoncn. De
resulaten tonen echter en ige evidentie voor een biologisch verschil tussen ecrstcgraads
familieleden van type 1 en type II patienten. Ten eerste induceert Trp ecn marginalc tocname
in manische Symptomen bij familieleden van type II patienlcn en met bij familieleden van
type I patienten en controle personen. Ten tweede lijkt de door Trp gel'nduceerde prolactine
respons bij familieleden van type II patienten hoger vergeleken met de andere groepen. De
effecten van Trp op stemming en hormonen bij familieleden van type I patienten verschillen
niet met de effecten in controle personen.
Bij het onderzoek dat beschreven wordt in /loo/cfr/w/t 7 is de serotonerge kwetsbaarheid bij
familieleden van MDS patienten aan de hand van cognitieve effecten van een acute i.v. Trp
toediening bestudeerd. De gemeten cognitieve parameters zijn o.a.: planning, leren,
werkgeheugen, gerichte, verdeelde en volgehouden aandacht en de snelheid van
psychomotorisch functioneren. De cognitieve prestaties werden gemetcn 3 uur na toediening
van Trp. De cognitieve prestaties op planning en aandacht taken is lager na Trp bij
familieleden, maar niet bij controle personen. Onafhankelijk van Trp. is het cognitief
functioneren van familieleden op geheugen, gerichte en verdeelde aandacht en psychomotorc
reactietijd significant slechter dan bij controle personen. De cognitieve disfuncties zijn meer
uitgesproken bij familieleden van type I dan bij familieleden van type II patienten. Trp
resulteert in een significante verslechtering van geheugen en psychomotore reactietijd bij
familieleden en controle personen. Er wordt geconcludeerd dat de gevonden cognitieve
beperkingen na Trp bij familieleden aanwijzingen zijn voor serotonerge kwetsbaarheid die
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frontaal-gemedieerde cognitieve processen beinvloeden. De cognitieve beperkingen bij
familieleden vormen mogelijke biologische markers voor een verhoogd risico MDS te
ontwikkelen.
De rol van afwijkingen in de cholesterol- en vetzuurhuishouding in de pathofysiologie van
MDS werd bestudeerd in /ioo/£frrw/t Ä. Een verlaagde 'high-density lipoprotein cholesterol'
(HDL-C) en een verhoogde to6 / co3 ratio is reeds eerder aangetoond bij zowel unipolair
depressieve en MDS patiönten. Deze veranderingen in cholesterol en vetzuren beinvloeden
het functioneren van de celmembraan, receptoren en celtransportmechanismen en zijn daarom
gerclateerd aan 5-HT neurotransmitter disfuncties in het brein. De primaire doelstellingen die
ten grondslag liggen aan dit onderzoek zijn: i) het bestuderen van mogelijke afwijkingen in de
cholesterol en vetzuur status bij familieleden van MDS patiönten welke indicatief zouden
kunncn zijn voor een verhoogd risico om MDS te ontwikkelen, ii) bestuderen of afwijkingen
in cholesterol en vetzuur status gerelateerd zijn aan de gemeten serotonerge kwetsbaarheid in
het brein gemeten m.b.v. maximale cortisol en prolactine respons na Trp. De baseline
bcpalingen van cholesterol en vetzuren werden gemeten bij familieleden en controle personen
volgens een parallclgroep design. Vergeleken met controle personen is HDL-C en C18:3<o3
significant lager en C20:4(o6 en totaal w6 vetzuren significant hoger bij familieleden. Een
lagere totaal o>3 vetzuurstatus is gerelateerd aan een lagere baseline stemming. Er is een
significant positieve correlatie tussen een läge totaal co3 en hoge totaal <o6 en maximale
prolactine respons na Trp. De afwijkingen in cholesterol- en vetzuurstatus bij familieleden
komen overeen met bevindingen bij MDS patiönten. Daarom wordt gesuggereerd dat de
gevonden afwijkingen een biologisch risico voor MDS reflecteren. Afwijkingen in w3 en co6
vet/uren zijn daamaast positief geassocieerd met indicatoren voor een serotonerge
kwetsbaarheid. Dit wijst mogelijk in de richting van een directe causale relatie tussen
disfunctioneren van S-HT in het brein en afwijkingen in de vetzuurhuishouding.
9 worden de bevindingen van de verschillende gerapporteerde onderzoeken in dit
proefschrift gcTntegreerd en bediscussieerd. Uit de onderzoeken in dit proefschrift blijkt dat
manipulaties van het aminozuur Trp goede mogelijkheden biedt om de serotonerge
kwetsbaarheid bij eerstegraads familieleden van MDS patiönten te onderzoeken. De door
ATD en Trp geVnduceerde veranderingen in stemming, cognitie en hormonen fungeren als
goede parameters voor de centrale serotonerge kwetsbaarheid. Uit de resultaten blijkt dat
familieleden van type II patiönten meer gevoelig zijn voor stemmingsverandenngen t.g.v. een
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serotonerge disbalans. Familieleden van type II patienten rapporteren na ATD en Trp ecn
vcrhogtng in stemming respectievelijk ecn marginale toenamc van manische Symptomen
Familieleden van type I patifnten en controle personen ervaren juist ecn dating in stemming
na beide expenmentele manipulates. Daarentegcn worden familieleden van type I paticnten
juist gekenmerkt door cognitieve defecten. Deze cognitieve disfuneties indicervn mogelijk ecn
biologisch risico voor MDS. De cognitieve effecten van ATD en Trp lijken mecr uitgesproken
bij familieleden van type I paticnten Hei gebruik van com sol en prolactine als perifere
markers geeft enige aanwijzingen voor cen serotonerge kwetsbaarhcid bij fumilicleden van
MDS paticnten. De hormoonparameters toonden geen ondcrschcid bij familieleden van type I
en type II paticnten. Mogelijk /ou de gevoeligheid van hormonale responsen uls biologische
markers bevorderd worden m.b.v. een strcssinduccrcndc procedure. Hit baseline mclingen van
cholesterol en vetzuren blijken lagere HDL-C* en 10.I en hogerc ii>6 vet/uur plusma spicgcis bi|
familieleden van MDS patienten Deze afwijkingen komen overecn met bewngen bij MDS en
unipolair depressieve patienten. Er wordt geconcludecrd dat deze vcrandcringcn in cholesterol
en vetzuren een biologische kwetsbaarhcid voor MDS indiccren. Lagere plasma «>3 cn hogerc
w6 plasma spiegeis zijn gerelatcerd aan een verhoogde maximale prolactine respons na Trp.
Dit implieeert een belangrijke verband tussen verandering in vetzuren en serotonerge
kwetsbaarheid voor MDS en mogelijk andere psychiatrische aandoeningen.
Concluderend kan gesteld worden dat de onderzoeken in dit proefschrift aanwijzingen geven
voor een biologisch onderscheid, familieleden van BD patit'nten en controle personen cn meer
in het bijzonder tussen familieleden van type I en type II patienten. Familieleden van type II
patienten tonen overeenkomsten met een affectief spectrum waarin serotonerge kwetsbaarheid
een rol speelt. Daarentegen lijkt de serotonerge kwetsbaarheid minder uitgesproken bij
familieleden van type I pationten. Zij vertonen juist meer eigenschappen die /ouden kunnen
passen bij een primair psychotische stoomis. Mogelijk speien andere neurotransmitter
Systemen zoals dopamine en noradrenaline bij deze laatste groep een meer prominente rol.
Verandenngen in cholesterol en vetzuur metabolisme zijn waarschijnlijk betrokken bij
biologische disfuneties die aan de pathofysiologie van MDS ten grondslag liggen. Ten eindc
de pathofysiologie bij BD beter te begrijpen is het belangrijk om de relaties van cholesterol,
vetzuren, cognitie, stemming en neurotransmitter disfuneties in het brein verder uit te diepen.
Het zou kunnen dat herstellen van een verstoorde cholesterol en vetzuur huishouding bij BD
patiönten een therapeutische werking heeft. Verder onderzoek is naar de speeificiteit van de
serotonerge kwetsbaarheidsfactoren die in dit proefschrift worden gerapporteerd is
gerechtvaardigd.
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Summary
Healthy first-degree relatives of bipolar patients (FH) poMHt • significantly increased risk to
develop BD later in life. The primary goal of this thesis was to search for biological factors
which reflect vulnerability to bipolar disorders (BD) in FH subjects. It was hypothesized that
one important factor is an imbalance of serotonin (5-hydroxytryptophan. 5-HT) in the brain. It
is assumed that investigating the 5-HT system in subjects at genetic risk for BD provides
information on 5-HT functioning in BI). The functions of 5-HT can be investigated by
experimental manipulations of the 5-HT system. In this thesis. 5-HT functioning was assessed
in FH and matched controls following two experimental procedures: Acute trypioplun
Depletion (ATD) and intravenous (i.v.) tryptophan loading (Trp). Abnormal 5-HT functions
in FH is called 'serotonergic vulnerability'. Serotonergic vulnerability in FH may be
generalized to BD patients and suggests involvement of 5-HT in BD psychopathology.
The first part of this thesis describes studies in which brain 5-HT was lowered by means of
ATD. In the second part, the effects of i.v. Trp loading and its relation with cholesterol and
fatty acids were presented. Central 5-HT vulnerability following ATD and i.v. Trp challenge
was assessed by 3 kinds of dependent measures: mood, cognition and hormonal responses. In
all studies, a distinction was made between relatives of BD type I (FH I) and BD type II
patients (FH II).
r / provides a general introduction to the topics and studies addressed in this thesis.
The genetic risk of FH subjects to BD was explained. The relevance of investigating
biological risk factors which indicate the true risk to develop BD was described. A short
introduction to the classification of BD and its symptomatology was given. The terms
depression, mania and hypomania and the difference between type I and type II BD
psychopathology were explained. The relevance of investigating the brain 5-HT system in FH
comes from previously described central 5-HT dysfunctions in BD. The production of 5-HT
in the brain is directly dependent on the availability of Trp. ATD can be achieved by
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consuming an amino-acid drink which is devoid of Trp. Intravenous Tip loading will increase
brain Trp and thus 5-HT. In this chapter, ATD and i.v. Trp loading are dietary manipulations
of the 5-HT system which were proposed as useful methods to investigate vulnerability to 5-
HT dysfunction in FH. The challenge of this thesis was primary to initiate a search for
biological markers in FH, based on the imbalance in brain 5-HT functioning. An overview of
aims of the different studies presented in this thesis was given.
In chapter 2,J am/«/ 5-HT vulnerability to BD was studied by means of ATD. A literature
review of ATD in BD patients was given in c/rap/er 2. C/iap/er i awd 4 provides results of a
study in which the effects of ATD and placebo were investigated in a double-blind cross-over
design in 30 healthy first-degree relatives of BD patients and 15 matched controls. The 75 g
amino-acid drink was devoid of Trp, but in the placebo mixture 3.0g Trp was added. Each
chapter dealt with specific hypothesis of this study.
In r/ia/?ter 2 a review of studies on ATD in BD patients is given. Literature was limited to
three studies, which revealed inconsistent results on mood modification. These
inconsistencies may be attributed to differences in methodological procedures and / or
characteristics of included BD patients. Patient selection, methodological aspects and
procedures of these studies were critically considered. Recommendations for a standardized
research protocol to test 5-HT vulnerability to BD were proposed.
In rAapfer i , 5-HT vulnerability was studied in FH by means of ATD. The effects on mood
and cortisol release in FH subjects were compared with effects in healthy matched controls.
Following ATD and placebo, salivary cortisol response was also assessed during a stress-
inducing speech task (SIST). The results described an elevation in mood in FH II subjects,
whereas mood was equally lowered in controls and FH I subjects following ATD. The SIST
resulted in a significant increase in saliva cortisol. ATD was followed by a decrease in SIST-
induced cortisol response in both FH subgroups, but not in the controls. The results were in
agreement with a previous study in which BD patients reported an increase in mood following
ATD. Thus it was concluded that this study showed 5-HT vulnerability in FH II subjects
which affected mood. 5-HT vulnerability reflected in hormonal abnormalities was seen in
both FH 1 and FH II subjects.
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Cfcop/er 4 describes the results of ATD on cognitive performance which WM matured in the
domains of planning, learning, working memory, retrieval, focused and divided attention and
concept-shifting. Serotonergic circuits have been proposed to mediate cognitive processes. In
BD. cognitive impairments are often seen, possibly in relation to lowered brain 5-HT.
Cognitive performance was assessed at baseline and 5 hours after ATD. The results showed
ATD-induced impairments on speed of information processing on the planning task in KM but
no« in controls. Independent of ATD. cognitive impairments were pronounced in KM I
compared to FH II and controls, i.e. on planning and memory. In all subjects, ATD impaired
consolidation of new information in long-term memory and speed of information processing.
The effects of ATD on planning were interpreted as S-HT vulnerability affecting frontal lobe
areas in FH subjects. It was suggested that the cognitive dysfunctions in HI I reflect
symptoms present in psychotic disorders and may be regarded as possible trait markers to BD.
- 5,6, 7 uwt/ if cover assessment of 5-HT vulnerability to BD by means of 5-HT
challenge procedures which stimulate brain 5-HT release. (7i«/?/tT .* describes a literature
review of 5-HT challenges in BD patients. In r/iup/er 6 am/ 7 the results of a study in which
the effects of an 7.0g i.v. Tip challenge (dissolved in lOOOcc water / saline) and placebo
(lOOOcc saline solution) on mood, neuroendocrine responses (r/uiy?f?r 6) and cognition
(cAapter 7) were investigated in 30 FH subjects and 15 matched controls in a double-blind
cross-over design. Oia/tfw <S describes the relationship between abnormalities in cholesterol,
fatty-acids (FAs) and central 5-HT vulnerability.
A literature review on 5-HT challenges in BD patients is presented in rAapfer 5. Assessment
of neuroendocrine functioning, i.e. cortisol, prolactin (PRL) and adrenocorticotropic hormone
(ACTH), following acute 5-HT challenging has been provided as a useful method to
investigate 5-HT vulnerability. In general it is assumed that following challenging, blunting of
hormonal responses is indicative of i.e. post-synaptic receptor desensitization or depiction of
presynaptic neurotransmitter whereas an enhanced response might suggest sensitization of
receptors. Reviewed 5-HT challenge paradigms were acute administration of oral and
intravenous (i.v.) dosage of: d.l-fenfluramine. tryptophan. 5-hydroxytryptophan, ipsapirone
and buspirone. Effects of challenges were described separately for manic, depressed and
euthymic BD patients. The literature shows evidence for a blunted PRL in mania and
depression as well as blunted cortisol in euthymic BD patients. This might suggest that in
both mania and depression similar 5-HT difunctions are involved. It is speculated that
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blunting of cortisol responses in euthymic BD patients may be a result of chronically altered
5-HT functioning, whereas changes in PRL release following 5-HT challenges reflect more
state-dependent changes in 5-HT activity. 5-HT responsivity in BD patients has also been
associated with pharmacological treatment, suicidal behavior, weight loss and age.
In c/w/Ver <5 intravenous Trp loading resulted in lowered mood and increased cortisol and
prolactine release. There were no differences in these mood and hormonal responses between
FH and control subjects. There was some evidence for different hormonal and mood
responses in FH II subjects compared to FH I and controls. FH II subjects showed an increase
in manic symptoms and attenuated mood-lowering effects of Trp compared to FH I and
healthy controls. There were no differences in mood response between FH I and controls.
PRL and cortisol responses increased following Trp, but did not differ between FH and
controls. PRL response was slightly higher in FH II compared to FH I and controls. The
results do not provide evidence for central 5-HT vulnerability in FH but might give some
indication of a biological differentiation between FH I and FH II.
The study presented in C/M/7/CT 7 investigated 5-HT vulnerability in FH indicated by cognitive
performance on planning, learning, working memory, retrieval, focused, divided and
sustained attention and psychomotor reaction time (RT) following i.v. Trp challenge.
Performance was assessed 3 hours after Trp infusion. The results showed impaired planning
and attention following Trp in FH subjects but not in controls. Independent of Trp, FH
subjects showed cognitive deficits on memory, focused and divided attention and
psychomotor performance. Compared to FH II. cognitive deficits in FH I were more
pronounced. Trp impaired memory and psychomotor performance significantly in all groups.
It was concluded that cognitive deficits in FH following Trp may reflect central 5-HT
vulnerability affecting cognitive domains localized in frontal brain areas. It was suggested
that the cognitive impairments in FH independent of Trp represent a trait maker for BD.
The role of abnormalities in cholesterol and fatty acids in BD pathophysiology has been
investigated in r/»<j/>fir #. In unipolar and BD patients, lower serum high-density lipoprotein
cholesterol (HDL-C) and increased ratio of to6 / u>3 FAs have been reported and related
membrane, receptor and 5-HT neurotransmitter dysfunctions in the brain. The aims of this
study were: i) to investigate whether FH subjects expressed abnormalities in baseline serum
cholesterol and FAs which may represent a trait marker for BD. ii) and whether these
164
abnormalities were related to central 5-HT vulnerability as assessed by peak cortisol and PRL
responses following i.v. Trp challenging. Baseline cholesterol and KAs were determined in
FH and controls according to a parallel-group design. The results showed significuntly lower
HDL-C and CI8:3to3 and increased C20:4<o6 and total w6 FAs compared to controls. Lower
total u)3 FAs were associated with lowered baseline mood. Lower total «3 and higher total «>6
FAs were positively associated w ith peak PRL response follow ing Trp. It was concluded that
the abnormalities in cholesterol and FAs in FH paralleled that found in BO patients and may
thus represent a trait rather than a state marker for BD. 5-HT vulnerability was positively
associated with lower u>3 and higher to6 FAs, which provided evidence for a direct cuusul
relationship between brain 5-HT dysfunction and abnormalities in FAs metabolism.
A summary of the findings and integrative results is provided in <7ky>/<r V. The studies
presented in this thesis show that dietary manipulations of Trp pro\ ide useful methods to
investigate 5-HT vulnerability for BD in FH. Changes in mood, cognition, and homionul
releases following ATD and i.v. Trp loading seem to be appropriate parameter«, to indicate
central 5-HT vulnerability. The results showed that FH II subjects were more vulnerable to
the effects of a serotonergic imbalance on mood. Whereas FH I and controls reported a
lowered mood following ATD and i.v. Trp. FH II subjects showed an elevation in mood and a
significant increase in manic symptomatology. On the other hand, FH I subjects were
characterized by cognitive deficits and a tendency towards more pronounced cognitive
impairments following ATD and Tip challenging. Cognitive deficits may therefore constitute
a trait marker to BD in FH I. Usage of cortisol and PRL responses following ATD and Trp as
biological markers provides some evidence for 5-HT vulnerability in FH but did not
differentiate between FH I and FH II. It was argued that including a stress-inducing procedure
might increase the sensitivity of hormonal parameters as peripheral markers of brain 5-HT
functioning in FH. Assessment of cholesterol and FAs showed significant lower baseline
HDL-C, to3 FAs and higher a>6 FAs in FH. These abnormalities were in agreement with
findings in BD and unipolar depressed patients. It was concluded that these abnormalities in
FH constitute a trait marker to BD rather than a state marker. Lower o>3 and higher o>6 FAs
were positively associated with an elevated PRL response following Trp. This indicates an
important association between altered FAs metabolism and 5-HT vulnerability.
In conclusion, the studies presented in this thesis provide evidence for a biological distinction
between FH I and FH II. FH II subjects show 5-HT vulnerability and characteristics of an
affective pattern. 5-HT vulnerability is less pronounced in FH I subjects. FH I subjects show
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symptoms of primary psychotic disorders in which other neurotransmitters e.g. dopamine,
noradrenaline might be involved. Abnormalities in cholesterol and FAs probably play an
important role in biological dysfunctions in BD. The relation between cholesterol, FAs,
cognition, mood and brain neurotransmitter functioning should be further elucidated.
Research is also necessary to investigate the specificity of factors of 5-HT vulnerability which
are described in this thesis.
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